Cover - USD ($) shares in Millions	12 Months Ended
Cover - USD ($) shares in Millions	Dec. 31, 2024	Jan. 31, 2025	Jun. 28, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-15525
Entity Registrant Name	EDWARDS LIFESCIENCES CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4316614
Entity Address, Address Line One	One Edwards Way
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92614
City Area Code	949
Local Phone Number	250-2500
Title of 12(b) Security	Common Stock, par value $1.00 per share
Trading Symbol	EW
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 55,525,009,946
Entity Common Stock, Shares Outstanding		587.9
Documents Incorporated by Reference	Portions of the registrant's proxy statement for the 2025 Annual Meeting of Stockholders (to be filed within 120 days of December 31, 2024) are incorporated by reference into Part III, as indicated herein.
Entity Central Index Key	0001099800
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2024
Audit Information [Abstract]
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Irvine, California

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 3,045.2	$ 1,132.3
Short-term investments (Note 8)	930.7	500.5
Accounts receivable, net of allowances of $11.6 and $8.2, respectively	609.1	771.5
Other receivables	118.3	56.6
Inventories (Note 6)	1,086.7	903.5
Prepaid expenses	121.0	128.8
Other current assets	347.6	224.9
Current assets of discontinued operations (Note 5)	26.8	317.6
Total current assets	6,285.4	4,035.7
Long-term investments (Note 8)	307.9	583.9
Property, plant, and equipment, net (Note 6)	1,686.0	1,591.0
Operating lease right-of-use assets (Note 7)	98.2	84.4
Goodwill (Note 11)	1,776.7	1,145.1
Other intangible assets, net (Note 11)	1,176.6	399.4
Deferred income taxes	992.1	749.4
Other assets	721.6	463.2
Non-current assets of discontinued operations (Note 5)	10.8	311.1
Total assets	13,055.3	9,363.2
Current liabilities
Accounts payable	197.4	186.6
Accrued and other liabilities (Note 6)	1,282.4	856.4
Operating lease liabilities (Note 7)	23.4	22.9
Current liabilities of discontinued operations (Note 5)	2.0	129.5
Total current liabilities	1,505.2	1,195.4
Long-term debt (Note 12)	597.7	597.0
Contingent consideration liabilities (Note 13)	14.5	0.0
Taxes payable (Note 19)	1.3	80.6
Operating lease liabilities (Note 7)	78.9	65.2
Uncertain tax positions (Note 19)	384.6	335.0
Litigation settlement accrual (Note 3)	52.7	94.2
Other liabilities	357.5	251.3
Non-current liabilities of discontinued operations (Note 5)	0.0	25.1
Total liabilities	2,992.4	2,643.8
Commitments and contingencies (Notes 7, 12, and 20)
Stockholders' equity (Note 16)
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding	0.0	0.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 654.8 and 650.5 shares issued, and 588.6 and 601.1 shares outstanding, respectively	654.8	650.5
Additional paid-in capital	2,613.4	2,274.4
Retained earnings	13,167.0	8,992.4
Accumulated other comprehensive loss (Note 17)	(244.5)	(242.8)
Treasury stock, at cost, 66.2 and 49.4 shares, respectively	(6,192.3)	(5,024.5)
Total Edwards Lifesciences Corporation stockholders' equity	9,998.4	6,650.0
Noncontrolling interest	64.5	69.4
Total stockholders' equity	10,062.9	6,719.4
Total liabilities and equity	$ 13,055.3	$ 9,363.2

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 11.6	$ 8.2
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized shares (in shares)	50,000,000.0	50,000,000.0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 1.00	$ 1.00
Common stock, shares authorized (in shares)	1,050,000,000	1,050,000,000
Common stock, shares issued (in shares)	654,800,000	650,500,000
Common stock, shares outstanding (in shares)	588,600,000	601,100,000
Treasury stock (in shares)	66,200,000	49,400,000

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net sales	$ 5,439.5	$ 5,010.0	$ 4,464.0
Cost of sales	1,117.5	978.4	723.7
Gross profit	4,322.0	4,031.6	3,740.3
Selling, general, and administrative expenses	1,789.2	1,582.5	1,357.6
Research and development expenses	1,053.0	962.9	843.6
Intellectual property agreement and certain litigation expenses (Note 3)	40.4	203.5	15.8
Change in fair value of contingent consideration liabilities (Note 13)	0.0	(26.2)	(35.8)
Restructuring charges, separation costs, and other (Note 4)	61.0	0.0	60.7
Other operating income, net	(0.3)	0.0	0.0
Operating income	1,378.7	1,308.9	1,498.4
Interest expense	19.8	17.6	19.2
Interest income	(120.3)	(67.2)	(35.5)
Other non-operating income, net (Note 18)	(68.9)	(13.9)	(4.8)
Income from continuing operations before provision for income taxes	1,548.1	1,372.4	1,519.5
Provision for income taxes (Note 19)	152.1	152.4	195.5
Net income from continuing operations	1,396.0	1,220.0	1,324.0
Income from discontinued operations, net of tax	2,773.7	179.4	197.9
Net income	4,169.7	1,399.4	1,521.9
Net loss attributable to noncontrolling interest	(4.9)	(3.0)	0.0
Net income attributable to Edwards Lifesciences Corporation.	$ 4,174.6	$ 1,402.4	$ 1,521.9
Basic
Continuing operations (in dollars per share)	$ 2.34	$ 2.02	$ 2.14
Discontinued operations (in dollars per share)	4.64	0.29	0.32
Basic earnings per share (in dollars per share)	6.98	2.31	2.46
Diluted:
Continuing operations (in dollars per share)	2.34	2.01	2.12
Discontinued operations (in dollars per share)	4.63	0.29	0.32
Diluted earnings per share (in dollars per share)	$ 6.97	$ 2.30	$ 2.44
Weighted-average number of common shares outstanding attributable to Edwards Lifesciences Corporation:
Basic (in shares)	597.7	606.7	619.0
Diluted (in shares)	599.3	609.4	624.2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 4,169.7	$ 1,399.4	$ 1,521.9
Other comprehensive (loss) income, net of tax (Note 17):
Foreign currency translation adjustments	(59.6)	4.3	(46.3)
Unrealized gain (loss) on hedges	37.0	(23.1)	(5.9)
Unrealized pension credits (costs)	0.1	(9.9)	13.7
Unrealized gain (loss) on available-for-sale investments	20.8	40.8	(58.7)
Other comprehensive (loss) income, net of tax	(1.7)	12.1	(97.2)
Comprehensive income	4,168.0	1,411.5	1,424.7
Comprehensive loss attributable to noncontrolling interest	(4.9)	(3.0)	0.0
Comprehensive income attributable to Edwards Lifesciences Corporation	$ 4,172.9	$ 1,414.5	$ 1,424.7

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net income	$ 4,169.7	$ 1,399.4	$ 1,521.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	155.2	144.9	139.6
Non-cash operating lease cost	27.8	28.2	27.2
Stock-based compensation (Notes 2 and 16)	162.3	139.4	126.8
Gain on sale of product group (Note 5)	(3,348.2)	0.0	0.0
Impairment charges (Note 4)	0.0	0.0	55.1
Change in fair value of contingent consideration liabilities (Note 13)	0.0	(26.2)	(35.8)
(Gain) loss on investments, net	(5.2)	0.1	51.5
Deferred income taxes	(323.4)	(272.1)	(254.5)
Gain on remeasurement of previously held equity interest upon acquisition (Note 10)	(55.0)	0.0	0.0
Other	18.4	8.4	7.8
Changes in operating assets and liabilities:
Accounts and other receivables, net	121.2	(141.2)	(84.1)
Inventories	(256.1)	(289.0)	(213.4)
Prepaid expenses and other current assets	22.7	(81.8)	0.1
Accounts payable and accrued liabilities	89.5	146.0	(21.4)
Intellectual property agreement accrual	(36.8)	(33.0)	(45.0)
Income taxes	(186.7)	(5.8)	(5.6)
Long-term prepaid royalties (Note 3)	8.3	(109.9)	0.0
Other	(21.4)	(11.6)	(52.0)
Net cash provided by operating activities	542.3	895.8	1,218.2
Cash flows from investing activities
Capital expenditures	(252.4)	(253.0)	(244.6)
Purchases of held-to-maturity investments (Note 8)	(45.9)	(66.4)	(353.5)
Proceeds from sales and maturities of held-to-maturity investments (Note 8)	57.5	97.9	419.5
Purchases of available-for-sale investments (Note 8)	(899.9)	(9.1)	(315.8)
Proceeds from sales and maturities of available-for-sale investments (Note 8)	800.1	617.9	939.6
Business combinations, net of cash (Note 10)	(1,061.8)	(95.2)	0.0
Payments for acquisition options (Note 9)	(46.2)	(30.0)	(109.6)
Issuances of notes receivable	(63.0)	(62.5)	(52.3)
Collections of notes receivable	0.0	0.0	18.0
Investments in intangible assets	(30.0)	(13.3)	(20.2)
Proceeds from sale of product group	3,927.4	0.0	0.0
Other	(72.9)	(12.5)	(28.8)
Net cash provided by investing activities	2,312.9	173.8	252.3
Cash flows from financing activities
Purchases of treasury stock	(1,159.4)	(879.6)	(1,727.1)
Proceeds from stock plans	179.5	169.9	146.4
Other	(3.1)	(1.3)	(3.8)
Net cash used in financing activities	(983.0)	(711.0)	(1,584.5)
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	38.6	16.8	19.2
Net increase (decrease) in cash, cash equivalents, and restricted cash	1,910.8	375.4	(94.8)
Cash, cash equivalents, and restricted cash at beginning of year	1,148.0	772.6	867.4
Cash, cash equivalents, and restricted cash at end of year (Note 6)	$ 3,058.8	$ 1,148.0	$ 772.6

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Millions, $ in Millions	Total	Total Edwards Lifesciences Corporation Stockholders' Equity	Common Stock	Treasury Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interest
Common stock, beginning balance (in shares) at Dec. 31, 2021			642.0
Beginning balance at Dec. 31, 2021	$ 5,835.9	$ 5,835.9	$ 642.0	$ (2,416.9)	$ 1,700.4	$ 6,068.1	$ (157.7)	$ 0.0
Treasury stock, beginning balance (in shares) at Dec. 31, 2021				17.9
Increase (Decrease) in Stockholders' Equity
Net income (loss)	1,521.9	1,521.9				1,521.9
Other comprehensive gain (loss), net of tax	(97.2)	(97.2)					(97.2)
Common stock issued under equity plans (in shares)			4.3
Common stock issued under equity plans	146.4	146.4	$ 4.3		142.1
Stock-based compensation expense	126.8	126.8			126.8
Purchases of treasury stock (in shares)				20.1
Purchases of treasury stock	(1,727.1)	(1,727.1)		$ (1,727.1)
Common stock, ending balance (in shares) at Dec. 31, 2022			646.3
Ending balance at Dec. 31, 2022	5,806.7	5,806.7	$ 646.3	$ (4,144.0)	1,969.3	7,590.0	(254.9)	0.0
Treasury stock, ending balance (in shares) at Dec. 31, 2022				38.0
Increase (Decrease) in Stockholders' Equity
Net income (loss)	1,399.4	1,402.4				1,402.4		(3.0)
Other comprehensive gain (loss), net of tax	12.1	12.1					12.1
Common stock issued under equity plans (in shares)			4.2
Common stock issued under equity plans	169.9	169.9	$ 4.2		165.7
Stock-based compensation expense	139.4	139.4			139.4
Purchases of treasury stock (in shares)				11.4
Purchases of treasury stock	(880.5)	(880.5)		$ (880.5)
Changes to noncontrolling interest (Note 9)	$ 72.4							72.4
Common stock, ending balance (in shares) at Dec. 31, 2023	601.1		650.5
Ending balance at Dec. 31, 2023	$ 6,719.4	6,650.0	$ 650.5	$ (5,024.5)	2,274.4	8,992.4	(242.8)	69.4
Treasury stock, ending balance (in shares) at Dec. 31, 2023	49.4			49.4
Increase (Decrease) in Stockholders' Equity
Net income (loss)	$ 4,169.7	4,174.6				4,174.6		(4.9)
Other comprehensive gain (loss), net of tax	(1.7)	(1.7)					(1.7)
Common stock issued under equity plans (in shares)			4.3
Common stock issued under equity plans	179.5	179.5	$ 4.3		175.2
Stock-based compensation expense	163.8	163.8			163.8
Purchases of treasury stock (in shares)				16.8
Purchases of treasury stock	$ (1,167.8)	(1,167.8)		$ (1,167.8)
Common stock, ending balance (in shares) at Dec. 31, 2024	588.6		654.8
Ending balance at Dec. 31, 2024	$ 10,062.9	$ 9,998.4	$ 654.8	$ (6,192.3)	$ 2,613.4	$ 13,167.0	$ (244.5)	$ 64.5
Treasury stock, ending balance (in shares) at Dec. 31, 2024	66.2			66.2

DESCRIPTION OF BUSINESS	12 Months Ended
DESCRIPTION OF BUSINESS	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	DESCRIPTION OF BUSINESSEdwards Lifesciences Corporation ("Edwards Lifesciences," "Edwards," or the "Company") conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. Edwards Lifesciences is focused on technologies that treat structural heart disease. The products and technologies provided by Edwards Lifesciences are categorized into the following main groups: Transcatheter Aortic Valve Replacement ("TAVR"), Transcatheter Mitral and Tricuspid Therapies ("TMTT"), and Surgical Structural Heart ("Surgical"). On September 3, 2024, the Company sold its Critical Care product group ("Critical Care"). The historical results of Critical Care are reflected as discontinued operations in the Company's consolidated financial statements for all periods presented. In addition, as a next step in the Company's disposal plan to exit businesses that are not focused on implantable medical innovations for structural heart disease, the historical results of a small non-core product group that the Company plans to sell are also included in discontinued operations. Unless otherwise indicated, the information in the notes to the consolidated financial statements refer only to Edwards Lifesciences' continuing operations. For further information, see Note 5.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Edwards Lifesciences, its wholly-owned subsidiaries, and variable interest entities ("VIEs") for which the Company is the primary beneficiary. For further information, see Note 9. The Company attributes the net income or losses of its consolidated VIEs to controlling and noncontrolling interests using the hypothetical liquidation at book value method. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The consolidated financial statements of Edwards Lifesciences have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") which have been applied consistently in all material respects. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.

Foreign Currency Translation

When the local currency of the Company's foreign entities is the functional currency, all assets and liabilities are translated into United States dollars at the rate of exchange in effect at the balance sheet date. Income and expense items are translated at the weighted-average exchange rate prevailing during the period. The effects of foreign currency translation adjustments for these entities are deferred and reported in stockholders' equity as a component of Accumulated Other Comprehensive Loss. The effects of foreign currency transactions denominated in a currency other than an entity's functional currency are included in Other Non-operating Income, net.

Revenue Recognition

Revenue is recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products or services.

The Company generates nearly all of its revenue from direct product sales and sales of products under consignment arrangements. Revenue from direct product sales is recognized at a point in time when the performance obligation is satisfied upon delivery of the product. Revenue from sales of consigned inventory is recognized at a point in time when the performance obligation is satisfied once the product has been implanted or used by the customer. The Company periodically reviews consignment inventories to confirm the accuracy of customer reporting. The Company also generates a small portion of its revenue from service contracts, which is recognized ratably over the term of the contracts. Sales taxes and other similar taxes

that the Company collects concurrent with revenue-producing activities are excluded from revenue. The Company does not typically have any significant unusual payment terms beyond 90 days in its contracts with customers. In addition, the Company receives royalty payments for the licensing of certain intellectual property and recognizes the royalty when the subsequent sale of product using the intellectual property occurs.

The amount of consideration the Company ultimately receives varies depending upon the return terms, sales rebates, discounts, and other incentives that the Company may offer, which are accounted for as variable consideration when estimating the amount of revenue to recognize. The Company includes estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely upon an assessment of historical payment experience, historical relationship to revenues, estimated customer inventory levels, and current contract sales terms with direct and indirect customers.

The Company's sales adjustment related to distributor rebates given to the Company's United States distributors represents the difference between the Company's sales price to the distributor and the negotiated price to be paid by the end-customer. This distributor rebate is recorded as a reduction to sales and a reduction to the distributor's accounts receivable at the time of sale to a distributor. The Company periodically monitors current pricing trends and distributor inventory levels to ensure the credit for future distributor rebates is fairly stated.

The Company offers volume rebates to certain group purchasing organizations ("GPOs") and customers based upon targeted sales levels. Volume rebates offered to GPOs are recorded as a reduction to sales and an obligation to the GPOs, as the Company expects to pay in cash. Volume rebates offered to customers are recorded as a reduction to sales and either a reduction to accounts receivable if the Company expects a net payment from the customer, or as an obligation to the customer if the Company expects to pay in cash. The provision for volume rebates is estimated based upon customers' contracted rebate programs, projected sales levels, and historical experience of rebates paid. The Company periodically monitors its customer rebate programs to ensure that the allowance and liability for accrued rebates is fairly stated.

Product returns are typically not significant because returns are generally not allowed unless the product is damaged at the time of receipt. In limited circumstances, the Company may allow customers to return previously purchased products, such as for next-generation product offerings. For these transactions, the Company defers recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer.

A limited number of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the transaction price is allocated to each performance obligation based on its relative standalone selling price charged to other customers.

The Company applies the optional exemption of not disclosing the amount of the transaction price allocated to unsatisfied performance obligations for contracts with an original expected duration of one year or less.

Shipping and Handling Costs

Shipping costs, which are costs incurred to physically move product from the Company's premises or third party distribution centers, including storage, to the customer's premises, are included in Selling, General, and Administrative Expenses. Handling costs, which are costs incurred to store at the Company's premises, move, and prepare products for shipment, are included in Cost of Sales. For the years ended December 31, 2024, 2023, and 2022, shipping costs of $83.9 million, $94.5 million, and $83.6 million, respectively, were included in Selling, General, and Administrative Expenses.

Cash Equivalents

The Company considers highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. These investments are valued at cost, which approximates fair value.

Investments

The Company invests its excess cash in debt securities, including time deposits, commercial paper, United States government and agency securities, asset-backed securities, corporate debt securities, and municipal debt securities. Investments with maturities of one year or less are classified as short-term, and investments with maturities greater than one year are classified as long-term. Investments that the Company has the ability and intent to hold until maturity are classified as held-to-maturity and carried at amortized cost. Investments in debt securities that are classified as available-for-sale are carried at fair value with unrealized gains and losses included in Accumulated Other Comprehensive Loss. The Company determines the appropriate classification of its investments in debt securities at the time of purchase and reevaluates such designation at each balance sheet date.

The Company also has long-term equity investments in companies that are in various stages of development. These investments are reported at fair value or under the equity method of accounting, as appropriate. Equity investments that do not have readily determinable fair values are recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The Company accounts for investments in limited partnerships and limited liability corporations, whereby the Company owns a minimum of 5% of the investee's outstanding voting stock, under the equity method of accounting. These investments are recorded at the amount of the Company's investment and adjusted each period for the Company's share of the investee's income or loss, and dividends paid.

Realized gains and losses on investments that are sold are determined using the specific identification method, or the first-in, first-out method, depending on the investment type, and recorded to Other Non-operating Income, net. Income relating to investments in debt securities is recorded to Interest Income.

Equity investments without readily determinable fair value are considered impaired when there is an indication that the fair value of the Company's interest is less than the carrying amount. Equity method investments are considered impaired when there is an indication of an other-than-temporary decline in value below the carrying amount. Impairments of equity investments are recorded in Other Non-operating Income, net.

Debt securities in an unrealized loss position are written down to fair value through Other Non-operating Income, net if the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the length of time and the extent to which the security's fair value has been below cost, changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security, among other factors. When a credit loss exists, the Company compares the present value of cash flows expected to be collected from the debt security to the amortized cost basis of the security to determine the allowance amount that should be recorded, if any.

Accounts Receivable

The majority of the Company’s accounts receivable arise from direct product sales and sales of products under consignment arrangements, and have payment terms that generally require payment within 30 to 90 days. The Company does not adjust its receivables for the effects of a significant financing component at contract inception if collection of the receivable is expected within one year or less from the time of sale. In countries where the Company has experienced a pattern of payments extending beyond the stated terms and collection of the receivable is expected beyond one year from the time of sale, the Company assesses whether the customer has a significant financing component and discounts the receivable and reduces the related revenues over the period of time that the Company estimates those amounts will be paid using the country’s market-based borrowing rate for such period.

The Company provides reserves against accounts receivable for estimated losses that may result from a customer’s inability to pay based on customer-specific analysis and general matters such as current assessments of past due balances, economic conditions and forecasts, and historical credit loss activity. Amounts determined to be uncollectible are charged or written-off against the reserve.

Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. Market value for raw materials is based on replacement costs, and for other inventory classifications is based on net realizable value.

A write-down for excess or slow moving inventory is recorded for inventory which is obsolete, damaged, nearing its expiration date (generally triggered at six months prior to expiration), or slow moving (generally defined as quantities in excess of a two-year supply).

The Company allocates to inventory general and administrative costs that are related to the production process. These costs include insurance, manufacturing accounting and human resources personnel, and information technology. During the years ended December 31, 2024, 2023, and 2022, the Company allocated $84.2 million, $78.0 million, and $71.3 million, respectively, of general and administrative costs to inventory. General and administrative costs included in inventory at December 31, 2024 and 2023 were $44.0 million and $36.3 million, respectively.

At December 31, 2024 and 2023, $181.7 million and $164.6 million, respectively, of the Company's finished goods inventories were held on consignment.

Property, Plant, and Equipment

Property, plant, and equipment are recorded at cost. Depreciation is principally calculated for financial reporting purposes on the straight-line method over the estimated useful lives of the related assets, which range from 10 to 40 years for buildings and improvements, from 3 to 15 years for machinery and equipment, and from 3 to 5 years for software. Leasehold improvements are amortized over the life of the related facility leases or the asset, whichever is shorter. Straight-line and accelerated methods of depreciation are used for income tax purposes. Construction in progress is not depreciated until the asset is ready for its intended use.

Depreciation expense for property, plant, and equipment was $137.6 million, $119.9 million, and $114.5 million for the years ended December 31, 2024, 2023, and 2022, respectively.

Leases

The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. The Company's incremental borrowing rate is determined based on the estimated rate of interest for collateralized borrowing over a similar term as the associated lease. Right-of-use assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received.

The Company determines the lease term as the noncancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Certain of the Company’s leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. The Company’s leases do not contain any residual value guarantees.

The Company accounts for the lease and non-lease components as a single lease component for all of its leases except vehicle leases, for which the lease and non-lease components are accounted for separately.

Operating leases are included in Operating Lease Right-of-Use Assets and Operating Lease Liabilities on the Company’s consolidated balance sheets. For further information, see Note 7.

Business Combinations

Businesses that the Company acquires are included in its results of operations as of the acquisition date. The purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase price over the fair values of identifiable assets and liabilities is recorded as goodwill. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. Contingent consideration obligations incurred in connection with a business combination are recorded at their fair values on the acquisition date and remeasured on a quarterly basis, with changes in their fair value recorded as an adjustment to earnings, until the related contingencies have been resolved. When the assets acquired do not meet the definition of a business combination, the transaction is accounted for as an asset acquisition. In an asset acquisition, the cost of the acquisition is allocated to the assets acquired and liabilities assumed based on their relative fair values. Upfront payments related to in-process research and development projects with no alternative future use are expensed upon acquisition.

Contingent Consideration

The Company records contingent consideration resulting from a business combination at its fair value on the acquisition date. The fair value of the contingent consideration is determined based primarily on the following factors:

•discount rates used to present value the projected cash flows;

•the probability of success of clinical events and regulatory approvals, and/or meeting commercial milestones; and

•projected payment dates.

On a quarterly basis, the Company revalues these obligations and records changes in their fair value as an adjustment to earnings. Changes to contingent consideration obligations can result from adjustments to discount rates, accretion of the discount rates due to the passage of time, changes in our estimates of the likelihood or timing of achieving development or commercial milestones, changes in the probability of certain clinical events, or changes in the assumed probability associated with regulatory approval.

The assumptions related to determining the value of contingent consideration include a significant amount of judgment, and any changes in the underlying estimates could have a material impact on the amount of contingent consideration expense recorded in any given period.

Intangible Assets and Long-lived Assets

The Company acquires intangible assets in connection with business combinations and asset purchases. The acquired intangible assets are recorded at fair value, which is determined based on a discounted cash flow analysis. The determination of fair value requires significant estimates, including, but not limited to, projected revenues, projected gross margins, the amount and timing of projected future cash flows, the discount rate used to discount those cash flows, the assessment of the asset's life cycle, including the timing and expected costs to complete in-process projects, and the consideration of legal, technical, regulatory, economic, and competitive risks. Discount rates may vary across acquisitions based on the purchase price, forecasts, and relative risks of each acquired company.

Goodwill is reviewed for impairment annually in the fourth quarter of each fiscal year, or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the reporting unit does not pass the qualitative assessment, then the Company performs a quantitative impairment test. The Company determined, after performing a qualitative review of each reporting unit, that it is more likely than not that the fair value of each of its reporting units substantially exceeds the respective carrying amounts. Accordingly, in 2024, 2023, and 2022, the Company did not record any goodwill impairment loss.

Indefinite-lived intangible assets relate to in-process research and development acquired in business combinations. The estimated fair values of in-process research and development projects acquired in a business combination which have not

reached technological feasibility are capitalized and accounted for as indefinite-lived intangible assets subject to impairment testing until completion or abandonment of the projects. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If the project is abandoned, all remaining capitalized amounts are written off immediately. Indefinite-lived intangible assets are reviewed for impairment annually in the fourth quarter of each fiscal year, or whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. An impairment loss is recognized when the asset's carrying value exceeds its fair value. In-process research and development projects acquired in an asset acquisition are expensed unless the project has an alternative future use.

Management reviews the carrying amounts of other finite-lived intangible assets and long-lived tangible assets whenever events or circumstances indicate that the carrying amounts of an asset may not be recoverable. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated declines in revenue or operating profit, and adverse legal or regulatory developments. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair market value. Estimated fair market value is determined primarily using the anticipated cash flows discounted at a rate commensurate with the risk involved. For the purposes of identifying and measuring impairment, long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.

In 2024 and 2023, the Company did not record any impairment loss related to its in-process research and development assets. In 2022, the Company recorded a $52.7 million impairment of certain developed technology and in-process research and development assets. For further information, see Note 4.

Income Taxes

The Company is subject to income taxes in the United States and numerous foreign jurisdictions. Significant judgment is required in evaluating the Company's uncertain tax positions and determining its provision for income taxes. The Company recognizes the financial statement benefit of a tax position only after determining that a position would more likely than not be sustained based upon its technical merit if challenged by the relevant taxing authority and taken by management to the court of last resort. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company has made an accounting policy election to recognize the United States tax effects of global intangible low-taxed income as a component of income tax expense in the period the tax arises.

Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. The Company evaluates quarterly the realizability of its deferred tax assets by assessing its valuation allowance and adjusting the amount, if necessary. The factors used to assess the likelihood of realization are both historical experience and the Company's forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in the applicable taxing jurisdictions could affect the ultimate realization of deferred tax assets and could result in an increase in the Company's effective tax rate on future earnings.

Research and Development Costs

Research and development costs are charged to expense when incurred.

Earnings per Share

Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, nonvested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive.

The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information):


	Years Ended December 31,
	2024		2023		2022
Net Income for Earnings Per Share Calculations:
Income from continuing operations, net of tax	$	1,396.0	$	1,220.0	$	1,324.0
Net loss attributable to noncontrolling interests	(4.9)		(3.0)		—
Income from continuing operations attributable to Edwards Lifesciences Corporation	1,400.9		1,223.0		1,324.0
Income from discontinued operations	2,773.7		179.4		197.9
Net income attributable to Edwards Lifesciences Corporation	$	4,174.6	$	1,402.4	$	1,521.9
Weighted Average Shares:
Basic weighted-average shares outstanding	597.7		606.7		619.0
Dilutive effect of stock plans	1.6		2.7		5.2
Dilutive weighted-average shares outstanding	599.3		609.4		624.2
Earnings per Share:
Basic:
Continuing operations	$	2.34	$	2.02	$	2.14
Discontinued operations	4.64		0.29		0.32
Basic earnings per share	$	6.98	$	2.31	$	2.46
Diluted:
Continuing operations	$	2.34	$	2.01	$	2.12
Discontinued operations	4.63		0.29		0.32
Diluted earnings per share	$	6.97	$	2.30	$	2.44

Outstanding stock options, unvested restricted stock units, and unvested market-based restricted stock units to purchase approximately 8.4 million, 6.6 million, and 3.6 million shares for the years ended December 31, 2024, 2023, and 2022, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive.

Stock-based Compensation

The Company measures and recognizes compensation expense for all stock-based awards based on estimated fair values. Stock-based awards consist of stock options, restricted stock units (service-based and market-based), and employee stock purchase subscriptions. Stock-based compensation expense is measured at the grant date based on the fair value of the award and is recognized as expense over each award's requisite service period (vesting period) on a straight-line basis. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Upon exercise of stock options or vesting of restricted stock units, the Company issues common stock.

Total stock-based compensation expense was as follows (in millions):


	Years Ended December 31,
	2024		2023		2022
Cost of sales	$	26.7	$	20.6	$	20.3
Selling, general, and administrative expenses	82.5		74.0		67.3
Research and development expenses	36.4		30.2		26.0
Total stock-based compensation expense	145.6		124.8		113.6
Income tax benefit	(24.8)		(21.8)		(19.6)
Total stock-based compensation expense, net of tax	$	120.8	$	103.0	$	94.0

Upon a participant's retirement, all unvested stock options are immediately forfeited. In addition, upon retirement, a participant will immediately vest in 25% of service-based restricted stock units for each full year of employment with the Company measured from the grant date. All remaining unvested service-based restricted stock units are immediately forfeited. For market-based restricted stock units, upon retirement and in certain other specified cases, a participant will receive a pro-rated portion of the shares that would ultimately be issued based on attainment of the performance goals as determined on the vesting date. The pro-rated portion is based on the participant's whole months of service with the Company during the performance period prior to the date of termination.

Derivatives

The Company uses derivative financial instruments to manage its currency exchange rate risk and its interest rate risk. It is the Company's policy not to enter into derivative financial instruments for speculative purposes.

Derivative financial instruments involve credit risk in the event the counterparty should default. It is the Company's policy to execute such instruments with global financial institutions that the Company believes to be creditworthy. The Company diversifies its derivative financial instruments among counterparties to minimize exposure to any one of these entities. The Company also uses International Swap Dealers Association master-netting agreements. The master-netting agreements provide for the net settlement of all contracts through a single payment in a single currency in the event of default, as defined by the agreements.

The Company uses foreign currency forward exchange contracts and cross currency swap contracts to manage its exposure to changes in currency exchange rates from (1) future cash flows associated with intercompany transactions and certain local currency expenses expected to occur within approximately one year (designated as cash flow hedges), (2) its net investment in certain foreign subsidiaries (designated as net investment hedges) and (3) foreign currency denominated assets or liabilities (designated as fair value hedges). The Company also uses foreign currency forward exchange contracts that are not designated as hedging instruments to offset the transaction gains and losses associated with the revaluation of certain assets and liabilities denominated in currencies other than their functional currencies, resulting principally from intercompany and local currency transactions.

All derivative financial instruments are recognized at fair value in the consolidated balance sheets. For each derivative instrument that is designated as a fair value hedge, the gain or loss on the derivative included in the assessment of hedge effectiveness is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. The Company reports in Accumulated Other Comprehensive Loss the gain or loss on derivative financial instruments that are designated, and that qualify, as cash flow hedges. The Company reclassifies these gains and losses into earnings in the same line item and in the same period in which the underlying hedged transactions affect earnings. Changes in the fair value of net investment hedges are reported in Accumulated Other Comprehensive Loss as a part of the cumulative translation adjustment and would be reclassified into earnings if the underlying net investment is sold or substantially liquidated. The portion of the change in fair value related to components excluded from the hedge effectiveness assessment are amortized into earnings over the life of the derivative. The gains and losses on derivative financial instruments for which the Company does not elect hedge accounting treatment are recognized in the consolidated statements of operations in each period based upon the change in the fair value of the derivative financial instrument. Upon settlement, cash flows from net investment hedges are reported as investing activities

in the consolidated statements of cash flows, and cash flows from all other derivative financial instruments are reported as operating activities.

Recently Adopted Accounting Standards

In November 2023, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting guidance on segment reporting. The amendments require disclosure of significant segment expenses and other segment items and requires entities to provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. The amendment also requires disclosure of the title and position of the chief operating decision maker ("CODM") and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The guidance was effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective application is required, and early adoption is permitted. The Company adopted this guidance for the year ended December 31, 2024 and applied the guidance retrospectively for all periods presented. For further information, see Note 21.

In March 2023, the FASB issued an amendment to the accounting guidance on investments in tax credit structures to allow entities to elect to account for their tax equity investments, regardless of the tax credit program from which the income tax credits are received, using the proportional amortization method if certain conditions are met. The guidance was effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.

New Accounting Standards Not Yet Adopted

In November 2024, the FASB issued an amendment to the accounting guidance on income statement presentation to require disclosure, in the notes to the financial statements, of disaggregated information about certain costs and expenses, including purchases of inventory, employee compensation, and depreciation and amortization included in each relevant expense caption within continuing operations. The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact the guidance will have on its consolidated financial statements.

In December 2023, the FASB issued an amendment to the accounting guidance on income taxes which requires entities to provide additional information in the rate reconciliation and additional disaggregated disclosures about income taxes paid. This guidance requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state, and foreign income taxes and to provide more details about the reconciling items in some categories if the items meet a quantitative threshold. The guidance is effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this guidance to impact its financial statements, but the guidance will impact its income tax disclosures.

INTELLECTUAL PROPERTY AGREEMENT AND CERTAIN LITIGATION EXPENSES	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
INTELLECTUAL PROPERTY AGREEMENT AND CERTAIN LITIGATION EXPENSES	INTELLECTUAL PROPERTY AGREEMENT AND CERTAIN LITIGATION EXPENSES The Company incurred intellectual property litigation expenses, including settlements and external legal costs, of $40.4 million, $203.5 million and $15.8 million during 2024, 2023 and 2022, respectively. On April 12, 2023, Edwards entered into an intellectual property agreement (the "Intellectual Property Agreement") with Medtronic, Inc. ("Medtronic") pursuant to which the parties agreed to a 15-year global covenant not to sue ("CNS") for infringement of certain patents in the structural heart space owned or controlled by each other. In consideration for the global CNS and related mutual access to certain intellectual property rights, Edwards paid to Medtronic a one-time, lump sum payment of $300.0 million and is making annual royalty payments that are tied to net sales of certain Edwards products. Based upon the terms of the Intellectual Property Agreement, the Company identified the relevant elements for accounting purposes and allocated the $300.0 million upfront payment based on their respective fair values. The Company recorded a $37.0 million pre-tax charge in Certain Litigation Expenses in March 2023 primarily related to prior commercial sales incurred through March 31, 2023. The Company recorded a prepaid royalty asset of $124.0 million in April 2023 related to future commercial sales, which will be amortized to expense during the term of the Intellectual Property Agreement. Separately, the Company recorded a $139.0 million pre-tax charge in Certain Litigation Expenses in April 2023 related to products currently in development. As of December 31, 2024 and 2023, the prepaid royalty asset balance was $109.9 million and $118.1 million, respectively, included in Prepaid Expenses and Other Assets.

RESTRUCTURING CHARGES, SEPARATION COSTS, AND OTHER

12 Months Ended

Dec. 31, 2024

Restructuring and Related Activities [Abstract]

RESTRUCTURING CHARGES, SEPARATION COSTS, AND OTHER

In September 2024, the Company recorded an expense of $32.9 million related to severance expenses associated with a global workforce realignment impacting approximately 360 employees. The following table presents details of the restructuring liability, which is included in Accrued and Other Liabilities:


	Restructuring Liability
	(in millions)
Balance at December 31, 2023	$	—
Restructuring charges	32.9
Payments	(12.8)
Balance at December 31, 2024	$	20.1

The Company's remaining severance obligations are expected to be substantially paid within the next 12 months.

On June 3, 2024, the Company entered into a definitive agreement to sell its Critical Care product group ("Critical Care") to Becton, Dickinson and Company ("BD") and the sale closed on September 3, 2024. In the fourth quarter of 2024, the Company recorded expenses of $19.0 million, primarily related to costs incurred for consulting, legal, tax, and other professional advisory services associated with the sale. For further information, see Note 5.

In September 2022, the Company decided to exit its HARPOON surgical mitral repair system program. As a result, the Company recorded expenses to its United States segment of $62.3 million, of which $60.7 million was included in Restructuring Charges, Separation Costs, and Other and $1.6 million was included in Cost of Sales on the consolidated statements of operations. The expenses primarily related to the full impairment of intangible assets associated with the technology for $52.7 million and other related exit costs. In September 2022, the Company recorded an $11.7 million contingent consideration gain associated with the exit and believes that no additional consideration is due. For further information, see Note 20.

DISCONTINUED OPERATIONS

12 Months Ended

Dec. 31, 2024

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS

On June 3, 2024, the Company entered into a definitive agreement to sell Critical Care to BD. In addition, as a next step in the Company's disposal plan to exit businesses that are not focused on implantable medical innovations for structural heart disease, the Company has committed to a plan to sell a non-core product group, with the sale expected to occur in 2025.

Critical Care and the aforementioned non-core product group (collectively, the "discontinued product groups") were historically reported in each of the Company's segments (United States, Europe, Japan, and Rest of World).

The Company concluded that Critical Care met the criteria to be classified as held-for-sale in June 2024 and that the non-core product group met the criteria to be classified as held-for-sale in September 2024. The Company determined that, when considered together, the conditions for discontinued operations presentation had been met with respect to the discontinued product groups. A component of an entity is reported in discontinued operations after meeting the criteria for held-for-sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. The Company analyzed the quantitative and qualitative factors relevant to the discontinued product groups, including their significance to the Company’s overall net income and total assets, and determined that those conditions for discontinued operations presentation had been met. As such, the historical financial condition and results of the discontinued product groups have been reflected as discontinued operations in the Company's Consolidated Financial Statements. The assets and liabilities associated with discontinued product groups are classified as assets and liabilities of discontinued operations in the Company's consolidated balance sheets. Prior period amounts have been adjusted to reflect the discontinued operations presentation.

On September 3, 2024, Critical Care was sold for $4.2 billion, which is subject to a further working capital adjustment, resulting in a gain of $3.3 billion (included in Income from Discontinued Operations, net of tax).

In connection with the sale of Critical Care, the Company entered into a transition services agreement ("TSA") to provide certain support services for up to 36 months from the closing date of the sale (with certain extension rights as provided therein). These support services may be in the areas of accounting, information technology, human resources, quality assurance, regulatory affairs, customer support, and global supply chain, among others. In connection with the TSA, the Company recognized an unfavorable contract liability of $115.1 million that will be recognized over the TSA term. As of December 31, 2024, the remaining unfavorable contract liability was $88.8 million, included in Accrued and Other Liabilities and Other Liabilities.

In addition, Edwards and BD entered into other agreements to provide a framework for the ongoing activities between the Company and BD after the sale and until the end of the TSA including, but not limited to, interim operating model agreements to support the commercial operations until there has been a full transfer of all regulatory licenses to BD and completion of services under the TSA agreement, a manufacturing and supply agreement, and a quality agreement. Under these agreements, the Company will continue to provide certain services to BD during the term of these agreements including serving as an undisclosed selling and purchasing agent for the Critical Care business on behalf of BD for a period of up to 36 months.

As of December 31, 2024, the Company had a net receivable of approximately $28.8 million from BD related to the services under the agreements. The Company recorded income from the TSA of $30.3 million during the year ended December 31, 2024, which was recorded in Other Operating Income, net on the Company's consolidated statements of operations.

Details of Income from Discontinued Operations are as follows (in millions):


	Twelve Months Ended December 31,
	2024		2023		2022
Net sales	$	730.7	$	994.8	$	918.4
Cost of sales	276.8		401.4		356.7
Gross profit	453.9		593.4		561.7
Selling, general, and administrative expenses	169.0		242.1		210.0
Research and development expenses	82.2		108.9		101.6


Separation costs and other	221.8		17.2		—

Operating (loss) income, net	(19.1)		225.2		250.1


Other non-operating (income) expense, net	(3,348.3)		(0.5)		2.2
Income from discontinued operations before provision for income taxes	3,329.2		225.7		247.9
Provision for income taxes from discontinued operations	555.5		46.3		50.0
Net income from discontinued operations	2,773.7		179.4		197.9

Separation costs primarily related to consulting, legal, tax, and other professional advisory services associated with the sale of Critical Care.

Details of assets and liabilities of discontinued operations are as follows (in millions):


	As of December 31,
	2024		2023
Cash and cash equivalents	$	9.6	$	11.7

Accounts receivable, net of allowances	—		3.6
Other receivables	—		5.2
Inventories	15.1		264.7
Prepaid expenses	2.1		18.0
Other current assets	—		14.4
Total current assets of discontinued operations	$	26.8	$	317.6

Property, plant, and equipment, net	3.4		158.4
Operating lease right-of-use assets	—		9.6
Goodwill	7.4		108.4
Other intangible assets, net	—		29.0
Deferred income taxes	—		5.2
Other assets	—		0.5
Total non-current assets of discontinued operations	$	10.8	$	311.1
Accounts payable	$	—	$	14.8
Accrued and other liabilities	2.0		112.7
Operating lease liabilities	—		2.0
Total current liabilities of discontinued operations	$	2.0	$	129.5



Operating lease liabilities	—		7.8
Uncertain tax positions	—		4.3

Other liabilities	—		13.0
Total non-current liabilities of discontinued operations	$	—	$	25.1

Cash flows attributable to the Company's discontinued operations are included in the Company's consolidated statements of cash flows. Significant non-cash operating and investing activities attributable to discontinued operations consisted of the following (in millions):


	Years Ended December 31,
	2024	2023	2022
Depreciation and amortization	12.0	22.9	22.7
Stock-based compensation	16.8	14.6	13.1
Inventory write off	8.2	23.5	6.2
Capital expenditures	16.6	35.4	36.3

OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS

12 Months Ended

Dec. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS

Composition of Certain Financial Statement Captions

Components of selected captions in the consolidated balance sheets are as follows (in millions):


	As of December 31,
	2024		2023
Inventories
Raw materials	$	241.1	$	196.3
Work in process	236.2		195.8
Finished products	609.4		511.4
	$	1,086.7	$	903.5
Property, plant, and equipment, net
Land	$	123.9	$	112.4
Buildings and leasehold improvements	1,339.8		1,189.0
Machinery and equipment	689.4		618.6

Software	83.4		77.1
Construction in progress	244.0		292.5
	2,480.5		2,289.6
Accumulated depreciation	(794.5)		(698.6)
	$	1,686.0	$	1,591.0
Other assets
Tax receivable (Note 19)	$	293.9	$	—
Notes and other receivables	129.3		155.1
Acquisition options	147.1		161.3
Long-term prepaid royalties	101.6		109.9
Fair value of derivatives	34.7		23.4
Other long-term assets	15.0		13.5
	$	721.6	$	463.2
Accrued and other liabilities
Employee compensation and withholdings	$	358.6	$	316.4
Accrued rebates	139.3		123.5
Property, payroll, and other taxes	88.1		53.8
Research and development accruals	74.1		71.6
Legal and insurance (Notes 3 and 20)	26.8		28.9
Litigation settlement	73.8		69.1
Taxes payable	286.6		52.7
Fair value of derivatives	8.3		15.2
Accrued marketing expenses	13.8		13.7
Accrued professional services	20.1		8.5
Accrued realignment reserves	27.4		6.4
Accrued relocation costs	15.4		16.9

Unfavorable contract liability	53.7		—
Other accrued liabilities	96.4		79.7
	$	1,282.4	$	856.4

Supplemental Cash Flow Information

(in millions)


	Years Ended December 31,
	2024		2023		2022
Cash paid during the year for:
Interest	$	19.6	$	19.9	$	19.3
Income taxes (a) (Note 19)	$	1,196.1	$	470.1	$	504.1
Amounts included in the measurement of operating lease liabilities	$	28.0	$	25.7	$	25.0
Non-cash investing and financing transactions:


Right-of-use assets obtained in exchange for new lease liabilities	$	42.8	$	27.3	$	23.4
Capital expenditures accruals	$	44.1	$	43.6	$	41.0

______________________________________

(a) Includes cash paid for income taxes from discontinued operations of $29.7 million, $25.2 million, and $37.4 million for the years ended December 31, 2024, 2023, and 2022, respectively.

Cash, Cash Equivalents, and Restricted Cash

(in millions)


	Years Ended December 31,
	2024		2023		2022
Continuing operations
Cash and cash equivalents	$	3,045.2	$	1,132.3	$	761.5
Restricted cash included in other current assets	3.2		3.3		0.5
Restricted cash included in other assets	0.8		0.7		3.1
Total	$	3,049.2	$	1,136.3	$	765.1
Discontinued operations
Cash and cash equivalents	$	9.6	$	11.7	$	7.5
Total	$	9.6	$	11.7	$	7.5
Total cash, cash equivalents, and restricted cash	$	3,058.8	$	1,148.0	$	772.6

Amounts included in restricted cash primarily represent funds placed in escrow related to litigation.

LEASES

12 Months Ended

Dec. 31, 2024

Leases [Abstract]

LEASES

The Company leases certain office space, manufacturing facilities, land, apartments, warehouses, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 16 years, some of which include options to extend or terminate the leases.

Operating lease costs for the years ended December 31, 2024, 2023, and 2022 were $28.1 million, $26.9 million, and $25.6 million, respectively. Short-term and variable lease costs were not material for the years ended December 31, 2024, 2023, and 2022.

Supplemental balance sheet information related to operating leases was as follows (in millions, except lease term and discount rate):


	As of December 31,
	2024		2023
Operating lease right-of-use assets	$	98.2	$	84.4

Operating lease liabilities, current portion	$	23.4	$	22.9
Operating lease liabilities, long-term portion	78.9		65.2
Total operating lease liabilities	$	102.3	$	88.1

Maturities of operating lease liabilities at December 31, 2024 were as follows (in millions):


2025	$	26.4
2026	23.3
2027	19.1
2028	13.2
2029	8.4
Thereafter	23.8
Total lease payments	114.2
Less: imputed interest	(11.9)
Total lease liabilities	$	102.3

The following table provides information on the lease terms and discount rates:


	Years Ended December 31,
	2024		2023
Weighted-average remaining lease term (in years)	5.9		5.8
Weighted-average discount rate	3.4	%	2.3	%

As of December 31, 2024, the Company had additional operating lease commitments of $1.7 million for office spaces that have not yet commenced.

INVESTMENTS

12 Months Ended

Dec. 31, 2024

Investments, Debt and Equity Securities [Abstract]

INVESTMENTS

Debt Securities

Investments in debt securities at the end of each period were as follows (in millions):


	December 31, 2024								December 31, 2023
Held-to-maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Bank time deposits	$	57.9	$	—	$	—	$	57.9	$	64.5	$	—	$	—	$	64.5








Available-for-sale
Bank time deposits	$	13.9	$	—	$	—	$	13.9	$	—	$	—	$	—	$	—
Commercial paper	236.5		—		—		236.5		—		—		—		—
U.S. government and agency securities	238.1		0.1		(1.1)		237.1		72.7		0.1		(2.8)		70.0

Asset-backed securities	70.2		—		(1.4)		68.8		192.1		—		(7.8)		184.3
Corporate debt securities	465.0		0.1		(2.8)		462.3		658.5		—		(16.7)		641.8
Municipal securities	2.7		—		—		2.7		2.8		—		(0.2)		2.6
	$	1,026.4	$	0.2	$	(5.3)	$	1,021.3	$	926.1	$	0.1	$	(27.5)	$	898.7

The cost and fair value of investments in debt securities, by contractual maturity, as of December 31, 2024 were as follows:


	Held-to-Maturity				Available-for-Sale
	Amortized Cost		Fair Value		Amortized Cost		Fair Value
	(in millions)
Due in 1 year or less	$	57.9	$	57.9	$	874.0	$	872.8
Due after 1 year through 5 years	—		—		64.3		62.8


Instruments not due at a single maturity date (a)	—		—		88.1		85.7
	$	57.9	$	57.9	$	1,026.4	$	1,021.3

_______________________________________

(a) Consists of mortgage-backed and asset-backed securities.

Actual maturities may differ from the contractual maturities due to call or prepayment rights.

The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2024 and 2023, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in millions):



	December 31, 2024
	Less than 12 Months				12 Months or Greater				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses


U.S. government and agency securities	$	—	$	—	$	19.9	$	(1.1)	$	19.9	$	(1.1)

Asset-backed securities	8.4		(0.1)		53.3		(1.3)		61.7		(1.4)
Corporate debt securities	—		—		141.0		(2.8)		141.0		(2.8)

	$	8.4	$	(0.1)	$	214.2	$	(5.2)	$	222.6	$	(5.3)



	December 31, 2023
	Less than 12 Months				12 Months or Greater				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses


U.S. government and agency securities	$	—	$	—	$	67.1	$	(2.8)	$	67.1	$	(2.8)

Asset-backed securities	10.2		(1.8)		172.7		(6.0)		182.9		(7.8)
Corporate debt securities	25.0		(0.1)		601.3		(16.6)		626.3		(16.7)
Municipal securities	—		—		2.6		(0.2)		2.6		(0.2)
	$	35.2	$	(1.9)	$	843.7	$	(25.6)	$	878.9	$	(27.5)

The Company reviews its investments in debt securities to determine if there has been an other-than-temporary decline in fair value. Consideration is given to (1) the financial condition and near-term prospects of the issuer, including the credit quality of the security's issuer, (2) the Company's intent to sell the security, and (3) whether it is more likely than not the Company will have to sell the security before recovery of its amortized cost. The unrealized losses on the debt securities were largely due to changes in interest rates, not credit quality, and as of December 31, 2024, the Company did not intend to sell the securities, and it was not more likely than not that it will be required to sell the securities before recovery of the unrealized losses, and, therefore, the unrealized losses are considered temporary.

Investments in Unconsolidated Entities

The Company has a number of equity investments in unconsolidated entities. These investments are recorded in Long-term Investments on the consolidated balance sheets, and are as follows:


	December 31,
	2024		2023
	(in millions)
Equity method investments
Carrying value of equity method investments	$	34.8	$	33.6
Equity securities
Carrying value of marketable equity securities	5.5		—
Carrying value of non-marketable equity securities	119.1		87.6
Total investments in unconsolidated entities	$	159.4	$	121.2

The Company makes equity investments in limited liability companies that invest in qualified community development entities through the New Markets Tax Credit ("NMTC") program. The NMTC program provides federal tax incentives to investors to make investments in distressed communities and promotes economic improvements through the development of successful businesses in these communities. The NMTC is equal to 39% of the qualified investment and is taken over seven years. These limited liability companies are VIEs. The Company determined that it is not the primary beneficiary of the VIEs because it does not have the power to direct the activities that most significantly impact the economic performance of the VIEs, and, therefore, the Company does not consolidate these entities. Instead, the NMTC investments are accounted for as equity method investments.

Marketable equity securities consist of investments with readily determinable fair values over which we do not own a

controlling interest or exercise significant influence. Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values, and are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. During 2024, the Company recorded an upward adjustment of $0.5 million and a downward adjustment of $3.1 million due to observable price changes. During 2023, the Company did not record any upward or downward adjustments due to observable price changes or impairments. As of December 31, 2024, the Company had recorded cumulative upward adjustments of $9.3 million based on observable price changes, and cumulative downward adjustments of $6.2 million due to impairments and observable price changes.

During 2024, 2023, and 2022, the gross realized gains or losses from sales of available-for-sale investments were not material.

INVESTMENTS IN VARIABLE INTEREST ENTITIES	12 Months Ended
INVESTMENTS IN VARIABLE INTEREST ENTITIES	Dec. 31, 2024
Variable Interest Entities [Abstract]
INVESTMENTS IN VARIABLE INTEREST ENTITIES	INVESTMENTS IN VARIABLE INTEREST ENTITIES The Company reviews its investments in other entities to determine whether the Company is the primary beneficiary of a VIE. The Company would be the primary beneficiary of the VIE, and would be required to consolidate the VIE, if it has the power to direct the significant activities of the entity and the obligation to absorb losses or receive benefits from the entity that may be significant to the VIE. The Company's maximum loss exposure to VIEs, prior to the exercise of options to acquire the entities, is limited to its investment in the VIEs, which include equity investments, options to acquire, and promissory notes. Consolidated VIEs In February 2023, the Company acquired a majority equity interest in a medical technology company pursuant to a preferred stock purchase agreement, and amended and restated a previous option agreement to acquire the remaining equity interest. Edwards concluded that it is the primary beneficiary and consolidated the VIE. The total assets and liabilities of the Company's consolidated VIE was $252.3 million and $24.3 million, respectively, as of December 31, 2024, and were $272.1 million and $31.5 million, respectively, as of December 31, 2023. The assets of the VIE can only be used to settle obligations of the VIE and general creditors have no recourse to the Company. Unconsolidated VIEs Edwards has relationships with various VIEs that it does not consolidate as Edwards lacks the power to direct the activities that significantly impact the economic success of these entities. In December 2024, the Company entered into an option agreement and an amended preferred stock purchase agreement with a medical technology company. The Company had previously made an investment in preferred stock of the medical technology company under the prior preferred stock purchase agreement dated in 2021. Under the option agreement, Edwards paid $30.0 million and agreed to pay up to an additional $10.0 million of milestone-based consideration for an option to acquire the medical technology company. As of December 31, 2024 and 2023, the Company had invested $20.0 million and $5.0 million, respectively, in the medical technology company's preferred equity securities (included in Long-term Investments). In addition, the Company agreed to loan the medical technology company up to $40.0 million upon the medical technology company's achievement of a certain clinical trial milestone. In July 2024, the Company entered into an agreement and plan of merger to acquire JenaValve Technology, Inc. ("JenaValve"). Concurrently, the Company entered into a promissory note agreement to loan JenaValve up to $75.0 million should the merger not close within 90 days, amongst certain other conditions. As of December 31, 2024, the Company had advanced $15.0 million under the note agreement (included in Other Assets on the consolidated balance sheets), and had advanced an additional $10.0 million through February 2025. In August 2022, the Company entered into an option agreement with a medical device company. Under the option agreement, Edwards paid $47.1 million for an option to acquire the medical device company. The $47.1 million option is included in Other Assets on the consolidated balance sheets. In June 2022, the Company entered into a convertible promissory note and amended its existing warrant agreement with a medical device company. Under the convertible promissory note agreement, the Company agreed to loan the medical device company up to $47.5 million, all of which had been advanced as of December 31, 2024. In addition, in 2019, the Company paid $35.0 million for an option to acquire the medical device company. The $35.0 million option and the $47.5 million note receivable are included in Other Assets on the consolidated balance sheets. In April 2021, the Company entered into a promissory note agreement, a preferred stock purchase agreement, and an option agreement with a privately-held medical device company (the "Investee"). The secured promissory note provides for borrowings up to $45.0 million. At both December 31, 2024 and December 31, 2023, the Company had advanced $45.0 million and $30.0 million, respectively, under the promissory note (included in Other Assets). As of December 31, 2024 and 2023, the Company had invested $42.8 million and $39.3 million, respectively, in the Investee's preferred equity securities (included in Long-term Investments), and had paid $20.9 million and $13.1 million, respectively, for an option to acquire the Investee (included in Other Assets). Pursuant to the agreement, the Company may be required to invest up to an additional $3.0 million in the Investee's preferred equity securities and up to an additional $6.6 million for the option to acquire the Investee. In addition, Edwards has made equity investments through the NMTC program in limited liability companies that are considered VIEs. For further information, see Note 8.

BUSINESS COMBINATIONS

12 Months Ended

Dec. 31, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

BUSINESS COMBINATIONS

Innovalve Bio Medical Ltd.

On October 1, 2024, the Company acquired all the remaining outstanding shares of Innovalve Bio Medical Ltd.

("Innovalve"). Innovalve is a developer of a minimally-invasive, catheterization-based procedure, to perform replacement of the mitral valve. The acquisition was completed primarily to expand the Company's transcatheter mitral valve replacement technologies to address large unmet structural heart patient needs and support sustainable long-term growth.

Prior to the acquisition date, the Company had previously paid $30.0 million for an option to acquire Innovalve, which was historically recorded in Other Assets using the measurement alternative for fair value, and had an existing preferred stock investment in Innovalve of $3.5 million, which represented an ownership interest in Innovalve of approximately 4% (collectively, the "previously held equity interest in Innovalve"). In July 2024, the Company exercised its option to acquire the remaining equity interest in Innovalve, which was accounted for as a step acquisition at the time of closing in accordance with Accounting Standards Codification Topic 805, "Business Combinations." Accordingly, the Company allocated the purchase price of the acquired company to the net tangible assets and intangible assets acquired based upon their preliminary estimated fair values. The Company remeasured the previously held equity interest in Innovalve to its fair value based upon a valuation of the acquired business, as of the date of acquisition. The Company considered multiple factors in determining the fair value of the previously held equity interest in Innovalve, including, (i) the price negotiated with the selling shareholders for the remaining 96% interest in Innovalve and (ii) an income approach valuation model. As a result of the remeasurement of the previously held equity interest in Innovalve, the Company recognized a gain of $30.5 million in Other Non-operating Income, net in the fourth quarter of 2024.

The purchase consideration for the acquisition of Innovalve was $380.9 million, which consisted of cash consideration of $298.2 million (net of cash acquired of $21.1 million), the fair value of the Company's previously held equity interest in Innovalve of $64.6 million, the settlement of pre-existing relationships of $5.4 million, and the fair value of contingent

consideration of $12.7 million relating to the Company's agreement to pay up to an additional $25.0 million in a pre-specified milestone-driven payment that is dependent on the receipt of pre-market approval from the United States Food and Drug Administration for a class III medical device on or prior to the five-year anniversary of the acquisition date. The Company recognized a $12.7 million contingent consideration liability for the estimated fair value of the contingent milestone payment. The fair value of the contingent milestone payment will be remeasured each quarter, with changes in the fair value recognized within operating expenses on the consolidated statements of operations.

In connection with the acquisition of Innovalve, the Company placed $34.6 million of the cash consideration paid at closing into escrow to satisfy any claims for indemnification made in accordance with the merger agreement and for purchase price adjustments. Acquisition-related costs of $2.3 million were recorded in Selling, General, and Administrative Expenses during the year ended December 31, 2024.

The following table summarizes the fair value of consideration transferred and the fair values of the assets acquired and liabilities assumed (in millions):


Cash consideration paid at closing	$	319.3
Settlement of pre-existing relationships	5.4
Fair value of previously held equity interest in Innovalve	64.6
Fair value of contingent consideration	12.7
Total purchase price	402.0
Less: cash acquired	(21.1)
Total purchase price, net of cash acquired	$	380.9

Current assets	$	26.5
Property and equipment, net	1.2
Goodwill	205.4
In-process research and development	218.4




Liabilities assumed	(8.2)
Deferred tax liabilities	(41.3)
Net assets acquired	402.0
Less: cash acquired	(21.1)
Total purchase price, net of cash acquired	$	380.9

The above purchase price allocation is preliminary and subject to revision for a one-year measurement period following the date of acquisition as additional information about the fair value of individual assets and liabilities becomes available. The preliminary measurement of intangible assets, goodwill, and deferred income taxes are subject to change. A change in the estimated fair value of the net assets acquired will change the amount of the purchase price allocable to goodwill.

Goodwill includes Innovalve's assembled workforce and expected synergies the Company believes will result from the acquisition. Additionally, goodwill reflects the value attributed to future iterations of the in-process research and development ("IPR&D"), potential future technologies, and future customer relationships. Goodwill was assigned to the Company’s Rest of World segment and is not deductible for tax purposes. IPR&D has been capitalized at fair value as an intangible asset with an indefinite life and will be assessed for impairment in subsequent periods. The fair value of the IPR&D was determined using the income approach. This approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return. The discount rate used to determine the fair value of the IPR&D was 10.5%, which was developed considering the technical and feasibility risk present in Innovalve's forecast. Completion of successful design developments, bench testing, pre-clinical studies and human clinical studies are required prior to selling any product. The risks and uncertainties associated with completing development within a reasonable period of time include those related to the design, development, and manufacturability of the product, the success of pre-clinical and clinical studies, and the timing of regulatory approvals. The valuation assumed $74.3 million of additional research and development expenditures would be

incurred prior to the date of product introduction. In the valuation, net cash inflows were modeled to commence in the United States in 2028, Europe in 2029, and Japan in 2030. Upon completion of development, the underlying research and development asset will be amortized over its estimated useful life.

The results of operations for Innovalve have been included in the accompanying consolidated financial statements from the date of acquisition. Pro forma results have not been presented as the results of Innovalve are not material in relation to the consolidated financial statements of Edwards Lifesciences.

Endotronix, Inc.

On August 19, 2024, the Company acquired all the remaining outstanding shares of Endotronix, Inc. ("Endotronix"). Endotronix is a developer of an implantable sensor for management of heart failure patients. The acquisition was completed primarily to expand the Company's structural heart portfolio into a new therapeutic area to address the large unmet needs of patients suffering from heart failure.

Prior to the acquisition date, the Company had previously paid $60.0 million for an option to acquire Endotronix, which was historically recorded in Other Assets using the measurement alternative for fair value, and had an existing preferred stock investment in Endotronix of $10.0 million, which represented an ownership interest in Endotronix of approximately 7% (collectively, the "previously held equity interest in Endotronix"). In July 2024, the Company exercised its option to acquire the remaining equity interest in Endotronix which was accounted for as a step acquisition in accordance with Accounting Standards Codification Topic 805, "Business Combinations." Accordingly, the Company allocated the purchase price of the acquired company to the net tangible assets and intangible assets acquired based upon their preliminary estimated fair values. The Company remeasured the previously held equity interest in Endotronix to its fair value, as of the date of acquisition. The Company considered multiple factors in determining the fair value of the previously held equity interest in Endotronix, including, (i) the price negotiated with the selling shareholders for the remaining 93% interest in Endotronix and (ii) an income approach valuation model. As a result of the remeasurement of the previously held equity interest in Endotronix, the Company recognized a gain of $24.6 million in Other income, net in the third quarter of 2024.

The purchase consideration for the acquisition of Endotronix was $798.8 million, which consisted of cash consideration of $649.1 million (net of cash acquired of $1.2 million), the fair value of the Company's previously held equity interest in Endotronix of $94.6 million, and the settlement of pre-existing relationships of $53.1 million. In addition, the Company agreed to pay an additional $2.0 million in a pre-specified milestone-driven payment that is dependent on the receipt of CE Mark approval for the CorPASS before June 30, 2025. The Company recognized a $2.0 million contingent consideration liability for the estimated fair value of the contingent milestone payment. The fair value of the contingent milestone payment will be remeasured each quarter, with changes in the fair value recognized within operating expenses on the consolidated statements of operations.

In connection with the acquisition of Endotronix, the Company placed $35.0 million of the cash consideration paid at closing into escrow to satisfy any claims for indemnification made in accordance with the merger agreement and for purchase price adjustments. Acquisition-related costs of $6.0 million were recorded in Selling, General, and Administrative Expenses during the year ended December 31, 2024.

The following table summarizes the fair value of consideration transferred and the fair values of the assets acquired and liabilities assumed (in millions):


Cash consideration paid at closing	$	650.3
Settlement of pre-existing relationships	53.1
Fair value of previously held equity interest in Endotronix	94.6
Fair value of contingent consideration	2.0
Total purchase price	800.0
Less: cash acquired	(1.2)
Total purchase price, net of cash acquired	$	798.8

Current assets	$	7.7
Property and equipment, net	12.6
Goodwill	382.8
In-process research and development	68.9
Developed technology	388.9
Operating lease right-of-use assets	9.9

Other assets	0.7
Liabilities assumed	(26.3)
Deferred tax liabilities	(45.2)
Net assets acquired	800.0
Less: cash acquired	(1.2)
Total purchase price, net of cash acquired	$	798.8

The above purchase price allocation is preliminary and subject to revision for a one-year measurement period following the date of acquisition as additional information about the fair value of individual assets and liabilities becomes available. The preliminary measurement of intangible assets, goodwill, and deferred income taxes are subject to change. A change in the estimated fair value of the net assets acquired will change the amount of the purchase price allocable to goodwill.

Goodwill includes Endotronix's assembled workforce and expected synergies the Company believes will result from the acquisition. Goodwill was assigned to the Company’s United States segment and is not deductible for tax purposes. The fair value of the developed technology was determined using the income approach. This approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return. The discount rate used to determine the fair value of the developed technology was 15.5%. The fair value of the IPR&D was also determined using the income approach. IPR&D has been capitalized at fair value as an intangible asset with an indefinite life and will be assessed for impairment in subsequent periods. The discount rate used to determine the fair value of the IPR&D was 18.0%. Completion of successful design developments, bench testing, pre-clinical studies and human clinical studies are required prior to selling any product. The risks and uncertainties associated with completing development within a reasonable period of time include those related to the design, development, and manufacturability of the product, the success of pre-clinical and clinical studies, and the timing of regulatory approvals. The valuation assumed $47.1 million of additional research and development expenditures would be incurred prior to the date of product introduction. In the valuation, net cash inflows were modeled to commence in the United States in 2027 and in Japan and Europe in 2028. Upon completion of development, the underlying research and development asset will be amortized over its estimated useful life.

The results of operations for Endotronix have been included in the accompanying consolidated financial statements from the date of acquisition. Pro forma results have not been presented as the results of Endotronix are not material in relation to the consolidated financial statements of Edwards Lifesciences.

JC Medical, Inc.

On July 22, 2024, the Company acquired all the outstanding shares of JC Medical, Inc. ("JC Medical") for purchase consideration of $116.3 million, net of cash acquired. In addition, the Company agreed to pay up to an additional $200.0 million in pre-specified milestone-driven payments over the next 12 years. The Company recognized a $1.8 million contingent consideration liability for the estimated fair value of the contingent milestone payments. The fair value of the contingent milestone payments will be remeasured each quarter, with changes in the fair value recognized within operating expenses on the consolidated statements of operations.

The Company placed $12.0 million of the cash consideration paid at closing into escrow to satisfy any claims for indemnification made in accordance with the merger agreement. Any funds remaining 15 months after the acquisition date will be disbursed to JC Medical's former shareholders. Acquisition-related costs of $1.6 million were recorded in Selling, General, and Administrative Expenses during the twelve months ended December 31, 2024.

JC Medical is a structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart disease. The acquisition was completed primarily to expand the Company's TAVR technologies to enable the treatment of patients with aortic regurgitation. The acquisition was accounted for as a business combination. Tangible and intangible assets acquired were recorded based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair value of net assets acquired was recorded to goodwill.

The following table summarizes the fair value of consideration transferred and the fair values of the assets acquired and liabilities assumed (in millions):


Cash consideration paid at closing	$	114.8


Fair value of contingent consideration	1.8
Total purchase price	116.6
Less: cash acquired	(0.3)
Total purchase price, net of cash acquired	$	116.3

Current assets	$	0.3
Property and equipment, net	0.3
Goodwill	46.4
In-process research and development	86.6




Current liabilities assumed	(1.0)
Deferred tax liabilities	(16.0)
Net assets acquired	116.6
Less: cash acquired	(0.3)
Total purchase price, net of cash acquired	$	116.3

The above purchase price allocation is preliminary and subject to revision for a one-year measurement period following the date of acquisition as additional information about the fair value of individual assets and liabilities becomes available. The preliminary measurement of intangible assets, goodwill, and deferred income taxes are subject to change. A change in the estimated fair value of the net assets acquired will change the amount of the purchase price allocable to goodwill.

Goodwill includes JC Medical's assembled workforce and expected synergies the Company believes will result from the acquisition. Goodwill was assigned to the Company’s United States segment and is not deductible for tax purposes. IPR&D has been capitalized at fair value as an intangible asset with an indefinite life and will be assessed for impairment in subsequent periods. The fair value of the IPR&D was determined using the income approach. This approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return. The discount rate used to determine the fair value of the IPR&D was 15.0%. Completion of successful design developments, bench testing, pre-clinical

studies and human clinical studies are required prior to selling any product. The risks and uncertainties associated with completing development within a reasonable period of time include those related to the design, development, and manufacturability of the product, the success of pre-clinical and clinical studies, and the timing of regulatory approvals. The valuation assumed $55.8 million of additional research and development expenditures would be incurred prior to the date of product introduction. In the valuation, net cash inflows were modeled to commence in the United States in 2028 and Europe in 2029. Upon completion of development, the underlying research and development asset will be amortized over its estimated useful life.

The results of operations for JC Medical have been included in the accompanying consolidated financial statements from the date of acquisition. Pro forma results have not been presented as the results of JC Medical are not material in relation to the consolidated financial statements of Edwards Lifesciences.

Other Acquisition

On February 28, 2023, the Company acquired 61% of the then outstanding shares of a medical technology company in an all-cash transaction. The Company determined it was the primary beneficiary of this VIE, and the VIE has been consolidated in the Company's consolidated financial statements. In addition, the Company amended and restated its previous option agreement with the medical technology company. The option agreement gives Edwards the option to acquire the remaining equity interest in the medical technology company.

The medical technology company is dedicated to developing technologies for detecting and managing patients with cardiovascular disease. The transaction was accounted for as a business combination. Tangible and intangible assets and liabilities acquired were recorded based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair value of net assets acquired was recorded to goodwill. The following table summarizes the fair values of the assets acquired and liabilities assumed (in millions):


Assets	$	8.1

Goodwill (b)	133.2


In-process research and development	136.6


Liabilities assumed	(1.7)
Deferred tax liabilities	(28.0)
Fair value of net assets acquired	248.2
Less: Noncontrolling interest (a)	(72.4)
Total purchase price	175.8
Less: cash acquired	(6.8)
Total purchase price, net of cash acquired (b)	$	169.0

_______________________________________

(a) Includes the fair value of the noncontrolling interest of $94.4 million, offset by the purchase consideration allocated to the option of $22.0 million, which was ascribed to the noncontrolling interest.

(b) Includes $22.5 million paid in a previous year under option agreements, $5.3 million for the settlement of a pre-existing note, and $46.0 million of cash paid directly to the acquired company which was included in Edwards' consolidated cash balance and offset against goodwill post acquisition.

Goodwill includes expected synergies and other benefits the Company believes will result from the acquisition. Goodwill was assigned to the Company’s Rest of World segment and is not deductible for tax purposes.

Pro forma results have not been presented as the results of the medical technology company are not material in relation to the consolidated financial statements of Edwards Lifesciences.

The valuation for the medical technology company assumed $68.6 million of additional research and development expenditures would be incurred prior to the date of product introduction and net cash inflows were modeled to commence in the United States and Europe in 2028 and in Japan in 2029. The Company does not currently anticipate significant changes to forecasted research and development expenditures or in the timing of net cash inflows. Upon completion of development, the underlying in-process research and development asset will be amortized over its estimated useful life. Upon completion of development, the underlying research and development asset will be amortized over its estimated useful life.

GOODWILL AND OTHER INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill and in-process research and development assets resulting from purchase business combinations are not subject to amortization. Other acquired intangible assets with finite lives are amortized over their expected useful lives on a straight-line basis, or if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be used. The Company expenses costs incurred to renew or extend the term of acquired intangible assets.

The changes in the carrying amount of goodwill, by segment, during the years ended December 31, 2024 and 2023 were as follows:


	United States		Europe		Rest of World		Total
	(in millions)
Goodwill at December 31, 2022	$	710.7	$	56.3	$	297.8	$	1,064.8
Goodwill acquired during the year	—		—		78.4		78.4
Currency translation adjustment	—		1.9		—		1.9
Goodwill at December 31, 2023	710.7		58.2		376.2		1,145.1
Goodwill acquired during the year (Note 10)	429.2		—		205.4		634.6
Currency translation adjustment	—		(3.0)		—		(3.0)
Goodwill at December 31, 2024	$	1,139.9	$	55.2	$	581.6	$	1,776.7

Other intangible assets consist of the following (in millions):


		December 31,
	Weighted-Average Useful Life (in years)	2024						2023
		Cost		Accumulated Amortization		Net Carrying Value		Cost		Accumulated Amortization		Net Carrying Value
Finite-lived intangible assets
Patents	10.0	$	138.8	$	(90.5)	$	48.3	$	119.0	$	(87.3)	$	31.7
Developed technology	12.2	665.2		(47.4)		617.8		155.8		(45.7)		110.1
Other	0.0	3.4		(3.4)		—		3.5		(3.5)		—
	12.1	807.4		(141.3)		666.1		278.3		(136.5)		141.8
Indefinite-lived intangible assets
In-process research and development		510.5		—		510.5		257.6		—		257.6
		$	1,317.9	$	(141.3)	$	1,176.6	$	535.9	$	(136.5)	$	399.4

Amortization expense related to other intangible assets for the years ended December 31, 2024, 2023, and 2022 was $5.6 million, $2.2 million, and $2.3 million, respectively. Estimated amortization expense for each of the years ending December 31 is as follows (in millions):


2025	$	9.8
2026	19.1
2027	33.0
2028	56.8
2029	81.3

DEBT AND CREDIT FACILITIES

12 Months Ended

Dec. 31, 2024

Debt Disclosure [Abstract]

DEBT AND CREDIT FACILITIES

In June 2018, the Company issued $600.0 million of fixed-rate unsecured senior notes (the "Notes") due June 15, 2028. Interest is payable semi-annually in arrears, with payments due in June and December of each year. The Company may redeem the Notes, in whole or in part, at any time and from time to time at specified redemption prices. In addition, upon the occurrence of certain change of control triggering events, the Company may be required to repurchase all or a portion of the Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest. The Notes also include covenants that limit the Company's ability to incur secured indebtedness, enter into sale and leaseback transactions, and consolidate, merge, or transfer all or substantially all of its assets.

The following is a summary of the Notes as of December 31, 2024 and 2023:


	December 31,
	2024				2023
	Amount		Effective Interest Rate		Amount		Effective Interest Rate
	(in millions)				(in millions)
Fixed-rate 4.3% Notes	$	600.0	4.329	%	$	600.0	4.329	%


Unamortized discount	(0.5)				(0.7)
Unamortized debt issuance costs	(1.8)				(2.3)

Total carrying amount	$	597.7			$	597.0

As of December 31, 2024 and 2023, the fair value of the Notes was $587.5 million and $591.6 million, respectively, based on observable market prices in less active markets and categorized as Level 2. For further information, see Note 13). The debt issuance costs, as well as the discount, are being amortized to interest expense over the term of the Notes.

The Company has a Five-Year Credit Agreement ("the Credit Agreement") that provides for a $750.0 million multi-currency unsecured revolving credit facility and matures on July 15, 2027. Subject to certain terms and conditions and the agreement of the lenders, the Company may increase the amount available under the Credit Agreement by up to an additional $250.0 million in the aggregate and extend the maturity date for an additional year. Borrowings under the Credit Agreement bear interest at a variable rate based on the Secured Overnight Financing Rate ("SOFR"), plus a spread ranging from 0.785% to 1.3%, depending on the leverage ratio or credit rating, as defined in the Credit Agreement, plus a 0.1% credit spread adjustment. The Company will also pay a facility fee ranging from 0.09% to 0.20%, depending on the Company's leverage ratio or credit rating, on the entire credit commitment available, whether or not drawn. The facility fee is expensed as incurred. During 2024, under the Credit Agreement, the spread over SOFR was 0.9% and the facility fee was 0.1%. Issuance costs of $2.1 million are being amortized to interest expense over the term of the Credit Agreement. As of December 31, 2024 and 2023, there were no borrowings outstanding. Amounts outstanding under the Credit Agreement, if any from time to time, are classified as long-term obligations in accordance with the terms of the Credit Agreement. The Credit Agreement is unsecured and contains various financial and other covenants, including a maximum leverage ratio, as defined in the Credit Agreement. The Company was in compliance with all covenants under the Credit Agreement at December 31, 2024.

The weighted-average interest rate under all debt obligations, including the impact of the cross currency swap contract (see Note 14), was 3.4% at both December 31, 2024 and 2023.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2024

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Company prioritizes the inputs used to determine fair values in one of the following three categories:

Level 1—Quoted market prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than quoted prices in active markets, that are observable, either directly or indirectly.

Level 3—Unobservable inputs that are not corroborated by market data.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety.

The consolidated financial statements include financial instruments for which the fair market value of such instruments may differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, accounts and other receivables, investments, accounts payable, certain accrued liabilities, and borrowings under a revolving credit agreement. The carrying value of these financial instruments generally approximates fair value due to their short-term nature. Financial instruments also include Notes payable. See Note 12 for further information on the fair value of the Notes payable.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes the Company's financial instruments which are measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in millions):


December 31, 2024	Level 1		Level 2		Level 3		Total
Assets
Cash equivalents	$	1,394.4	$	985.5	$	—	$	2,379.9
Available-for-sale investments:
Bank time deposits	—		13.9		—		13.9
Corporate debt securities	—		462.3		—		462.3
Asset-backed securities	—		68.8		—		68.8
United States government and agency securities	—		237.1		—		237.1

Commercial paper	—		236.5		—		236.5
Municipal securities	—		2.7		—		2.7
Equity investments in unconsolidated entities	5.5		—		—		5.5
Investments held for deferred compensation plans	146.6		—		—		146.6
Derivatives	—		82.1		—		82.1
	$	1,546.5	$	2,088.9	$	—	$	3,635.4
Liabilities
Derivatives	$	—	$	8.2	$	—	$	8.2

Contingent consideration liabilities	—		—		16.5		16.5
Other	—		—		5.0		5.0
	$	—	$	8.2	$	21.5	$	29.7

December 31, 2023
Assets
Cash equivalents	$	579.2	$	—	$	—	$	579.2
Available-for-sale investments:

Corporate debt securities	—		641.8		—		641.8
Asset-backed securities	—		184.3		—		184.3
United States government and agency securities	—		70.0		—		70.0


Municipal securities	—		2.6		—		2.6

Investments held for deferred compensation plans	125.8		—		—		125.8
Derivatives	—		39.5		—		39.5
	$	705.0	$	938.2	$	—	$	1,643.2
Liabilities
Derivatives	$	—	$	15.2	$	—	$	15.2


Other	—		—		10.3		10.3
	$	—	$	15.2	$	10.3	$	25.5

Cash Equivalents and Available-for-sale Investments

Cash equivalents included money market funds for the periods presented above. The Company estimates the fair values of its money market funds based on quoted prices in active markets for identical assets. The Company estimates the fair values of its corporate debt securities, asset-backed securities, commercial paper, United States and foreign government and agency securities, and municipal securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades and broker-dealer quotes on the same or similar securities, benchmark yields, credit spreads, prepayment and default projections based on historical data, and other observable inputs. The Company independently reviews and validates the pricing received from the third-party pricing service by comparing the prices to prices reported by a secondary pricing source. The Company’s validation procedures have not resulted in an adjustment to the pricing received from the pricing service.

Deferred Compensation Plans

The Company holds investments related to its deferred compensation plans. The fair values of these investments are in a variety of stock, bond, and money market mutual funds. The fair values of these investments are based on quoted market prices.

Derivative Instruments

The Company uses derivative financial instruments in the form of foreign currency forward exchange contracts and cross currency swap contracts to manage foreign currency exposures. All derivative instruments are recognized on the balance sheet at their fair value. Fair value was measured using quoted foreign exchange rates, interest rates, yield curves, and cross currency swap basis rates. The estimates presented herein are not necessarily indicative of the amounts that the Company could realize in a current market exchange.

Contingent Consideration Liabilities

Certain of the Company's acquisitions involve contingent consideration arrangements. Payment of additional consideration is contingent upon the acquired company reaching certain performance milestones, such as attaining specified sales levels or obtaining regulatory approvals. These contingent consideration liabilities are measured at estimated fair value using either a probability weighted discounted cash flow analysis or a Monte Carlo simulation model, both of which consider significant unobservable inputs. These inputs include (1) the discount rate used to calculate the present value of the projected cash flows (ranging from 0.0% to 11.8%; with a weighted average of 4.7%), (2) the probability of milestone achievement (ranging from 60% to 100%; with a weighted average of 64.8%), (3) the projected payment dates (ranging from 2025 to 2032; with a weighted average of 2028), and (4) the volatility of future revenue (27%). The weighted average of each of the above inputs was determined based on the relative fair value of each obligation. The use of different assumptions could have a material effect on the estimated fair value amounts.

The following table summarizes the changes in fair value of Level 3 financial instruments measured at fair value on a recurring basis for the years ended December 31, 2024 and 2023 (in millions):


	Contingent Consideration		Other		Total
Fair value, December 31, 2022	$	26.2	$	14.0	$	40.2


Changes in fair value	(26.2)		(3.7)		(29.9)

Fair value, December 31, 2023	$	—	$	10.3	$	10.3
Additions	16.5		—		16.5

Changes in fair value	—		(5.3)		(5.3)

Fair value, December 31, 2024	$	16.5	$	5.0	$	21.5

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

12 Months Ended

Dec. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

The Company uses derivative financial instruments to manage its currency exchange rate risk and its interest rate risk as summarized below. Notional amounts are stated in United States dollar equivalents at spot exchange rates at the respective dates. The Company does not enter into these arrangements for trading or speculation purposes.


	Notional Amount
	As of December 31,
	2024		2023
	(in millions)
Foreign currency forward exchange contracts	$	1,926.9	$	1,460.3
Cross currency swap contracts	300.0		300.0

The following table presents the location and fair value amounts of derivative instruments reported in the consolidated balance sheets (in millions):


		Fair Value
		As of December 31,
	Balance Sheet Location	2024		2023
Derivatives designated as hedging instruments
Assets
Foreign currency contracts	Other current assets	$	47.4	$	16.1

Cross currency swap contracts	Other assets	$	34.7	$	23.4

Liabilities
Foreign currency contracts	Accrued and other liabilities	$	6.4	$	15.2



Derivatives not designated as hedging instruments



Liabilities
Foreign currency contracts	Accrued and other liabilities	$	1.8	$	—

The following table presents the effect of master-netting agreements and rights of offset on the consolidated balance sheets (in millions):


							Gross Amounts Not Offset in the Consolidated Balance Sheet
			Gross Amounts Offset in the Consolidated Balance Sheet		Net Amounts Presented in the Consolidated Balance Sheet
December 31, 2024	Gross Amounts						Financial Instruments		Cash Collateral Received		Net Amount
Derivative Assets
Foreign currency contracts	$	47.4	$	—	$	47.4	$	(5.4)	$	—	$	42.0
Cross currency swap contracts	$	34.7	$	—	$	34.7	$	—	$	—	$	34.7
Derivative Liabilities
Foreign currency contracts	$	8.2	$	—	$	8.2	$	(5.4)	$	—	$	2.8

December 31, 2023
Derivative Assets
Foreign currency contracts	$	16.1	$	—	$	16.1	$	(9.4)	$	—	$	6.7
Cross currency swap contracts	$	23.4	$	—	$	23.4	$	—	$	—	$	23.4
Derivative Liabilities
Foreign currency contracts	$	15.2	$	—	$	15.2	$	(9.4)	$	—	$	5.8

The following table presents the effect of derivative and non-derivative hedging instruments on the consolidated statements of operations and consolidated statements of comprehensive income:


	Amount of Gain or (Loss) Recognized in Other Comprehensive Income on Derivative (Effective Portion)
	2024		2023
Cash flow hedges
Foreign currency contracts	$	83.8	$	29.2
Net investment hedges
Cross-currency swap contracts	$	11.3	$	(17.3)

The cross currency swap contracts have an expiration date of June 15, 2028. At maturity of the cross currency swap contracts, the Company will deliver the notional amount of €257.2 million and will receive $300.0 million from the counterparties. The Company receives semi-annual interest payments from the counterparties based on a fixed interest rate until maturity of the agreements.

The following tables present the effect of fair value and cash flow hedge accounting on the consolidated statements of operations:


	Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships
	Year Ended December 31, 2024
	Cost of sales		Interest income, net		Other non-operating income, net

Total amounts presented in the consolidated statements of operations	$	(1,117.5)	$	(19.8)	$	68.9
The effects of fair value hedges:
Foreign currency contracts:
Hedged items	—		—		(4.0)
Derivatives designated as hedging instruments	—		—		4.0
Amount excluded from effectiveness testing (amortized)	—		—		0.8
The effects of cash flow hedges:
Foreign currency contracts:
Amount of gain (loss) reclassified from accumulated other comprehensive loss into income	35.8		—		—
The effects of net investment hedges:
Cross currency swap contracts
Amount excluded from effectiveness testing	—		7.0		—
The effects of non-designated hedges:
Foreign currency contracts:	—		—		22.4


	Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships
	Year Ended December 31, 2023
	Cost of sales		Interest income, net		Other non-operating income, net

Total amounts presented in the consolidated statements of operations	$	(978.4)	$	(17.6)	$	13.9
The effects of fair value hedges:
Foreign currency contracts:
Hedged items	—		—		(9.2)
Derivatives designated as hedging instruments	—		—		9.2
Amount excluded from effectiveness testing (amortized)	—		—		4.7
The effects of cash flow hedges:
Foreign currency contracts:
Amount of gain (loss) reclassified from accumulated other comprehensive loss into income	58.9		—		—
The effects of net investment hedges:
Cross currency swap contracts
Amount excluded from effectiveness testing	—		6.9		—
The effects of non-designated hedges:
Foreign currency contracts:	—		—		7.4

The Company expects that during 2025 it will reclassify to earnings a $10.7 million gain currently recorded in Accumulated Other Comprehensive Loss. For the years ended December 31, 2024, 2023, and 2022, the Company did not record any gains or losses due to hedge ineffectiveness.

EMPLOYEE BENEFIT PLANS

12 Months Ended

Dec. 31, 2024

Retirement Benefits [Abstract]

EMPLOYEE BENEFIT PLANS

Defined Benefit Plans

The Company maintains defined benefit pension plans in Japan and certain European countries.


	Years Ended December 31,
	2024		2023
	(in millions)
Change in projected benefit obligation:
Beginning of year	$	111.7	$	94.1
Service cost	5.0		4.3
Interest cost	1.9		2.3
Participant contributions	2.0		1.9
Actuarial loss	3.6		9.9
Benefits paid	(1.5)		(3.8)
Plan amendment	(0.5)		(0.4)
Divestiture (Note 5)	(4.4)		—
Settlements and curtailment gain (Note 5)	(5.4)		—

Currency exchange rate changes and other	(5.7)		3.4
End of year	$	106.7	$	111.7




Change in fair value of plan assets:
Beginning of year	$	75.5	$	70.6
Actual return on plan assets	6.3		0.8
Employer contributions	6.4		3.5
Participant contributions	2.0		1.9
Divestiture (Note 5)	(4.4)		—
Settlements	(5.9)		—
Benefits paid	(1.5)		(3.8)
Currency exchange rate changes and other	(3.8)		2.5
End of year	$	74.6	$	75.5
Funded Status
Projected benefit obligation	$	(106.7)	$	(111.7)
Plan assets at fair value	74.6		75.5
Underfunded status	$	(32.1)	$	(36.2)
Net amounts recognized on the consolidated balance sheet:
Other liabilities	$	32.1	$	36.2
Accumulated other comprehensive loss, net of tax:
Net actuarial loss	$	(9.1)	$	(10.3)
Net prior service credit	4.4		5.2
Deferred income tax benefit	0.6		0.9
Total	$	(4.1)	$	(4.2)

The accumulated benefit obligation for all defined benefit pension plans was $102.1 million and $106.8 million as of December 31, 2024 and 2023, respectively. Pension plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets were as follows:


	December 31,
	2024		2023
	(in millions)
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	$	89.1	$	106.8
Fair value of plan assets	61.6		75.5
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$	106.7	$	111.7
Fair value of plan assets	74.6		75.5

The components of net periodic pension benefit cost are as follows (in millions):


	Years Ended December 31,
	2024		2023		2022
Service cost, net	$	5.0	$	4.3	$	5.5
Interest cost	1.9		2.3		0.5
Expected return on plan assets	(3.1)		(2.7)		(1.5)
Settlements and curtailment gain	1.2		—		0.1

Amortization of actuarial loss	0.2		—		0.5
Amortization of prior service credit	(0.8)		(0.8)		(0.7)

Net periodic pension benefit cost	$	4.4	$	3.1	$	4.4

Expected long-term returns for each of the plans' strategic asset classes were developed through consultation with investment advisors. Several factors were considered, including a survey of investment managers' expectations, current market data, minimum guaranteed returns in certain insurance contracts, and historical market returns over long periods. Using policy target allocation percentages and the asset class expected returns, a weighted-average expected return was calculated.

To select the discount rates for the defined benefit pension plans, the Company uses a modeling process that involves matching the expected duration of its benefit plans to a yield curve constructed from a portfolio of AA-rated fixed-income debt instruments, or their equivalent. For each country, the Company uses the implied yield of this hypothetical portfolio at the appropriate duration as a discount rate benchmark.

The weighted-average assumptions used to determine the benefit obligations are as follows:


	December 31,
	2024		2023
Discount rate	1.5	%	1.8	%
Rate of compensation increase	2.8	%	2.9	%
Cash balance interest crediting rate	1.5	%	1.5	%
Social securities increase	1.8	%	1.8	%
Pension increase	2.2	%	2.2	%

The weighted-average assumptions used to determine the net periodic pension benefit cost are as follows:


	Years ended December 31,
	2024		2023		2022
Discount rate	1.8	%	2.5	%	0.5	%
Expected return on plan assets	4.3	%	3.7	%	2.1	%
Rate of compensation increase	2.9	%	2.9	%	2.6	%
Cash balance interest crediting rate	1.5	%	1.5	%	1.5	%
Social securities increase	1.8	%	1.8	%	1.6	%
Pension increase	2.2	%	2.2	%	1.8	%

Plan Assets

The Company's investment strategy for plan assets is to seek a competitive rate of return relative to an appropriate level of risk and to earn performance rates of return in accordance with the benchmarks adopted for each asset class. Risk management practices include diversification across asset classes and investment styles, and periodic rebalancing toward asset allocation targets.

The Company's Administrative and Investment Committee decides on the defined benefit plan provider in each location and that provider decides the target allocation for the Company's defined benefit plan at that location. The target asset allocation selected reflects a risk/return profile the Company feels is appropriate relative to the plans' liability structure and return goals. In certain plans, asset allocations may be governed by local requirements. Target weighted-average asset allocations at December 31, 2024, by asset category, are as follows:


Equity securities	30.9	%
Debt securities	37.2	%
Real estate	14.7	%
Other	17.2	%
Total	100.0	%

The fair values of the Company's defined benefit plan assets at December 31, 2024 and 2023, by asset category, are as follows (in millions):


December 31, 2024	Level 1		Level 2		Level 3		Total
Asset Category
Cash	$	1.1	$	—	$	—	$	1.1
Equity securities:
United States equities	2.0		—		—		2.0
International equities	21.1		—		—		21.1
Debt securities:
United States government bonds	3.2		—		—		3.2
International government bonds	24.6		—		—		24.6
Real estate	—		11.0		—		11.0
Mortgages	—		3.0		—		3.0
Insurance contracts	—		—		0.7		0.7
Total plan assets measured at fair value	$	52.0	$	14.0	$	0.7	$	66.7
Alternative investments measured at net asset value (a)							7.9
Total plan assets							$	74.6


December 31, 2023	Level 1		Level 2		Level 3		Total
Asset Category
Cash	$	2.0	$	—	$	—	$	2.0
Equity securities:
United States equities	2.6		—		—		2.6
International equities	21.0		—		—		21.0
Debt securities:
United States government bonds	3.5		—		—		3.5
International government bonds	26.0		—		—		26.0
Real estate	—		8.7		—		8.7
Mortgages	—		4.0		—		4.0
Insurance contracts	—		—		0.8		0.8
Total plan assets	$	55.1	$	12.7	$	0.8	$	68.6
Alternative investments measured at net asset value (a)							6.9
Total plan assets							$	75.5

_______________________________________

(a) Certain investments that were measured at net asset value per share have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the total plan assets.

The following table summarizes the changes in fair value of the Company's defined benefit plan assets that have been classified as Level 3 for the years ended December 31, 2024 and 2023 (in millions):


	Insurance Contracts
Balance at December 31, 2022	$	0.8
Actual return on plan assets:
Relating to assets still held at December 31, 2023	0.2

Purchases, sales and settlements	(0.2)


Balance at December 31, 2023	0.8
Actual return on plan assets:
Relating to assets still held at December 31, 2024	0.4

Purchases, sales and settlements	(0.5)


Balance at December 31, 2024	$	0.7

Equity and debt securities are valued at fair value based on quoted market prices reported on the active markets on which the individual securities are traded. Real estate investments are valued by discounting to present value the cash flows expected to be generated by the specific properties. Investments in mortgages are valued at cost, which is deemed to approximate its fair value. The insurance contracts are valued at the cash surrender value of the contracts, which is deemed to approximate its fair value. Alternative investments include hedge funds, private equity funds and other miscellaneous investments, and are valued using the net asset value provided by the fund administrator as a practical expedient. The net asset value is based on the fair value of the underlying assets owned by the fund divided by the number of shares outstanding.

The following benefit payments, which reflect expected future service, as appropriate, at December 31, 2024, are expected to be paid (in millions):


2025	$	6.9
2026	5.5
2027	5.8
2028	7.5
2029	7.2
2030-2034	36.5

As of December 31, 2024, expected employer contributions for 2025 are $2.6 million.

Defined Contribution Plans

The Company's employees in the United States are eligible to participate in a qualified defined contribution plan. In the United States, participants may contribute up to 25% of their eligible compensation (subject to tax code limitation) to the plan. Edwards Lifesciences matches the first 4% of the participant's annual eligible compensation contributed to the plan on a dollar-for-dollar basis. Edwards Lifesciences matches the next 2% of the participant's annual eligible compensation to the plan on a 50% basis. Prior to the sale of the Company's Critical Care product group (see Note 5), participants in Puerto Rico could contribute up to 25% of their annual compensation (subject to tax code limitation) to the plan. Edwards Lifesciences matched the first 4% of participant's annual eligible compensation contributed to the plan on a 50% basis. The Company also provided a 2% profit sharing contribution calculated on eligible earnings for each employee. Matching contributions relating to Edwards Lifesciences employees were $56.2 million, $51.0 million, and $45.1 million in 2024, 2023, and 2022, respectively.

The Company also has nonqualified deferred compensation plans for a select group of employees. The plans provide eligible participants the opportunity to defer eligible compensation to future dates specified by the participant with a return based on investment alternatives selected by the participant. The amount accrued under these nonqualified plans was $146.5 million and $125.6 million at December 31, 2024 and 2023, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

+ Details

COMMON STOCK

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

COMMON STOCK

Treasury Stock

In December 2023, the Board of Directors approved a stock repurchase program authorizing the Company to purchase up to $1.0 billion of the Company's common stock. In August 2024, the Board of Directors approved an additional $1.5 billion of repurchases of the Company's common stock under this program. The repurchase program does not have an expiration date. Stock repurchased under the program may be used to offset the impact of the Company's employee stock-based benefit programs and stock-based business acquisitions, and will reduce the total shares outstanding.

During 2024, 2023, and 2022, the Company repurchased 16.8 million, 11.4 million, and 20.1 million shares, respectively, at an aggregate cost of $1.2 billion, $880.5 million, and $1.7 billion, respectively, including shares purchased under a Rule 10b5-1 trading plan, the accelerated share repurchase ("ASR") agreements described below, and shares acquired to satisfy tax withholding obligations in connection with the vesting of restricted stock units issued to employees. The timing and size of any future stock repurchases are subject to a variety of factors, including expected dilution from stock plans, cash capacity, and the market price of the Company's common stock.

Accelerated Share Repurchase

During 2024 and 2023, the Company entered into ASR agreements providing for the repurchase of the Company's common stock based on the volume-weighted average price ("VWAP") of the Company's common stock during the term of the applicable agreements, less a discount. The following table summarizes the terms of the ASR agreements (dollars and shares in millions, except per share data):


			Initial Delivery					Final Settlement
Agreement Date	Amount Paid		Shares Received	Price per Share		Value of Shares as % of Contract Value		Settlement Date	Total Shares Received	Average Price per Share
February 2023	$	200.0	2.0	$	80.44	80	%	March 2023	2.5	$	79.28
December 2023	$	400.0	4.6	$	70.31	80	%	December 2023	5.3	$	72.91
April 2024	$	150.0	1.4	$	85.95	80	%	May 2024	1.7	$	86.72
August 2024	$	500.0	5.8	$	68.93	80	%	December 2024	7.5	$	66.60

The ASR agreements were each accounted for as two separate transactions: (1) the value of the initial delivery of shares was recorded as shares of common stock acquired in a treasury stock transaction on the acquisition date and (2) the remaining amount of the purchase price paid was recorded as a forward contract indexed to the Company's own common stock and was initially recorded in Additional Paid-in Capital and subsequently, upon settlement, was transferred to Treasury Stock on the consolidated balance sheets. The initial delivery of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares outstanding for basic and diluted earnings per share. The Company determined that the forward contracts indexed to the Company's common stock met all the applicable criteria for equity classification and, therefore, were not accounted for as a derivative instrument.

Employee and Director Stock Plans

The Edwards Lifesciences Corporation Long-term Stock Incentive Compensation Program (the "Program") provides for the grant of incentive and non-qualified stock options, restricted stock, and restricted stock units for eligible employees of the Company. Under the Program, these grants are awarded at a price equal to the fair market value at the date of grant based upon the closing price on that date. Options to purchase shares of the Company's common stock granted under the Program generally vest over predetermined periods of between three to four years and expire seven years after the date of grant. Service-based restricted stock units of the Company's common stock granted under the Program generally vest over predetermined periods, typically four years after the date of grant. Market-based restricted stock units of the Company's common stock granted under the Program vest over three years based on a combination of certain service and market conditions. The actual number of shares issued will be determined based on the Company's total stockholder return relative to a selected industry peer group. On May 7, 2024, the Company’s stockholders approved an amendment and restatement of the Program to (1) increase the total number of shares of the Company’s common stock available for issuance under the Program by 6.9 million shares to a new total share limit of 334.5 million shares, (2) increase the total number of shares of the Company’s common stock available for issuance as restricted stock and restricted stock unit awards under the Program by 2.0 million shares to a new limit on the total number of shares available for these types of awards of 35.6 million shares, and (3) extend the term within which new awards may be granted under the Program through February 21, 2034.

The Company also maintains the Nonemployee Directors Stock Incentive Compensation Program (the "Nonemployee Directors Program"). Under the Nonemployee Directors Program, annually each nonemployee director may receive up to 120,000 stock options or 48,000 restricted stock units of the Company's common stock, or a combination thereof. These grants generally vest over one year from the date of grant. Under the Nonemployee Directors Program, an aggregate of 8.4 million shares of the Company's common stock has been authorized for issuance.

The Company has an employee stock purchase plan for United States employees and a plan for employees outside of the United States (collectively "ESPP"). Under the ESPP, eligible employees may purchase shares of the Company's common stock at 85% of the lower of the fair market value of Edwards Lifesciences common stock on the effective date of subscription or the date of purchase. Under the ESPP, employees can authorize the Company to withhold up to 15% of their compensation for

common stock purchases, subject to certain limitations. The ESPP is available to all active employees of the Company paid from the United States payroll and to eligible employees of the Company outside of the United States, to the extent permitted by local law. The ESPP for United States employees is qualified under Section 423 of the Internal Revenue Code. The number of shares of common stock authorized for issuance under the ESPP was 50.4 million shares.

The fair value of each option award and employee stock purchase subscription is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following tables. The risk-free interest rate is estimated using the United States Treasury yield curve and is based on the expected term of the award. Expected volatility is estimated based on a blend of the weighted-average of the historical volatility of Edwards Lifesciences' stock and the implied volatility from traded options on Edwards Lifesciences' stock. The expected term of awards granted is estimated from the vesting period of the award, as well as historical exercise behavior, and represents the period of time that awards granted are expected to be outstanding. The Company uses historical data to estimate forfeitures and has estimated an annual forfeiture rate of 5.9%.

The Black-Scholes option pricing model was used with the following weighted-average assumptions for options granted during the following periods:

Option Awards


	Years Ended December 31,
	2024			2023			2022
Risk-free interest rate	4.5		%	3.4		%	3.0		%
Expected dividend yield	None			None			None
Expected volatility	30.9		%	32.8		%	31.4		%
Expected term (years)	5.3			5.1			5.0
Fair value, per share	$	31.14		$	30.97		$	34.59

The Black-Scholes option pricing model was used with the following weighted-average assumptions for ESPP subscriptions granted during the following periods:

ESPP


	Years Ended December 31,
	2024			2023			2022
Risk-free interest rate	5.2		%	4.6		%	0.5		%
Expected dividend yield	None			None			None
Expected volatility	33.5		%	31.5		%	32.0		%
Expected term (years)	0.6			0.6			0.6
Fair value, per share	$	25.01		$	19.03		$	28.18

The fair value of market-based restricted stock units was determined using a Monte Carlo simulation model, which uses multiple input variables to determine the probability of satisfying the market condition requirements. The weighted-average assumptions used to determine the fair value of the market-based restricted stock units granted during the years ended December 31, 2024, 2023, and 2022 included a risk-free interest rate of 4.5%, 3.6%, and 2.9%, respectively, and an expected volatility rate of 32.4%, 32.6%, and 33.9%, respectively.

Stock option activity during the year ended December 31, 2024 under the Program and the Nonemployee Directors Program was as follows (in millions, except years and per-share amounts):


	Shares	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	11.0	$	71.90
Options granted	1.5	85.46
Options exercised	(2.1)	43.12
Options forfeited	(0.4)	91.39
Outstanding as of December 31, 2024	10.0	79.15		3.4 years	$	57.9
Exercisable as of December 31, 2024	6.7	73.63		2.4 years	$	57.5
Vested and expected to vest as of December 31, 2024	9.6	78.61		3.3 years	$	57.9

The following table summarizes nonvested restricted stock unit activity during the year ended December 31, 2024 under the Program and the Nonemployee Directors Program (in millions, except per-share amounts):


	Shares	Weighted- Average Grant-Date Fair Value
Nonvested as of December 31, 2023	2.1	$	94.35
Granted	2.1	85.48
Vested	(0.7)	92.79
Forfeited	(0.3)	90.13
Nonvested as of December 31, 2024	3.2	89.16

The intrinsic value of stock options exercised and restricted stock units vested during the years ended December 31, 2024, 2023, and 2022 was $150.2 million, $162.7 million, and $264.5 million, respectively. The intrinsic value of stock options is calculated as the amount by which the market price of the Company's common stock exceeds the exercise price of the option. During the years ended December 31, 2024, 2023, and 2022, the Company received cash from exercises of stock options of $90.6 million, $83.4 million, and $64.8 million, respectively, and tax benefits from exercises of stock options and vesting of restricted stock units of $32.6 million, $35.9 million, and $56.9 million, respectively. The total grant-date fair value of stock options vested during the years ended December 31, 2024, 2023, and 2022 were $44.8 million, $41.3 million, and $40.4 million, respectively.

As of December 31, 2024, the total remaining unrecognized compensation expense related to nonvested stock options, restricted stock units, market-based restricted stock units, and employee stock purchase plan subscription awards amounted to $258.1 million, which will be amortized on a straight-line basis over each award's requisite service period. The weighted-average remaining requisite service period is 31 months.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

ACCUMULATED OTHER COMPREHENSIVE LOSS

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

Presented below is a summary of activity for each component of Accumulated Other Comprehensive Loss for the years ended December 31, 2024, 2023, and 2022.


	Foreign Currency Translation Adjustments		Unrealized Gain (Loss) on Hedges		Unrealized (Loss) Gain on Available-for-sale Investments		Unrealized Pension (Costs) Credits (a)		Total Accumulated Other Comprehensive Loss
	(in millions)
December 31, 2021	$	(172.5)	$	29.7	$	(6.9)	$	(8.0)	$	(157.7)
Other comprehensive (loss) income before reclassifications	(33.9)		75.2		(77.9)		17.3		(19.3)
Amounts reclassified from accumulated other comprehensive loss	(7.0)		(84.5)		18.8		(0.1)		(72.8)
Deferred income tax (expense) benefit	(5.4)		3.4		0.4		(3.5)		(5.1)
December 31, 2022	(218.8)		23.8		(65.6)		5.7		(254.9)
Other comprehensive income (loss) before reclassifications	6.9		43.3		32.6		(11.1)		71.7
Amounts reclassified from accumulated other comprehensive loss	(6.9)		(72.8)		8.1		(0.8)		(72.4)
Deferred income tax benefit	4.3		6.4		0.1		2.0		12.8
December 31, 2023	(214.5)		0.7		(24.8)		(4.2)		(242.8)
Other comprehensive (loss) income before reclassifications	(49.9)		91.0		34.8		(0.2)		75.7
Amounts reclassified from accumulated other comprehensive loss	(7.0)		(40.6)		(12.5)		0.6		(59.5)
Deferred income tax expense	(2.7)		(13.4)		(1.5)		(0.3)		(17.9)
December 31, 2024	$	(274.1)	$	37.7	$	(4.0)	$	(4.1)	$	(244.5)

_______________________________________________________________________________

(a)For the years ended December 31, 2024, 2023, and 2022, the change in unrealized pension costs consisted of the following (in millions):


	Pre-Tax Amount		Tax (Expense) Benefit		Net of Tax Amount
2024
Prior service credit arising during period	$	—	$	(0.1)	$	(0.1)
Amortization of prior service credit	(0.8)		0.2		(0.6)
Net prior service cost arising during period	(0.8)		0.1		(0.7)
Net actuarial loss arising during period	1.2		(0.4)		0.8
Unrealized pension costs, net	$	0.4	$	(0.3)	$	0.1
2023
Prior service credit arising during period	$	0.7	$	0.9	$	1.6
Amortization of prior service credit	(0.8)		0.1		(0.7)
Net prior service cost arising during period	(0.1)		1.0		0.9
Net actuarial gain arising during period	(11.8)		1.0		(10.8)
Unrealized pension credits, net	$	(11.9)	$	2.0	$	(9.9)
2022
Prior service cost arising during period	$	—	$	(1.1)	$	(1.1)
Amortization of prior service credit	(0.7)		0.3		(0.4)
Net prior service cost arising during period	(0.7)		(0.8)		(1.5)
Net actuarial gain arising during period	17.9		(2.7)		15.2
Unrealized pension credits, net	$	17.2	$	(3.5)	$	13.7

The following table provides information about amounts reclassified from Accumulated Other Comprehensive Loss (in millions):


	Years Ended December 31,
Details about Accumulated Other Comprehensive Loss Components	2024		2023		Affected Line on Consolidated Statements of Operations
Foreign currency translation adjustments	$	7.0	$	6.9	Other non-operating income, net
	(1.7)		(1.7)		Provision for income taxes
	$	5.3	$	5.2	Net of tax
Gain (loss) on hedges	$	35.8	$	58.9	Cost of sales

	4.8		13.9		Other non-operating income, net
	40.6		72.8		Total before tax
	(10.1)		(15.8)		Provision for income taxes
	$	30.5	$	57.0	Net of tax
(Loss) gain on available-for-sale investments	$	12.5	$	(8.1)	Other non-operating income, net
	(3.1)		2.2		Provision for income taxes
	$	9.4	$	(5.9)	Net of tax

Amortization of pension adjustments	$	(0.6)	$	0.8	Other non-operating income, net

	0.5		(0.2)		Provision for income taxes
	$	(0.1)	$	0.6	Net of tax

OTHER NON-OPERATING INCOME, NET

12 Months Ended

Dec. 31, 2024

Other Income and Expenses [Abstract]

OTHER NON-OPERATING INCOME, NET


	Years Ended December 31,
	2024		2023		2022
	(in millions)
Foreign exchange gains, net	$	(7.1)	$	(10.0)	$	(1.0)
Loss on investments	0.6		0.7		1.1
Non-service cost components of net periodic pension benefit cost	(0.6)		(1.2)		(1.1)
Gain on remeasurement of previously held equity interest upon acquisition	(55.0)		—		—
Gain on insurance settlement	—		—		(3.8)

Other	(6.8)		(3.4)		—
Total other non-operating income, net	$	(68.9)	$	(13.9)	$	(4.8)

INCOME TAXES

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

INCOME TAXES

The Company's income from continuing operations before provision for income taxes was generated from operations in the United States and outside of the United States as follows (in millions):


	Years Ended December 31,
	2024		2023		2022
United States	$	265.7	$	290.1	$	586.0
Outside of the United States, including Puerto Rico	1,282.4		1,082.3		933.5
	$	1,548.1	$	1,372.4	$	1,519.5

The provision for income taxes consists of the following (in millions):


	Years Ended December 31,
	2024		2023		2022
Current
United States:
Federal	$	248.4	$	291.7	$	365.8
State and local	40.7		50.1		54.3
Outside of the United States, including Puerto Rico	25.8		53.0		37.1
Current income tax expense	$	314.9	$	394.8	$	457.2
Deferred
United States:
Federal	$	(117.8)	$	(165.7)	$	(197.8)
State and local	(31.0)		(54.2)		(58.9)
Outside of the United States, including Puerto Rico	(14.0)		(22.5)		(5.0)
Deferred income tax benefit	(162.8)		(242.4)		(261.7)
Total income tax provision	$	152.1	$	152.4	$	195.5

The components of deferred tax assets and liabilities are as follows (in millions):


	December 31,
	2024		2023
Deferred tax assets
Capitalized research and development expenses (a)	$	533.8	$	371.1
Compensation and benefits	123.7		117.9
Benefits from uncertain tax positions	89.6		63.4
Net tax credit carryforwards	289.1		144.2
Net operating loss carryforwards	132.1		73.0
Accrued liabilities	145.2		131.7
Inventories	14.9		15.1
Cash flow and net investment hedges	—		1.3
State income taxes	3.2		0.2
Investments	1.2		0.6
Lease liability obligations	6.5		5.8
Other	2.8		0.7
Total deferred tax assets	1,342.1		925.0
Deferred tax liabilities
Property, plant, and equipment	(76.4)		(78.2)
Cash flow and net investment hedges	(11.8)		—
Deferred tax on foreign earnings	(3.6)		(3.6)
Right-of-use assets	(4.3)		(4.7)

Other intangible assets	(230.3)		(46.1)
Other	(4.8)		(2.4)
Total deferred tax liabilities	(331.2)		(135.0)
Valuation allowance	(87.8)		(62.1)
Net deferred tax assets	$	923.1	$	727.9

______________________________________

(a) As required by Public Law 115-97, commonly referred to as the Tax Cuts and Jobs Act (the "2017 Act"), effective January 1, 2022, the Company's research and development expenditures were capitalized and amortized which resulted in substantially higher cash paid for taxes in 2023 and 2022 with an equal amount of deferred tax benefits.

During 2024, net deferred tax assets increased $195.2 million, including items that were recorded to stockholders' equity and which did not impact the Company's income tax provision.

The valuation allowance of $87.8 million as of December 31, 2024 reduces certain deferred tax assets to amounts that are more likely than not to be realized. This allowance primarily relates to the net operating loss carryforwards of certain non-United States subsidiaries and certain United States foreign tax credit carryforwards.

Net operating loss and capital loss carryforwards and the related carryforward periods at December 31, 2024 are summarized as follows (in millions):


	Carryforward Amount		Tax Benefit Amount		Valuation Allowance		Net Tax Benefit		Carryforward Period Ends
United States federal net operating losses	$	9.4	$	2.0	$	—	$	2.0	2026-2037
United States federal net operating losses	132.9		27.9		—		27.9		Indefinite
United States state net operating losses	180.7		12.6		(3.7)		8.9		2029-2044
United States state net operating losses	0.4		—		—		—		Indefinite
Non-United States net operating losses	1.3		0.3		—		0.3		2028
Non-United States net operating losses	517.8		89.3		(63.2)		26.1		Indefinite

Total	$	842.5	$	132.1	$	(66.9)	$	65.2

The gross tax credit carryforwards and the related carryforward periods at December 31, 2024 are summarized as follows (in millions):


	Carryforward Amount		Valuation Allowance		Net Tax Benefit		Carryforward Period Ends
California research expenditure tax credits	$	232.7	$	—	$	232.7	Indefinite
Federal research expenditure tax credits	1.9		—		1.9		2025-2034
United States foreign tax credits	121.6		(17.8)		103.8		2025-2034
Non-United States tax credits	6.0		—		6.0		2025-2028
Total	$	362.2	$	(17.8)	$	344.4

The Company has $232.7 million of gross California research expenditure tax credits it expects to use in future periods. The credits may be carried forward indefinitely. Based upon anticipated future taxable income, the Company expects that it is more likely than not that all California research expenditure tax credits will be utilized, although the utilization of the full benefit is expected to be realized over an extended period of time. Accordingly, no valuation allowance has been provided. The Company has $121.6 million of United States foreign tax credits of which $103.8 million are expected to be utilized before the end of the 10-year carryforward period. As a result, the Company recorded a valuation allowance of $17.8 million on the United States foreign tax credit carryforwards which have been determined to be unrealizable.

On December 22, 2017, the 2017 Act was signed into law. The 2017 Act (a) reduced the United States federal corporate tax rate from 35 percent to 21 percent for tax years beginning after December 31, 2017, (b) required companies to pay a one-time mandatory deemed repatriation tax on the cumulative earnings of certain foreign subsidiaries that were previously tax deferred, and (c) created new taxes on certain foreign earnings in future years. The Company elected to pay the repatriation tax in installments over eight years. The final installment of $78.5 million is due in the second quarter of 2025.

The Company asserts that $555.2 million of its foreign earnings continue to be indefinitely reinvested and it intends to repatriate $1.0 billion of its foreign earnings as of December 31, 2024. The estimated net tax liability on the indefinitely reinvested earnings if repatriated is $2.5 million.

The Company has received tax incentives in certain non-United States tax jurisdictions, the primary benefit for which will expire in 2029. The tax reductions as compared to the local statutory rates were $271.9 million ($0.45 per diluted share), $333.2 million ($0.55 per diluted share), and $247.4 million ($0.40 per diluted share) for the years ended December 31, 2024, 2023, and 2022, respectively.

A reconciliation of the United States federal statutory income tax rate to the Company's effective income tax rate is as follows (in millions):


	Years Ended December 31,
	2024		2023		2022
Income tax expense at United States federal statutory rate	$	325.1	$	288.1	$	323.7
Foreign income taxed at different rates	(190.6)		(133.8)		(135.4)
State and local taxes, net of federal tax benefit	16.0		15.9		11.3
Tax credits, federal and state	(58.9)		(55.9)		(43.4)
Build of reserve for prior years' uncertain tax positions	(31.3)		(2.9)		11.6

Tax on global intangible low-taxed income	90.2		82.3		68.4
Foreign-derived intangible income deduction	(16.5)		(20.9)		(14.3)
Contingent consideration liabilities	—		(5.5)		(7.5)
United States federal deductible employee share-based compensation	(8.3)		(11.9)		(28.5)
Nondeductible employee share-based compensation	6.2		5.7		4.9



Other	20.2		(8.7)		4.7
Income tax provision	$	152.1	$	152.4	$	195.5

The Company's effective tax rate for 2024 decreased in comparison to 2023 primarily due to an increase in tax benefits from foreign earnings taxed at lower rates net of an increase in tax on global intangible low-taxed income and favorable global income tax audit settlements. The Company's effective tax rate for 2023 decreased in comparison to 2022 primarily due to the tax benefit from the Intellectual Property Agreement with Medtronic (see Note 3), partially offset by a reduced tax benefit from employee share-based compensation

Uncertain Tax Positions

As of December 31, 2024 and 2023, the gross uncertain tax positions were $678.8 million and $583.9 million, respectively. The Company estimates that these liabilities would be reduced by $319.9 million and $250.7 million, respectively, from offsetting tax benefits associated with the correlative effects of potential transfer pricing adjustments, state income taxes, and timing adjustments. The net amounts of $358.9 million and $333.2 million, respectively, if not required, would favorably affect the Company's effective tax rate.

A reconciliation of the beginning and ending amount of uncertain tax positions, excluding interest, penalties, and foreign exchange, is as follows (in millions):


	December 31,
	2024		2023		2022
Uncertain gross tax positions, January 1	$	583.9	$	475.3	$	358.4
Current year tax positions	125.8		127.0		120.6
Increase in prior year tax positions	3.2		0.8		3.8
Decrease in prior year tax positions	(34.1)		(16.2)		(0.6)
Settlements	—		(3.0)		(0.4)
Lapse of statutes of limitations	—		—		(6.5)
Uncertain gross tax positions, December 31	$	678.8	$	583.9	$	475.3

The table above summarizes the gross amounts of uncertain tax positions without regard to reductions in tax liabilities or additions to deferred tax assets and liabilities if such uncertain tax positions were settled.

The Company recognizes interest and penalties, if any, related to uncertain tax positions in the provision for income taxes. As of December 31, 2024, the Company had accrued $55.4 million (net of $52.5 million tax benefit) of interest related to uncertain tax positions, and as of December 31, 2023, the Company had accrued $41.4 million (net of $29.9 million tax benefit) of interest related to uncertain tax positions. During 2024, 2023, and 2022, the Company recognized interest expense, net of tax benefit, of $14.0 million, $12.3 million, and $9.6 million, respectively, in Provision for Income Taxes on the consolidated statements of operations.

In the normal course of business, the Internal Revenue Service ("IRS") and other taxing authorities are in different stages of examining various years of the Company's tax filings. During these audits the Company may receive proposed audit adjustments that could be material. Therefore, there is a possibility that an adverse outcome in these audits could have a material effect on the Company's results of operations and financial condition. The Company strives to resolve open matters with each tax authority at the examination level and could reach an agreement with a tax authority at any time. While the Company has accrued for matters it believes are more likely than not to require settlement, the final outcome with a tax authority may result in a tax liability that is materially different from that reflected in the consolidated financial statements. Furthermore, the Company may later decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations between tax authorities, identification of new issues, and issuance of new legislation, regulations, or case law. Management believes that adequate amounts of tax and related penalty and interest have been provided for any adjustments that may result from these uncertain tax positions.

In the first quarter of 2022, the Company executed an Advance Pricing Agreement (“APA”) between Japan and Switzerland covering distribution transactions for tax years 2020 through 2024, and in 2023, executed an APA between Japan and the United States covering tax years 2020 through 2024. The Company also executed an APA in the fourth quarter of 2024 between Japan and Singapore covering tax years 2022 through 2026 with roll-back terms to cover the distribution of TAVR products beginning in 2020 and the distribution of Surgical products beginning in 2018. Also in the fourth quarter of 2024, the Company filed with the Japanese tax authorities an APA renewal application between Japan and the United States covering tax years 2025 through 2029. The Company intends to file the APA renewal application with the United States tax authorities in the first quarter of 2025.

The audits of the Company’s United States federal income tax returns through 2014 have been closed. The IRS audit field work for the 2015 through 2017 tax years was completed during the second quarter of 2021, except for transfer pricing and related matters. The IRS is currently examining the 2018 through 2020 tax years.

At December 31, 2024, all material state, local, and foreign income tax matters have been concluded for years through 2015.

During 2021, the Company received a Notice of Proposed Adjustment (“NOPA”) from the IRS for the 2015 through 2017 tax years relating to transfer pricing involving Surgical/TAVR intercompany royalty transactions between the Company's United States and Switzerland subsidiaries. The NOPA proposed a substantial increase to the Company's United States taxable income, which could result in additional tax expense for the 2015 through 2017 period of approximately $240.0 million and reflects a departure from a transfer pricing method the Company had previously agreed upon with the IRS. The Company disagreed with the NOPA and pursued an administrative appeal with the IRS Independent Office of Appeals ("Appeals"). The Appeals process culminated in the third quarter of 2023 when the Company and Appeals concluded that a satisfactory resolution of the matter at the administrative level was not possible.

During the fourth quarter of 2023, Appeals issued a notice of deficiency ("NOD") increasing the Company's 2015 through 2017 United States federal income tax in amounts resulting from the income adjustments previously reflected in the NOPA. The additional tax sought in excess of the Company's filing position is $269.3 million before consideration of interest and a repatriation tax offset.

The Company plans to vigorously contest the additional tax claimed by the IRS through the judicial process. Final resolution of this matter is not likely within the next 12 months. The Company believes the amounts previously accrued related to this uncertain tax position are appropriate for a number of reasons, including the interpretation and application of relevant tax

law and accounting standards to the Company's facts and, accordingly, has not accrued any additional amount based on the NOD and other proceedings to date.Nonetheless, the outcome of the judicial process cannot be predicted with certainty, and it is possible that the outcome of that process could have a material impact on the Company's consolidated financial statements. As noted below, similar material tax disputes may arise for the 2018 through 2024 tax years. The Company made deposits with the IRS of $75 million in November 2022 and $305.1 million in March 2024 to prevent the further accrual of interest on that portion of any additional tax and interest the Company may ultimately be found to owe while the Company prepares to contest through the judicial process the IRS's entitlement to any of the additional tax claimed by the IRS. The IRS converted those deposits to advance payments and, on December 20, 2024, the Company filed administrative claims for refunds of those payments with the IRS for the 2015 through 2017 tax years. The Company expects that the IRS will either deny or fail to act on those refund claims, thereby enabling the Company to sue for refunds in the appropriate judicial forum.

Surgical/TAVR intercompany royalty transactions covering tax years 2018 through 2024 remain subject to IRS examination, and those transactions and related tax positions remain uncertain as of December 31, 2024. The Company has considered this information, as well as information regarding the NOD and other proceedings described above, in its evaluation of its uncertain tax positions. The impact of these unresolved transfer pricing matters, net of any correlative tax adjustments, may be significant to the Company’s consolidated financial statements. Based on the information currently available and numerous possible outcomes, the Company cannot reasonably estimate what, if any, changes in its existing uncertain tax positions may occur in the next 12 months and, therefore, has continued to record the uncertain tax positions as a long-term liability.

During the first quarter of 2024, the Company received a notice of assessment from the Israel Tax Authority (the "ITA") wherein the ITA claimed that the Company owes approximately $110 million of tax excluding interest and penalties in connection with a claimed 2017 transfer of intellectual property. The Company maintains that it did not transfer intellectual property outside of Israel and intends to vigorously defend that position through administrative proceedings including with a formal appeal of the assessment that was filed during the third quarter of 2024. If necessary, the Company expects to defend that position through judicial proceedings. During the fourth quarter of 2024, the Company received a notice of assessment from the ITA claiming that the Company owes additional tax of approximately $16 million excluding interest and penalties for the 2018 through 2022 tax years based entirely on the collateral impacts of the 2017 assessment. The Company plans to file a formal appeal in the first quarter of 2025 and, if necessary, expects to defend its position through judicial proceedings. There can be no assurance that this matter will be resolved in the Company's favor and an adverse outcome could have a material effect on the Company's consolidated financial statements.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

LEGAL PROCEEDINGS	12 Months Ended
LEGAL PROCEEDINGS	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
LEGAL PROCEEDINGS	LEGAL PROCEEDINGS On September 28, 2021, Aortic Innovations LLC, a non-practicing entity, filed a lawsuit against Edwards Lifesciences Corporation and certain of its subsidiaries (“Edwards”) in the United States District Court for the District of Delaware alleging that Edwards’ SAPIEN 3 Ultra product infringes certain of its patents. The Company is unable to predict the ultimate outcome of this matter or estimate a range of possible exposure; therefore, no amounts have been accrued. The Company is vigorously defending itself in this litigation. The European Commission (the “Commission”) is investigating certain business practices of Edwards including its unilateral pro-innovation (anti-copycat) policy and patent practices. The Company is cooperating with the Commission and believes its business practices support healthy competition. The Company cannot predict the outcome of the investigation or the potential impact on its financial statements. On March 22, 2024, Fortis Advisors, LLC, in its capacity as the designated representative of the former stockholders of Harpoon Medical, Inc. filed suit against the Company in the Court of Chancery of the State of Delaware, alleging breach of the Agreement and Plan of Merger, dated December 8, 2015, by and between Harpoon Medical, Inc. and Edwards (the “Agreement”). Fortis seeks acceleration and payment of all contingent milestone payments in the Agreement. The trial is scheduled for December 2025. The Company is unable to predict the ultimate outcome of this matter or estimate a range of possible exposure; therefore, no amounts have been accrued. The Company is vigorously defending itself in this litigation. On October 14, 2024, a purported stockholder of Edwards filed a putative securities class action complaint against the Company and certain of its executive officers in the United States District Court for the Central District of California, captioned Patel v. Edwards Lifesciences Corporation, et al., No. 24-cv-02221. The complaint alleges violations of various securities laws based on alleged false or misleading statements regarding our business prospects. The complaint seeks damages, interest, costs and other fees. The Company is unable to predict the ultimate outcome of this matter or estimate a range of possible exposure; therefore, no amounts have been accrued. The Company intends to defend itself against the lawsuit vigorously. The Company is or may be a party to, or may otherwise be responsible for, pending or threatened lawsuits including those related to products and services currently or formerly manufactured or performed, as applicable, by the Company, workplace and employment matters, matters involving real estate, the Company's operations or health care regulations, contingent consideration, commercial matters, or governmental investigations (the “Lawsuits”). The Lawsuits raise difficult and complex factual and legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. Management does not believe that any loss relating to the Lawsuits would have a material adverse effect on the Company's overall financial condition, results of operations or cash flows. However, the resolution of one or more of the Lawsuits in any reporting period, could have a material adverse impact on the Company's financial results for that period. The Company is not able to estimate the amount or range of any loss for legal contingencies related to the Lawsuits for which there is no reserve or additional loss for matters already reserved. The Company is subject to various environmental laws and regulations both within and outside of the United States. The Company's operations, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes. While it is difficult to quantify the potential impact of continuing compliance with environmental protection laws, management believes that such compliance will not have a material impact on the Company's financial results. The Company's threshold for disclosing material environmental legal proceedings involving a governmental authority where potential monetary sanctions are involved is $1 million.

SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

SEGMENT INFORMATION

Edwards Lifesciences conducts operations worldwide and is managed in the following four reportable segments: United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company's operating segments are organized primarily based on economic characteristics as well as other characteristics, including types of customers, nature of the regulatory environment, and product offerings.

The Company's geographic segments are reported based on the financial information provided to the Chief Operating Decision Maker ("CODM"), which is the Company's Chief Executive Officer. The CODM evaluates the performance of the Company's reportable segments based on segment net sales and segment operating income. The CODM considers budget or forecast-to-actual results variances for segment operating income on a periodic basis for evaluating the performance of each segment and making decisions about allocating capital and other resources to each segment.

Segment net sales are based on actual foreign exchange rates. Segment expenses and segment operating income are based on internally derived foreign exchange rates and do not include inter-segment profits. Because of the interdependence of the reportable segments, the operating profit as presented may not be representative of the geographical distribution that would occur if the segments were not interdependent. Net sales by geographic area are based on the location of the customer. There were no customers that represented 10% or more of the Company's total net sales.

Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate research and development expenses, manufacturing variances, corporate headquarters costs, net interest income, global marketing expenses, special gains and charges, stock-based compensation, foreign currency hedging activities, certain litigation costs, changes in the fair value of contingent consideration liabilities, most of the Company's amortization, and a portion of the Company's depreciation expense. The CODM does not receive information on total assets by reportable segment.

The table below presents information about Edwards Lifesciences' reportable segments (in millions):


	Years Ended December 31,
	2024		2023		2022
Segment Net Sales
United States	$	3,206.0	$	2,947.9	$	2,628.2
Europe	1,321.7		1,180.2		1,040.3
Japan	339.8		350.8		359.5
Rest of World	572.0		531.1		436.0
Total segment net sales	$	5,439.5	$	5,010.0	$	4,464.0
Cost of Sales
United States	$	546.6	$	505.2	$	418.9
Europe	299.1		268.5		237.9
Japan	48.1		46.6		41.5
Rest of World	158.1		136.2		118.2
Total segment cost of sales	$	1,051.9	$	956.5	$	816.5
Selling, general, and administrative expenses
United States	$	498.0	$	432.8	$	340.7
Europe	282.6		260.6		233.0
Japan	85.1		70.1		77.4
Rest of World	181.4		166.4		142.6
Total segment selling, general, and administrative expenses	$	1,047.1	$	929.9	$	793.7
Other Segment Items
United States	$	2.4	$	2.1	$	4.8
Europe	14.9		(4.0)		(34.9)
Japan	(6.8)		21.3		(58.1)
Rest of World	(10.5)		(0.5)		(1.9)
Total other segment items (a)	$	—	$	18.9	$	(90.1)
Segment Operating Income
United States	$	2,159.0	$	2,007.8	$	1,863.8
Europe	725.1		655.1		604.3
Japan	213.4		212.8		298.7
Rest of World	243.0		229.0		177.1
Total segment operating income	$	3,340.5	$	3,104.7	$	2,943.9

_______________________________________________________________________________

(a) Other segment items include research and development expenses and foreign currency.


	Years Ended December 31,
	2024		2023		2022
Pre-tax Income Reconciliation
Segment operating income	$	3,340.5	$	3,104.7	$	2,943.9
Unallocated amounts:
Corporate items	(1,886.8)		(1,684.4)		(1,504.2)
Restructuring charges, separation costs, and other	(61.0)		—		(60.7)
Intellectual property agreement and certain litigation expenses	(40.4)		(203.5)		(15.8)
Change in fair value of contingent consideration liabilities	—		26.2		35.8
Foreign currency	26.4		65.9		99.4
Consolidated operating income	$	1,378.7	$	1,308.9	$	1,498.4
Non-operating income	169.4		63.5		21.1
Consolidated pre-tax income	$	1,548.1	$	1,372.4	$	1,519.5

Enterprise-Wide Information

(in millions)

Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements. Refer to the segment information above for United States net sales for the years ended December 31, 2024, 2023, and 2022. Sales within any other individual country were less than 10 percent of the Company's consolidated net sales in each of those years.


	As of or for the Years Ended December 31,
	2024		2023		2022
Net Sales by Major Product Group
Transcatheter Aortic Valve Replacement	$	4,106.1	$	3,879.8	$	3,518.2
Transcatheter Mitral and Tricuspid Therapies	352.1		197.6		116.1
Surgical Structural Heart	981.3		932.6		829.7
	$	5,439.5	$	5,010.0	$	4,464.0
Long-lived Tangible Assets by Geographic Region
United States	$	1,249.6	$	1,186.9	$	1,113.3
Other countries	534.6		488.5		457.0
	$	1,784.2	$	1,675.4	$	1,570.3

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

VALUATION AND QUALIFYING ACCOUNTS

12 Months Ended

Dec. 31, 2024

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

VALUATION AND QUALIFYING ACCOUNTS


			Additions
	Balance at Beginning of Period		Charged to Costs and Expenses		Charged to Other Accounts		Deductions		Balance at End of Period
	(in millions)
Year ended December 31, 2024
Allowance for credit losses (a)	$	11.7	$	7.6	$	2.7	$	(9.7)	$	12.3
Tax valuation allowance (b)	62.1		25.2		4.5		(4.0)		87.8
Year ended December 31, 2023
Allowance for credit losses (a)	$	11.6	$	2.0	$	—	$	(1.9)	$	11.7
Tax valuation allowance (b)	72.0		—		0.1		(10.0)		62.1
Year ended December 31, 2022
Allowance for credit losses (a)	$	15.6	$	0.9	$	0.1	$	(5.0)	$	11.6
Tax valuation allowance (b)	58.4		—		14.2		(0.6)		72.0

_______________________________________________________________________________

(a) The deductions related to allowances for credit losses represent accounts receivable which are written off.

(b) The tax valuation allowances are provided for other-than-temporary impairments and unrealized losses related to certain investments that may not be recognized due to the uncertainty of the ready marketability of certain impaired investments, and net operating loss and credit carryforwards that may not be recognized due to insufficient taxable income.

SUMMARIZED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)

12 Months Ended

Dec. 31, 2024

Quarterly Financial Information Disclosure [Abstract]

SUMMARIZED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)


Years Ended December 31,	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
	(in millions, except per share data)
2024
Net sales	$	1,329.9	$	1,369.4	$	1,354.4	$	1,385.8	$	5,439.5
Gross profit	1,043.0		1,093.9		1,091.5		1,093.6		4,322.0
Income from continuing operations, net of tax	324.9		364.0		362.1		345.0		1,396.0
Income from discontinued operations, net of tax (a)	26.1		1.0		2,707.3		39.3		2,773.7
Net income (a)	351.0		365.0		3,069.4		384.3		4,169.7
Net income attributable to Edwards Lifesciences Corporation (a)	351.9		366.3		3,070.8		385.6		4,174.6
Basic earnings per share:
Continuing operations	0.54		0.61		0.61		0.58		2.34
Discontinued operations	0.04		—		4.53		0.07		4.64
Basic earnings per share	0.58		0.61		5.14		0.65		6.98
Diluted earnings per share:
Continuing operations	0.54		0.61		0.61		0.58		2.34
Discontinued operations	0.04		—		4.52		0.07		4.63
Diluted earnings per share	0.58		0.61		5.13		0.65		6.97
2023
Net sales	$	1,221.3	$	1,278.9	$	1,243.4	$	1,266.4	$	5,010.0
Gross profit	992.3		1,031.1		992.8		1,015.4		4,031.6
Income from continuing operations	300.6		251.4		334.9		333.1		1,220.0
Income from discontinued operations, net of tax	39.9		54.1		48.8		36.6		179.4
Net income	340.5		305.5		383.7		369.7		1,399.4
Net income attributable to Edwards Lifesciences Corporation	340.5		307.1		384.9		369.9		1,402.4
Basic earnings per share:
Continuing operations	0.49		0.42		0.55		0.55		2.02
Discontinued operations	0.07		0.09		0.08		0.06		0.29
Basic earnings per share	0.56		0.51		0.63		0.61		2.31
Diluted earnings per share:
Continuing operations	0.49		0.41		0.55		0.55		2.01
Discontinued operations	0.07		0.09		0.08		0.06		0.29
Diluted earnings per share	0.56		0.50		0.63		0.61		2.30

_______________________________________________________________________________

(a) The third quarter of 2024 includes a $3.3 billion gain from the sale of Critical Care. See Note 5 for additional information.

SUBSEQUENT EVENT	12 Months Ended
SUBSEQUENT EVENT	Dec. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENT	SUBSEQUENT EVENT In February 2025, the Company entered into an ASR agreement to repurchase $250.0 million of Edwards Lifesciences' common stock based on the volume-weighted average price ("VWAP") of Edwards Lifesciences' common stock during the term of the agreements, less a discount. Upon entering into the agreement, the Company received an initial delivery of approximately 2.6 million shares, representing approximately 80% of the shares to be repurchased. At the termination of the ASR, the Company may receive additional shares or may be required to pay additional cash or shares (at the Company's election). The final settlement is based on the VWAP over the term of the agreement, less a discount. The ASR agreement has a scheduled termination date of July 25, 2025.

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended								12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net income attributable to Edwards Lifesciences Corporation.	$ 385.6	$ 3,070.8	$ 366.3	$ 351.9	$ 369.9	$ 384.9	$ 307.1	$ 340.5	$ 4,174.6	$ 1,402.4	$ 1,521.9

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Insider Trading Arrangements	3 Months Ended	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2024 shares	Dec. 31, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Bernard J. Zovighian [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On December 6, 2024, Bernard J. Zovighian, Chief Executive Officer and Director, entered into a 10b5-1 trading plan (the “Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The Plan provides for the potential sale of 14,925 shares of the Company’s stock commencing March 10, 2025. The Plan terminates on the earlier of May 16, 2025 or the date all shares are sold.
Name	Bernard J. Zovighian
Title	Chief Executive Officer and Director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 6, 2024
Expiration Date	May 16, 2025
Arrangement Duration	67 days
Aggregate Available	14,925	14,925

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Our Information Security team manages Edwards’ Information Security Program, which is focused on assessing, identifying, and managing cybersecurity risk and information security threats. We evaluate cybersecurity risk on an ongoing basis, and it is a risk monitored through our overall enterprise risk management program, including by the executive leadership and the Board of Directors, described below under Governance. To proactively manage cybersecurity risk in our organization, our management team has instituted an Edwards Information Technology Security Policy that is available to all employees through the employee handbook and on our intranet. We also conduct regular cybersecurity awareness and training campaigns for existing employees. Internal and external stakeholders can access the Edwards Integrity Helpline 24/7 online or by phone, to report any security incidents for escalation. We also disclose information about our product security and provide relevant contact information for our stakeholders to report any product vulnerabilities. To proactively identify, mitigate, and prepare for potential cybersecurity incidents, we maintain both a business continuity plan and cyber incident response plan with formalized workflows and playbooks. We periodically conduct simulation exercises involving employees at various levels of the organization. We also periodically engage external partners to conduct annual audits of our systems and test our IT infrastructure. Through these channels and others, we work to proactively identify potential vulnerabilities in our information security system. We recognize that we are exposed to cybersecurity threats associated with our use of third-party service providers. To minimize the risk and vulnerabilities to our own systems stemming from such use, our Information Security team identifies and addresses known cybersecurity threats and incidents at third-party service providers on a continuous basis. In addition, we strive to minimize cybersecurity risks when we first select or renew a vendor by including cybersecurity risk as part of our overall vendor evaluation and due diligence process. Based on information known to us, we do not believe any risks from cybersecurity threats, including as a result of previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. Our risks associated with cybersecurity threats are set forth under "Risk Factors" in Part I, Item 1A in this report.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Our Information Security team manages Edwards’ Information Security Program, which is focused on assessing, identifying, and managing cybersecurity risk and information security threats. We evaluate cybersecurity risk on an ongoing basis, and it is a risk monitored through our overall enterprise risk management program, including by the executive leadership and the Board of Directors, described below under Governance.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our Board of Directors and our Audit Committee oversee our enterprise-wide risk management, including with respect to cybersecurity. Our Chief Financial Officer presents information on our enterprise-wide risks to the Board of Directors at each of its regularly scheduled meetings. Our Senior Vice President ("SVP"), Enterprise Risk Management presents to our Board of Directors and our Audit Committee at least once a year on our significant enterprise-wide risks as well as our enterprise-wide risk program. In addition, our Chief Information Security Officer (“CISO”) meets regularly with the Audit Committee on risks related to cybersecurity and information security. The oversight of our cybersecurity program at the management level rests with the Executive Leadership Team (“ELT”) who has designated the CISO to lead and execute on the cybersecurity program. The CISO provides regular updates to the executive leadership team, including the CEO, on our cybersecurity program and cybersecurity risks. Our cybersecurity leaders have extensive experience in cybersecurity, including in consulting and corporate roles at Forbes 100 companies and experience leading security incident detection and response, security architecture, and strategy programs. Finally, management has instituted our Information Security Council and Enterprise Risk Management Council both of which are made up of senior leaders of the Company. The Information Security Council is tasked with overseeing information security matters at Edwards, including cybersecurity. This council serves as an escalation point for issues requiring concerted action, and in turn, informs executive management regarding information security and cybersecurity risks and issues. The Enterprise Risk Management Council is tasked with proactive management of our enterprise-wide risks, including information security risks that also include cybersecurity. This council is responsible for assessing and providing input into the enterprise risks that are presented to the Board of Directors.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Board of Directors and our Audit Committee oversee our enterprise-wide risk management, including with respect to cybersecurity. Our Chief Financial Officer presents information on our enterprise-wide risks to the Board of Directors at each of its regularly scheduled meetings.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Chief Financial Officer presents information on our enterprise-wide risks to the Board of Directors at each of its regularly scheduled meetings. Our Senior Vice President ("SVP"), Enterprise Risk Management presents to our Board of Directors and our Audit Committee at least once a year on our significant enterprise-wide risks as well as our enterprise-wide risk program. In addition, our Chief Information Security Officer (“CISO”) meets regularly with the Audit Committee on risks related to cybersecurity and information security.
Cybersecurity Risk Role of Management [Text Block]	Our Chief Financial Officer presents information on our enterprise-wide risks to the Board of Directors at each of its regularly scheduled meetings. Our Senior Vice President ("SVP"), Enterprise Risk Management presents to our Board of Directors and our Audit Committee at least once a year on our significant enterprise-wide risks as well as our enterprise-wide risk program. In addition, our Chief Information Security Officer (“CISO”) meets regularly with the Audit Committee on risks related to cybersecurity and information security.The oversight of our cybersecurity program at the management level rests with the Executive Leadership Team (“ELT”) who has designated the CISO to lead and execute on the cybersecurity program. The CISO provides regular updates to the executive leadership team, including the CEO, on our cybersecurity program and cybersecurity risks.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our Board of Directors and our Audit Committee oversee our enterprise-wide risk management, including with respect to cybersecurity. Our Chief Financial Officer presents information on our enterprise-wide risks to the Board of Directors at each of its regularly scheduled meetings. Our Senior Vice President ("SVP"), Enterprise Risk Management presents to our Board of Directors and our Audit Committee at least once a year on our significant enterprise-wide risks as well as our enterprise-wide risk program. In addition, our Chief Information Security Officer (“CISO”) meets regularly with the Audit Committee on risks related to cybersecurity and information security.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our cybersecurity leaders have extensive experience in cybersecurity, including in consulting and corporate roles at Forbes 100 companies and experience leading security incident detection and response, security architecture, and strategy programs.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The oversight of our cybersecurity program at the management level rests with the Executive Leadership Team (“ELT”) who has designated the CISO to lead and execute on the cybersecurity program. The CISO provides regular updates to the executive leadership team, including the CEO, on our cybersecurity program and cybersecurity risks.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Dec. 31, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Edwards Lifesciences, its wholly-owned subsidiaries, and variable interest entities ("VIEs") for which the Company is the primary beneficiary. For further information, see Note 9. The Company attributes the net income or losses of its consolidated VIEs to controlling and noncontrolling interests using the hypothetical liquidation at book value method. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The consolidated financial statements of Edwards Lifesciences have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") which have been applied consistently in all material respects. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates.
Foreign Currency Translation	Foreign Currency Translation When the local currency of the Company's foreign entities is the functional currency, all assets and liabilities are translated into United States dollars at the rate of exchange in effect at the balance sheet date. Income and expense items are translated at the weighted-average exchange rate prevailing during the period. The effects of foreign currency translation adjustments for these entities are deferred and reported in stockholders' equity as a component of Accumulated Other Comprehensive Loss. The effects of foreign currency transactions denominated in a currency other than an entity's functional currency are included in Other Non-operating Income, net.
Revenue Recognition and Shipping and Handling Costs	Revenue Recognition Revenue is recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products or services. The Company generates nearly all of its revenue from direct product sales and sales of products under consignment arrangements. Revenue from direct product sales is recognized at a point in time when the performance obligation is satisfied upon delivery of the product. Revenue from sales of consigned inventory is recognized at a point in time when the performance obligation is satisfied once the product has been implanted or used by the customer. The Company periodically reviews consignment inventories to confirm the accuracy of customer reporting. The Company also generates a small portion of its revenue from service contracts, which is recognized ratably over the term of the contracts. Sales taxes and other similar taxes that the Company collects concurrent with revenue-producing activities are excluded from revenue. The Company does not typically have any significant unusual payment terms beyond 90 days in its contracts with customers. In addition, the Company receives royalty payments for the licensing of certain intellectual property and recognizes the royalty when the subsequent sale of product using the intellectual property occurs. The amount of consideration the Company ultimately receives varies depending upon the return terms, sales rebates, discounts, and other incentives that the Company may offer, which are accounted for as variable consideration when estimating the amount of revenue to recognize. The Company includes estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely upon an assessment of historical payment experience, historical relationship to revenues, estimated customer inventory levels, and current contract sales terms with direct and indirect customers. The Company's sales adjustment related to distributor rebates given to the Company's United States distributors represents the difference between the Company's sales price to the distributor and the negotiated price to be paid by the end-customer. This distributor rebate is recorded as a reduction to sales and a reduction to the distributor's accounts receivable at the time of sale to a distributor. The Company periodically monitors current pricing trends and distributor inventory levels to ensure the credit for future distributor rebates is fairly stated. The Company offers volume rebates to certain group purchasing organizations ("GPOs") and customers based upon targeted sales levels. Volume rebates offered to GPOs are recorded as a reduction to sales and an obligation to the GPOs, as the Company expects to pay in cash. Volume rebates offered to customers are recorded as a reduction to sales and either a reduction to accounts receivable if the Company expects a net payment from the customer, or as an obligation to the customer if the Company expects to pay in cash. The provision for volume rebates is estimated based upon customers' contracted rebate programs, projected sales levels, and historical experience of rebates paid. The Company periodically monitors its customer rebate programs to ensure that the allowance and liability for accrued rebates is fairly stated. Product returns are typically not significant because returns are generally not allowed unless the product is damaged at the time of receipt. In limited circumstances, the Company may allow customers to return previously purchased products, such as for next-generation product offerings. For these transactions, the Company defers recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. A limited number of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the transaction price is allocated to each performance obligation based on its relative standalone selling price charged to other customers. The Company applies the optional exemption of not disclosing the amount of the transaction price allocated to unsatisfied performance obligations for contracts with an original expected duration of one year or less. Shipping and Handling Costs Shipping costs, which are costs incurred to physically move product from the Company's premises or third party distribution centers, including storage, to the customer's premises, are included in Selling, General, and Administrative Expenses. Handling costs, which are costs incurred to store at the Company's premises, move, and prepare products for shipment, are included in Cost of Sales.
Cash Equivalents	Cash Equivalents The Company considers highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. These investments are valued at cost, which approximates fair value.
Investments	Investments The Company invests its excess cash in debt securities, including time deposits, commercial paper, United States government and agency securities, asset-backed securities, corporate debt securities, and municipal debt securities. Investments with maturities of one year or less are classified as short-term, and investments with maturities greater than one year are classified as long-term. Investments that the Company has the ability and intent to hold until maturity are classified as held-to-maturity and carried at amortized cost. Investments in debt securities that are classified as available-for-sale are carried at fair value with unrealized gains and losses included in Accumulated Other Comprehensive Loss. The Company determines the appropriate classification of its investments in debt securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company also has long-term equity investments in companies that are in various stages of development. These investments are reported at fair value or under the equity method of accounting, as appropriate. Equity investments that do not have readily determinable fair values are recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The Company accounts for investments in limited partnerships and limited liability corporations, whereby the Company owns a minimum of 5% of the investee's outstanding voting stock, under the equity method of accounting. These investments are recorded at the amount of the Company's investment and adjusted each period for the Company's share of the investee's income or loss, and dividends paid. Realized gains and losses on investments that are sold are determined using the specific identification method, or the first-in, first-out method, depending on the investment type, and recorded to Other Non-operating Income, net. Income relating to investments in debt securities is recorded to Interest Income. Equity investments without readily determinable fair value are considered impaired when there is an indication that the fair value of the Company's interest is less than the carrying amount. Equity method investments are considered impaired when there is an indication of an other-than-temporary decline in value below the carrying amount. Impairments of equity investments are recorded in Other Non-operating Income, net. Debt securities in an unrealized loss position are written down to fair value through Other Non-operating Income, net if the Company intends to sell the security or it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the length of time and the extent to which the security's fair value has been below cost, changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the security, among other factors. When a credit loss exists, the Company compares the present value of cash flows expected to be collected from the debt security to the amortized cost basis of the security to determine the allowance amount that should be recorded, if any.
Accounts Receivable	Accounts Receivable The majority of the Company’s accounts receivable arise from direct product sales and sales of products under consignment arrangements, and have payment terms that generally require payment within 30 to 90 days. The Company does not adjust its receivables for the effects of a significant financing component at contract inception if collection of the receivable is expected within one year or less from the time of sale. In countries where the Company has experienced a pattern of payments extending beyond the stated terms and collection of the receivable is expected beyond one year from the time of sale, the Company assesses whether the customer has a significant financing component and discounts the receivable and reduces the related revenues over the period of time that the Company estimates those amounts will be paid using the country’s market-based borrowing rate for such period. The Company provides reserves against accounts receivable for estimated losses that may result from a customer’s inability to pay based on customer-specific analysis and general matters such as current assessments of past due balances, economic conditions and forecasts, and historical credit loss activity. Amounts determined to be uncollectible are charged or written-off against the reserve.
Inventories	Inventories Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. Market value for raw materials is based on replacement costs, and for other inventory classifications is based on net realizable value. A write-down for excess or slow moving inventory is recorded for inventory which is obsolete, damaged, nearing its expiration date (generally triggered at six months prior to expiration), or slow moving (generally defined as quantities in excess of a two-year supply). The Company allocates to inventory general and administrative costs that are related to the production process. These costs include insurance, manufacturing accounting and human resources personnel, and information technology.
Property, Plant and Equipment	Property, Plant, and Equipment Property, plant, and equipment are recorded at cost. Depreciation is principally calculated for financial reporting purposes on the straight-line method over the estimated useful lives of the related assets, which range from 10 to 40 years for buildings and improvements, from 3 to 15 years for machinery and equipment, and from 3 to 5 years for software. Leasehold improvements are amortized over the life of the related facility leases or the asset, whichever is shorter. Straight-line and accelerated methods of depreciation are used for income tax purposes. Construction in progress is not depreciated until the asset is ready for its intended use.
Leases	Leases The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. The Company's incremental borrowing rate is determined based on the estimated rate of interest for collateralized borrowing over a similar term as the associated lease. Right-of-use assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received. The Company determines the lease term as the noncancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Certain of the Company’s leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. The Company’s leases do not contain any residual value guarantees. The Company accounts for the lease and non-lease components as a single lease component for all of its leases except vehicle leases, for which the lease and non-lease components are accounted for separately. Operating leases are included in Operating Lease Right-of-Use Assets and Operating Lease Liabilities on the Company’s consolidated balance sheets. For further information, see Note 7.
Business Combinations and Contingent Consideration	Business Combinations Businesses that the Company acquires are included in its results of operations as of the acquisition date. The purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase price over the fair values of identifiable assets and liabilities is recorded as goodwill. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. Contingent consideration obligations incurred in connection with a business combination are recorded at their fair values on the acquisition date and remeasured on a quarterly basis, with changes in their fair value recorded as an adjustment to earnings, until the related contingencies have been resolved. When the assets acquired do not meet the definition of a business combination, the transaction is accounted for as an asset acquisition. In an asset acquisition, the cost of the acquisition is allocated to the assets acquired and liabilities assumed based on their relative fair values. Upfront payments related to in-process research and development projects with no alternative future use are expensed upon acquisition. Contingent Consideration The Company records contingent consideration resulting from a business combination at its fair value on the acquisition date. The fair value of the contingent consideration is determined based primarily on the following factors: •discount rates used to present value the projected cash flows; •the probability of success of clinical events and regulatory approvals, and/or meeting commercial milestones; and •projected payment dates. On a quarterly basis, the Company revalues these obligations and records changes in their fair value as an adjustment to earnings. Changes to contingent consideration obligations can result from adjustments to discount rates, accretion of the discount rates due to the passage of time, changes in our estimates of the likelihood or timing of achieving development or commercial milestones, changes in the probability of certain clinical events, or changes in the assumed probability associated with regulatory approval. The assumptions related to determining the value of contingent consideration include a significant amount of judgment, and any changes in the underlying estimates could have a material impact on the amount of contingent consideration expense recorded in any given period.
Intangible Assets and Long-lived Assets	Intangible Assets and Long-lived Assets The Company acquires intangible assets in connection with business combinations and asset purchases. The acquired intangible assets are recorded at fair value, which is determined based on a discounted cash flow analysis. The determination of fair value requires significant estimates, including, but not limited to, projected revenues, projected gross margins, the amount and timing of projected future cash flows, the discount rate used to discount those cash flows, the assessment of the asset's life cycle, including the timing and expected costs to complete in-process projects, and the consideration of legal, technical, regulatory, economic, and competitive risks. Discount rates may vary across acquisitions based on the purchase price, forecasts, and relative risks of each acquired company. Goodwill is reviewed for impairment annually in the fourth quarter of each fiscal year, or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Goodwill is tested for impairment at the reporting unit level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the reporting unit does not pass the qualitative assessment, then the Company performs a quantitative impairment test. The Company determined, after performing a qualitative review of each reporting unit, that it is more likely than not that the fair value of each of its reporting units substantially exceeds the respective carrying amounts. Accordingly, in 2024, 2023, and 2022, the Company did not record any goodwill impairment loss. Indefinite-lived intangible assets relate to in-process research and development acquired in business combinations. The estimated fair values of in-process research and development projects acquired in a business combination which have not reached technological feasibility are capitalized and accounted for as indefinite-lived intangible assets subject to impairment testing until completion or abandonment of the projects. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If the project is abandoned, all remaining capitalized amounts are written off immediately. Indefinite-lived intangible assets are reviewed for impairment annually in the fourth quarter of each fiscal year, or whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired. An impairment loss is recognized when the asset's carrying value exceeds its fair value. In-process research and development projects acquired in an asset acquisition are expensed unless the project has an alternative future use. Management reviews the carrying amounts of other finite-lived intangible assets and long-lived tangible assets whenever events or circumstances indicate that the carrying amounts of an asset may not be recoverable. Impairment indicators include, among other conditions, cash flow deficits, historic or anticipated declines in revenue or operating profit, and adverse legal or regulatory developments. If it is determined that such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair market value. Estimated fair market value is determined primarily using the anticipated cash flows discounted at a rate commensurate with the risk involved. For the purposes of identifying and measuring impairment, long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. In 2024 and 2023, the Company did not record any impairment loss related to its in-process research and development assets. In 2022, the Company recorded a $52.7 million impairment of certain developed technology and in-process research and development assets. For further information, see Note 4.
Income Taxes	Income Taxes The Company is subject to income taxes in the United States and numerous foreign jurisdictions. Significant judgment is required in evaluating the Company's uncertain tax positions and determining its provision for income taxes. The Company recognizes the financial statement benefit of a tax position only after determining that a position would more likely than not be sustained based upon its technical merit if challenged by the relevant taxing authority and taken by management to the court of last resort. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company has made an accounting policy election to recognize the United States tax effects of global intangible low-taxed income as a component of income tax expense in the period the tax arises. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. The Company evaluates quarterly the realizability of its deferred tax assets by assessing its valuation allowance and adjusting the amount, if necessary. The factors used to assess the likelihood of realization are both historical experience and the Company's forecast of future taxable income and available tax planning strategies that could be implemented to realize the net deferred tax assets. Failure to achieve forecasted taxable income in the applicable taxing jurisdictions could affect the ultimate realization of deferred tax assets and could result in an increase in the Company's effective tax rate on future earnings.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense when incurred.
Earnings per Share	Earnings per Share Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, nonvested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive.
Stock-based Compensation	Stock-based Compensation The Company measures and recognizes compensation expense for all stock-based awards based on estimated fair values. Stock-based awards consist of stock options, restricted stock units (service-based and market-based), and employee stock purchase subscriptions. Stock-based compensation expense is measured at the grant date based on the fair value of the award and is recognized as expense over each award's requisite service period (vesting period) on a straight-line basis. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Upon exercise of stock options or vesting of restricted stock units, the Company issues common stock. Upon a participant's retirement, all unvested stock options are immediately forfeited. In addition, upon retirement, a participant will immediately vest in 25% of service-based restricted stock units for each full year of employment with the Company measured from the grant date. All remaining unvested service-based restricted stock units are immediately forfeited. For market-based restricted stock units, upon retirement and in certain other specified cases, a participant will receive a pro-rated portion of the shares that would ultimately be issued based on attainment of the performance goals as determined on the vesting date. The pro-rated portion is based on the participant's whole months of service with the Company during the performance period prior to the date of termination.
Derivatives	Derivatives The Company uses derivative financial instruments to manage its currency exchange rate risk and its interest rate risk. It is the Company's policy not to enter into derivative financial instruments for speculative purposes. Derivative financial instruments involve credit risk in the event the counterparty should default. It is the Company's policy to execute such instruments with global financial institutions that the Company believes to be creditworthy. The Company diversifies its derivative financial instruments among counterparties to minimize exposure to any one of these entities. The Company also uses International Swap Dealers Association master-netting agreements. The master-netting agreements provide for the net settlement of all contracts through a single payment in a single currency in the event of default, as defined by the agreements. The Company uses foreign currency forward exchange contracts and cross currency swap contracts to manage its exposure to changes in currency exchange rates from (1) future cash flows associated with intercompany transactions and certain local currency expenses expected to occur within approximately one year (designated as cash flow hedges), (2) its net investment in certain foreign subsidiaries (designated as net investment hedges) and (3) foreign currency denominated assets or liabilities (designated as fair value hedges). The Company also uses foreign currency forward exchange contracts that are not designated as hedging instruments to offset the transaction gains and losses associated with the revaluation of certain assets and liabilities denominated in currencies other than their functional currencies, resulting principally from intercompany and local currency transactions. All derivative financial instruments are recognized at fair value in the consolidated balance sheets. For each derivative instrument that is designated as a fair value hedge, the gain or loss on the derivative included in the assessment of hedge effectiveness is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. The Company reports in Accumulated Other Comprehensive Loss the gain or loss on derivative financial instruments that are designated, and that qualify, as cash flow hedges. The Company reclassifies these gains and losses into earnings in the same line item and in the same period in which the underlying hedged transactions affect earnings. Changes in the fair value of net investment hedges are reported in Accumulated Other Comprehensive Loss as a part of the cumulative translation adjustment and would be reclassified into earnings if the underlying net investment is sold or substantially liquidated. The portion of the change in fair value related to components excluded from the hedge effectiveness assessment are amortized into earnings over the life of the derivative. The gains and losses on derivative financial instruments for which the Company does not elect hedge accounting treatment are recognized in the consolidated statements of operations in each period based upon the change in the fair value of the derivative financial instrument. Upon settlement, cash flows from net investment hedges are reported as investing activities in the consolidated statements of cash flows, and cash flows from all other derivative financial instruments are reported as operating activities.
Recently Adopted Accounting Standards and New Accounting Standards Not Yet Adopted	Recently Adopted Accounting Standards In November 2023, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting guidance on segment reporting. The amendments require disclosure of significant segment expenses and other segment items and requires entities to provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. The amendment also requires disclosure of the title and position of the chief operating decision maker ("CODM") and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The guidance was effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective application is required, and early adoption is permitted. The Company adopted this guidance for the year ended December 31, 2024 and applied the guidance retrospectively for all periods presented. For further information, see Note 21. In March 2023, the FASB issued an amendment to the accounting guidance on investments in tax credit structures to allow entities to elect to account for their tax equity investments, regardless of the tax credit program from which the income tax credits are received, using the proportional amortization method if certain conditions are met. The guidance was effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2024. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements. New Accounting Standards Not Yet Adopted In November 2024, the FASB issued an amendment to the accounting guidance on income statement presentation to require disclosure, in the notes to the financial statements, of disaggregated information about certain costs and expenses, including purchases of inventory, employee compensation, and depreciation and amortization included in each relevant expense caption within continuing operations. The guidance is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The Company is currently evaluating the impact the guidance will have on its consolidated financial statements. In December 2023, the FASB issued an amendment to the accounting guidance on income taxes which requires entities to provide additional information in the rate reconciliation and additional disaggregated disclosures about income taxes paid. This guidance requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state, and foreign income taxes and to provide more details about the reconciling items in some categories if the items meet a quantitative threshold. The guidance is effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this guidance to impact its financial statements, but the guidance will impact its income tax disclosures.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Schedule of Computation of Basic and Diluted Earnings Per Share

The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information):


	Years Ended December 31,
	2024		2023		2022
Net Income for Earnings Per Share Calculations:
Income from continuing operations, net of tax	$	1,396.0	$	1,220.0	$	1,324.0
Net loss attributable to noncontrolling interests	(4.9)		(3.0)		—
Income from continuing operations attributable to Edwards Lifesciences Corporation	1,400.9		1,223.0		1,324.0
Income from discontinued operations	2,773.7		179.4		197.9
Net income attributable to Edwards Lifesciences Corporation	$	4,174.6	$	1,402.4	$	1,521.9
Weighted Average Shares:
Basic weighted-average shares outstanding	597.7		606.7		619.0
Dilutive effect of stock plans	1.6		2.7		5.2
Dilutive weighted-average shares outstanding	599.3		609.4		624.2
Earnings per Share:
Basic:
Continuing operations	$	2.34	$	2.02	$	2.14
Discontinued operations	4.64		0.29		0.32
Basic earnings per share	$	6.98	$	2.31	$	2.46
Diluted:
Continuing operations	$	2.34	$	2.01	$	2.12
Discontinued operations	4.63		0.29		0.32
Diluted earnings per share	$	6.97	$	2.30	$	2.44

Schedule of Stock-Based Compensation Expense

Total stock-based compensation expense was as follows (in millions):


	Years Ended December 31,
	2024		2023		2022
Cost of sales	$	26.7	$	20.6	$	20.3
Selling, general, and administrative expenses	82.5		74.0		67.3
Research and development expenses	36.4		30.2		26.0
Total stock-based compensation expense	145.6		124.8		113.6
Income tax benefit	(24.8)		(21.8)		(19.6)
Total stock-based compensation expense, net of tax	$	120.8	$	103.0	$	94.0

RESTRUCTURING CHARGES, SEPARATION COSTS, AND OTHER (Tables)

12 Months Ended

Dec. 31, 2024

Restructuring and Related Activities [Abstract]

Summary of Restructuring Liability

The following table presents details of the restructuring liability, which is included in Accrued and Other Liabilities:


	Restructuring Liability
	(in millions)
Balance at December 31, 2023	$	—
Restructuring charges	32.9
Payments	(12.8)
Balance at December 31, 2024	$	20.1

DISCONTINUED OPERATIONS (Tables)

12 Months Ended

Dec. 31, 2024

Discontinued Operations and Disposal Groups [Abstract]

Summary of Disposal Group Including Discontinued Operations

Details of Income from Discontinued Operations are as follows (in millions):


	Twelve Months Ended December 31,
	2024		2023		2022
Net sales	$	730.7	$	994.8	$	918.4
Cost of sales	276.8		401.4		356.7
Gross profit	453.9		593.4		561.7
Selling, general, and administrative expenses	169.0		242.1		210.0
Research and development expenses	82.2		108.9		101.6


Separation costs and other	221.8		17.2		—

Operating (loss) income, net	(19.1)		225.2		250.1


Other non-operating (income) expense, net	(3,348.3)		(0.5)		2.2
Income from discontinued operations before provision for income taxes	3,329.2		225.7		247.9
Provision for income taxes from discontinued operations	555.5		46.3		50.0
Net income from discontinued operations	2,773.7		179.4		197.9

Details of assets and liabilities of discontinued operations are as follows (in millions):


	As of December 31,
	2024		2023
Cash and cash equivalents	$	9.6	$	11.7

Accounts receivable, net of allowances	—		3.6
Other receivables	—		5.2
Inventories	15.1		264.7
Prepaid expenses	2.1		18.0
Other current assets	—		14.4
Total current assets of discontinued operations	$	26.8	$	317.6

Property, plant, and equipment, net	3.4		158.4
Operating lease right-of-use assets	—		9.6
Goodwill	7.4		108.4
Other intangible assets, net	—		29.0
Deferred income taxes	—		5.2
Other assets	—		0.5
Total non-current assets of discontinued operations	$	10.8	$	311.1
Accounts payable	$	—	$	14.8
Accrued and other liabilities	2.0		112.7
Operating lease liabilities	—		2.0
Total current liabilities of discontinued operations	$	2.0	$	129.5



Operating lease liabilities	—		7.8
Uncertain tax positions	—		4.3

Other liabilities	—		13.0
Total non-current liabilities of discontinued operations	$	—	$	25.1

Cash flows attributable to the Company's discontinued operations are included in the Company's consolidated statements of cash flows. Significant non-cash operating and investing activities attributable to discontinued operations consisted of the following (in millions):


	Years Ended December 31,
	2024	2023	2022
Depreciation and amortization	12.0	22.9	22.7
Stock-based compensation	16.8	14.6	13.1
Inventory write off	8.2	23.5	6.2
Capital expenditures	16.6	35.4	36.3

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

+ Details

OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables)

12 Months Ended

Dec. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Components of Selected Captions in the Consolidated Balance Sheets

Components of selected captions in the consolidated balance sheets are as follows (in millions):


	As of December 31,
	2024		2023
Inventories
Raw materials	$	241.1	$	196.3
Work in process	236.2		195.8
Finished products	609.4		511.4
	$	1,086.7	$	903.5
Property, plant, and equipment, net
Land	$	123.9	$	112.4
Buildings and leasehold improvements	1,339.8		1,189.0
Machinery and equipment	689.4		618.6

Software	83.4		77.1
Construction in progress	244.0		292.5
	2,480.5		2,289.6
Accumulated depreciation	(794.5)		(698.6)
	$	1,686.0	$	1,591.0
Other assets
Tax receivable (Note 19)	$	293.9	$	—
Notes and other receivables	129.3		155.1
Acquisition options	147.1		161.3
Long-term prepaid royalties	101.6		109.9
Fair value of derivatives	34.7		23.4
Other long-term assets	15.0		13.5
	$	721.6	$	463.2
Accrued and other liabilities
Employee compensation and withholdings	$	358.6	$	316.4
Accrued rebates	139.3		123.5
Property, payroll, and other taxes	88.1		53.8
Research and development accruals	74.1		71.6
Legal and insurance (Notes 3 and 20)	26.8		28.9
Litigation settlement	73.8		69.1
Taxes payable	286.6		52.7
Fair value of derivatives	8.3		15.2
Accrued marketing expenses	13.8		13.7
Accrued professional services	20.1		8.5
Accrued realignment reserves	27.4		6.4
Accrued relocation costs	15.4		16.9

Unfavorable contract liability	53.7		—
Other accrued liabilities	96.4		79.7
	$	1,282.4	$	856.4

Schedule of Cash Flow Information

Supplemental Cash Flow Information

(in millions)


	Years Ended December 31,
	2024		2023		2022
Cash paid during the year for:
Interest	$	19.6	$	19.9	$	19.3
Income taxes (a) (Note 19)	$	1,196.1	$	470.1	$	504.1
Amounts included in the measurement of operating lease liabilities	$	28.0	$	25.7	$	25.0
Non-cash investing and financing transactions:


Right-of-use assets obtained in exchange for new lease liabilities	$	42.8	$	27.3	$	23.4
Capital expenditures accruals	$	44.1	$	43.6	$	41.0

______________________________________

(a) Includes cash paid for income taxes from discontinued operations of $29.7 million, $25.2 million, and $37.4 million for the years ended December 31, 2024, 2023, and 2022, respectively.

Schedule of Cash and Cash Equivalents

Cash, Cash Equivalents, and Restricted Cash

(in millions)


	Years Ended December 31,
	2024		2023		2022
Continuing operations
Cash and cash equivalents	$	3,045.2	$	1,132.3	$	761.5
Restricted cash included in other current assets	3.2		3.3		0.5
Restricted cash included in other assets	0.8		0.7		3.1
Total	$	3,049.2	$	1,136.3	$	765.1
Discontinued operations
Cash and cash equivalents	$	9.6	$	11.7	$	7.5
Total	$	9.6	$	11.7	$	7.5
Total cash, cash equivalents, and restricted cash	$	3,058.8	$	1,148.0	$	772.6

Schedule of Restricted Cash

Cash, Cash Equivalents, and Restricted Cash

(in millions)


	Years Ended December 31,
	2024		2023		2022
Continuing operations
Cash and cash equivalents	$	3,045.2	$	1,132.3	$	761.5
Restricted cash included in other current assets	3.2		3.3		0.5
Restricted cash included in other assets	0.8		0.7		3.1
Total	$	3,049.2	$	1,136.3	$	765.1
Discontinued operations
Cash and cash equivalents	$	9.6	$	11.7	$	7.5
Total	$	9.6	$	11.7	$	7.5
Total cash, cash equivalents, and restricted cash	$	3,058.8	$	1,148.0	$	772.6

LEASES (Tables)

12 Months Ended

Dec. 31, 2024

Leases [Abstract]

Schedule of Assets And Liabilities of Lessee

Supplemental balance sheet information related to operating leases was as follows (in millions, except lease term and discount rate):


	As of December 31,
	2024		2023
Operating lease right-of-use assets	$	98.2	$	84.4

Operating lease liabilities, current portion	$	23.4	$	22.9
Operating lease liabilities, long-term portion	78.9		65.2
Total operating lease liabilities	$	102.3	$	88.1

Schedule of Lessee, Operating Lease, Liability, Maturity

Maturities of operating lease liabilities at December 31, 2024 were as follows (in millions):


2025	$	26.4
2026	23.3
2027	19.1
2028	13.2
2029	8.4
Thereafter	23.8
Total lease payments	114.2
Less: imputed interest	(11.9)
Total lease liabilities	$	102.3

The following table provides information on the lease terms and discount rates:


	Years Ended December 31,
	2024		2023
Weighted-average remaining lease term (in years)	5.9		5.8
Weighted-average discount rate	3.4	%	2.3	%

INVESTMENTS (Tables)

12 Months Ended

Dec. 31, 2024

Investments, Debt and Equity Securities [Abstract]

Schedule of Investments in Debt Securities

Investments in debt securities at the end of each period were as follows (in millions):


	December 31, 2024								December 31, 2023
Held-to-maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Bank time deposits	$	57.9	$	—	$	—	$	57.9	$	64.5	$	—	$	—	$	64.5








Available-for-sale
Bank time deposits	$	13.9	$	—	$	—	$	13.9	$	—	$	—	$	—	$	—
Commercial paper	236.5		—		—		236.5		—		—		—		—
U.S. government and agency securities	238.1		0.1		(1.1)		237.1		72.7		0.1		(2.8)		70.0

Asset-backed securities	70.2		—		(1.4)		68.8		192.1		—		(7.8)		184.3
Corporate debt securities	465.0		0.1		(2.8)		462.3		658.5		—		(16.7)		641.8
Municipal securities	2.7		—		—		2.7		2.8		—		(0.2)		2.6
	$	1,026.4	$	0.2	$	(5.3)	$	1,021.3	$	926.1	$	0.1	$	(27.5)	$	898.7

Schedule of Cost and Fair Value of Investments in Debt Securities, by Contractual Maturity

The cost and fair value of investments in debt securities, by contractual maturity, as of December 31, 2024 were as follows:


	Held-to-Maturity				Available-for-Sale
	Amortized Cost		Fair Value		Amortized Cost		Fair Value
	(in millions)
Due in 1 year or less	$	57.9	$	57.9	$	874.0	$	872.8
Due after 1 year through 5 years	—		—		64.3		62.8


Instruments not due at a single maturity date (a)	—		—		88.1		85.7
	$	57.9	$	57.9	$	1,026.4	$	1,021.3

_______________________________________

(a) Consists of mortgage-backed and asset-backed securities.

Schedule of Gross Unrealized Losses and Fair Values for Investments in Unrealized Loss Position

The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2024 and 2023, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in millions):



	December 31, 2024
	Less than 12 Months				12 Months or Greater				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses


U.S. government and agency securities	$	—	$	—	$	19.9	$	(1.1)	$	19.9	$	(1.1)

Asset-backed securities	8.4		(0.1)		53.3		(1.3)		61.7		(1.4)
Corporate debt securities	—		—		141.0		(2.8)		141.0		(2.8)

	$	8.4	$	(0.1)	$	214.2	$	(5.2)	$	222.6	$	(5.3)



	December 31, 2023
	Less than 12 Months				12 Months or Greater				Total
	Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses


U.S. government and agency securities	$	—	$	—	$	67.1	$	(2.8)	$	67.1	$	(2.8)

Asset-backed securities	10.2		(1.8)		172.7		(6.0)		182.9		(7.8)
Corporate debt securities	25.0		(0.1)		601.3		(16.6)		626.3		(16.7)
Municipal securities	—		—		2.6		(0.2)		2.6		(0.2)
	$	35.2	$	(1.9)	$	843.7	$	(25.6)	$	878.9	$	(27.5)

Schedule of Investments in Unconsolidated Affiliates

The Company has a number of equity investments in unconsolidated entities. These investments are recorded in Long-term Investments on the consolidated balance sheets, and are as follows:


	December 31,
	2024		2023
	(in millions)
Equity method investments
Carrying value of equity method investments	$	34.8	$	33.6
Equity securities
Carrying value of marketable equity securities	5.5		—
Carrying value of non-marketable equity securities	119.1		87.6
Total investments in unconsolidated entities	$	159.4	$	121.2

BUSINESS COMBINATIONS (Tables)

12 Months Ended

Dec. 31, 2024

Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]

Schedule of Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the fair value of consideration transferred and the fair values of the assets acquired and liabilities assumed (in millions):


Cash consideration paid at closing	$	319.3
Settlement of pre-existing relationships	5.4
Fair value of previously held equity interest in Innovalve	64.6
Fair value of contingent consideration	12.7
Total purchase price	402.0
Less: cash acquired	(21.1)
Total purchase price, net of cash acquired	$	380.9

Current assets	$	26.5
Property and equipment, net	1.2
Goodwill	205.4
In-process research and development	218.4




Liabilities assumed	(8.2)
Deferred tax liabilities	(41.3)
Net assets acquired	402.0
Less: cash acquired	(21.1)
Total purchase price, net of cash acquired	$	380.9

The following table summarizes the fair value of consideration transferred and the fair values of the assets acquired and liabilities assumed (in millions):


Cash consideration paid at closing	$	650.3
Settlement of pre-existing relationships	53.1
Fair value of previously held equity interest in Endotronix	94.6
Fair value of contingent consideration	2.0
Total purchase price	800.0
Less: cash acquired	(1.2)
Total purchase price, net of cash acquired	$	798.8

Current assets	$	7.7
Property and equipment, net	12.6
Goodwill	382.8
In-process research and development	68.9
Developed technology	388.9
Operating lease right-of-use assets	9.9

Other assets	0.7
Liabilities assumed	(26.3)
Deferred tax liabilities	(45.2)
Net assets acquired	800.0
Less: cash acquired	(1.2)
Total purchase price, net of cash acquired	$	798.8

The following table summarizes the fair value of consideration transferred and the fair values of the assets acquired and liabilities assumed (in millions):


Cash consideration paid at closing	$	114.8


Fair value of contingent consideration	1.8
Total purchase price	116.6
Less: cash acquired	(0.3)
Total purchase price, net of cash acquired	$	116.3

Current assets	$	0.3
Property and equipment, net	0.3
Goodwill	46.4
In-process research and development	86.6




Current liabilities assumed	(1.0)
Deferred tax liabilities	(16.0)
Net assets acquired	116.6
Less: cash acquired	(0.3)
Total purchase price, net of cash acquired	$	116.3

The following table summarizes the fair values of the assets acquired and liabilities assumed (in millions):


Assets	$	8.1

Goodwill (b)	133.2


In-process research and development	136.6


Liabilities assumed	(1.7)
Deferred tax liabilities	(28.0)
Fair value of net assets acquired	248.2
Less: Noncontrolling interest (a)	(72.4)
Total purchase price	175.8
Less: cash acquired	(6.8)
Total purchase price, net of cash acquired (b)	$	169.0

_______________________________________

(a) Includes the fair value of the noncontrolling interest of $94.4 million, offset by the purchase consideration allocated to the option of $22.0 million, which was ascribed to the noncontrolling interest.

(b) Includes $22.5 million paid in a previous year under option agreements, $5.3 million for the settlement of a pre-existing note, and $46.0 million of cash paid directly to the acquired company which was included in Edwards' consolidated cash balance and offset against goodwill post acquisition.

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in the Carrying Amount of Goodwill, by Segment

The changes in the carrying amount of goodwill, by segment, during the years ended December 31, 2024 and 2023 were as follows:


	United States		Europe		Rest of World		Total
	(in millions)
Goodwill at December 31, 2022	$	710.7	$	56.3	$	297.8	$	1,064.8
Goodwill acquired during the year	—		—		78.4		78.4
Currency translation adjustment	—		1.9		—		1.9
Goodwill at December 31, 2023	710.7		58.2		376.2		1,145.1
Goodwill acquired during the year (Note 10)	429.2		—		205.4		634.6
Currency translation adjustment	—		(3.0)		—		(3.0)
Goodwill at December 31, 2024	$	1,139.9	$	55.2	$	581.6	$	1,776.7

Schedule of Finite-Lived Other Intangible Assets

Other intangible assets consist of the following (in millions):


		December 31,
	Weighted-Average Useful Life (in years)	2024						2023
		Cost		Accumulated Amortization		Net Carrying Value		Cost		Accumulated Amortization		Net Carrying Value
Finite-lived intangible assets
Patents	10.0	$	138.8	$	(90.5)	$	48.3	$	119.0	$	(87.3)	$	31.7
Developed technology	12.2	665.2		(47.4)		617.8		155.8		(45.7)		110.1
Other	0.0	3.4		(3.4)		—		3.5		(3.5)		—
	12.1	807.4		(141.3)		666.1		278.3		(136.5)		141.8
Indefinite-lived intangible assets
In-process research and development		510.5		—		510.5		257.6		—		257.6
		$	1,317.9	$	(141.3)	$	1,176.6	$	535.9	$	(136.5)	$	399.4

Schedule of Indefinite-Lived Other Intangible Assets

Other intangible assets consist of the following (in millions):


		December 31,
	Weighted-Average Useful Life (in years)	2024						2023
		Cost		Accumulated Amortization		Net Carrying Value		Cost		Accumulated Amortization		Net Carrying Value
Finite-lived intangible assets
Patents	10.0	$	138.8	$	(90.5)	$	48.3	$	119.0	$	(87.3)	$	31.7
Developed technology	12.2	665.2		(47.4)		617.8		155.8		(45.7)		110.1
Other	0.0	3.4		(3.4)		—		3.5		(3.5)		—
	12.1	807.4		(141.3)		666.1		278.3		(136.5)		141.8
Indefinite-lived intangible assets
In-process research and development		510.5		—		510.5		257.6		—		257.6
		$	1,317.9	$	(141.3)	$	1,176.6	$	535.9	$	(136.5)	$	399.4

Schedule of Estimated Amortization Expense

Estimated amortization expense for each of the years ending December 31 is as follows (in millions):


2025	$	9.8
2026	19.1
2027	33.0
2028	56.8
2029	81.3

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

DEBT AND CREDIT FACILITIES (Tables)

12 Months Ended

Dec. 31, 2024

Debt Disclosure [Abstract]

Schedule of the Notes

The following is a summary of the Notes as of December 31, 2024 and 2023:


	December 31,
	2024				2023
	Amount		Effective Interest Rate		Amount		Effective Interest Rate
	(in millions)				(in millions)
Fixed-rate 4.3% Notes	$	600.0	4.329	%	$	600.0	4.329	%


Unamortized discount	(0.5)				(0.7)
Unamortized debt issuance costs	(1.8)				(2.3)

Total carrying amount	$	597.7			$	597.0

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis

The following table summarizes the Company's financial instruments which are measured at fair value on a recurring basis as of December 31, 2024 and 2023 (in millions):


December 31, 2024	Level 1		Level 2		Level 3		Total
Assets
Cash equivalents	$	1,394.4	$	985.5	$	—	$	2,379.9
Available-for-sale investments:
Bank time deposits	—		13.9		—		13.9
Corporate debt securities	—		462.3		—		462.3
Asset-backed securities	—		68.8		—		68.8
United States government and agency securities	—		237.1		—		237.1

Commercial paper	—		236.5		—		236.5
Municipal securities	—		2.7		—		2.7
Equity investments in unconsolidated entities	5.5		—		—		5.5
Investments held for deferred compensation plans	146.6		—		—		146.6
Derivatives	—		82.1		—		82.1
	$	1,546.5	$	2,088.9	$	—	$	3,635.4
Liabilities
Derivatives	$	—	$	8.2	$	—	$	8.2

Contingent consideration liabilities	—		—		16.5		16.5
Other	—		—		5.0		5.0
	$	—	$	8.2	$	21.5	$	29.7

December 31, 2023
Assets
Cash equivalents	$	579.2	$	—	$	—	$	579.2
Available-for-sale investments:

Corporate debt securities	—		641.8		—		641.8
Asset-backed securities	—		184.3		—		184.3
United States government and agency securities	—		70.0		—		70.0


Municipal securities	—		2.6		—		2.6

Investments held for deferred compensation plans	125.8		—		—		125.8
Derivatives	—		39.5		—		39.5
	$	705.0	$	938.2	$	—	$	1,643.2
Liabilities
Derivatives	$	—	$	15.2	$	—	$	15.2


Other	—		—		10.3		10.3
	$	—	$	15.2	$	10.3	$	25.5

Schedule of Changes in Fair Value of Contingent Consideration Obligation

The following table summarizes the changes in fair value of Level 3 financial instruments measured at fair value on a recurring basis for the years ended December 31, 2024 and 2023 (in millions):


	Contingent Consideration		Other		Total
Fair value, December 31, 2022	$	26.2	$	14.0	$	40.2


Changes in fair value	(26.2)		(3.7)		(29.9)

Fair value, December 31, 2023	$	—	$	10.3	$	10.3
Additions	16.5		—		16.5

Changes in fair value	—		(5.3)		(5.3)

Fair value, December 31, 2024	$	16.5	$	5.0	$	21.5

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)

12 Months Ended

Dec. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Financial Instruments Used to Manage Currency Exchange and Interest Rate Risk

The Company uses derivative financial instruments to manage its currency exchange rate risk and its interest rate risk as summarized below. Notional amounts are stated in United States dollar equivalents at spot exchange rates at the respective dates. The Company does not enter into these arrangements for trading or speculation purposes.


	Notional Amount
	As of December 31,
	2024		2023
	(in millions)
Foreign currency forward exchange contracts	$	1,926.9	$	1,460.3
Cross currency swap contracts	300.0		300.0

Schedule of Location and Fair Value Amounts of Derivative Instruments Reported in Consolidated Balance Sheets

The following table presents the location and fair value amounts of derivative instruments reported in the consolidated balance sheets (in millions):


		Fair Value
		As of December 31,
	Balance Sheet Location	2024		2023
Derivatives designated as hedging instruments
Assets
Foreign currency contracts	Other current assets	$	47.4	$	16.1

Cross currency swap contracts	Other assets	$	34.7	$	23.4

Liabilities
Foreign currency contracts	Accrued and other liabilities	$	6.4	$	15.2



Derivatives not designated as hedging instruments



Liabilities
Foreign currency contracts	Accrued and other liabilities	$	1.8	$	—

Schedule of Effect of Master-Netting Agreements and Rights of Offset, Derivative Assets

The following table presents the effect of master-netting agreements and rights of offset on the consolidated balance sheets (in millions):


							Gross Amounts Not Offset in the Consolidated Balance Sheet
			Gross Amounts Offset in the Consolidated Balance Sheet		Net Amounts Presented in the Consolidated Balance Sheet
December 31, 2024	Gross Amounts						Financial Instruments		Cash Collateral Received		Net Amount
Derivative Assets
Foreign currency contracts	$	47.4	$	—	$	47.4	$	(5.4)	$	—	$	42.0
Cross currency swap contracts	$	34.7	$	—	$	34.7	$	—	$	—	$	34.7
Derivative Liabilities
Foreign currency contracts	$	8.2	$	—	$	8.2	$	(5.4)	$	—	$	2.8

December 31, 2023
Derivative Assets
Foreign currency contracts	$	16.1	$	—	$	16.1	$	(9.4)	$	—	$	6.7
Cross currency swap contracts	$	23.4	$	—	$	23.4	$	—	$	—	$	23.4
Derivative Liabilities
Foreign currency contracts	$	15.2	$	—	$	15.2	$	(9.4)	$	—	$	5.8

Schedule of Effect of Master-Netting Agreements and Rights of Offset, Derivative Liabilities

The following table presents the effect of master-netting agreements and rights of offset on the consolidated balance sheets (in millions):


							Gross Amounts Not Offset in the Consolidated Balance Sheet
			Gross Amounts Offset in the Consolidated Balance Sheet		Net Amounts Presented in the Consolidated Balance Sheet
December 31, 2024	Gross Amounts						Financial Instruments		Cash Collateral Received		Net Amount
Derivative Assets
Foreign currency contracts	$	47.4	$	—	$	47.4	$	(5.4)	$	—	$	42.0
Cross currency swap contracts	$	34.7	$	—	$	34.7	$	—	$	—	$	34.7
Derivative Liabilities
Foreign currency contracts	$	8.2	$	—	$	8.2	$	(5.4)	$	—	$	2.8

December 31, 2023
Derivative Assets
Foreign currency contracts	$	16.1	$	—	$	16.1	$	(9.4)	$	—	$	6.7
Cross currency swap contracts	$	23.4	$	—	$	23.4	$	—	$	—	$	23.4
Derivative Liabilities
Foreign currency contracts	$	15.2	$	—	$	15.2	$	(9.4)	$	—	$	5.8

Schedule of Effect of Derivative Instruments on Consolidated Statements of Operations and Consolidated Statements of Comprehensive Income

The following table presents the effect of derivative and non-derivative hedging instruments on the consolidated statements of operations and consolidated statements of comprehensive income:


	Amount of Gain or (Loss) Recognized in Other Comprehensive Income on Derivative (Effective Portion)
	2024		2023
Cash flow hedges
Foreign currency contracts	$	83.8	$	29.2
Net investment hedges
Cross-currency swap contracts	$	11.3	$	(17.3)

Schedule of Effect of Fair Value and Cash Flow Hedge Accounting on the Consolidated Statements of Operations

The following tables present the effect of fair value and cash flow hedge accounting on the consolidated statements of operations:


	Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships
	Year Ended December 31, 2024
	Cost of sales		Interest income, net		Other non-operating income, net

Total amounts presented in the consolidated statements of operations	$	(1,117.5)	$	(19.8)	$	68.9
The effects of fair value hedges:
Foreign currency contracts:
Hedged items	—		—		(4.0)
Derivatives designated as hedging instruments	—		—		4.0
Amount excluded from effectiveness testing (amortized)	—		—		0.8
The effects of cash flow hedges:
Foreign currency contracts:
Amount of gain (loss) reclassified from accumulated other comprehensive loss into income	35.8		—		—
The effects of net investment hedges:
Cross currency swap contracts
Amount excluded from effectiveness testing	—		7.0		—
The effects of non-designated hedges:
Foreign currency contracts:	—		—		22.4


	Location and Amount of Gain or (Loss) Recognized in Income on Fair Value and Cash Flow Hedging Relationships
	Year Ended December 31, 2023
	Cost of sales		Interest income, net		Other non-operating income, net

Total amounts presented in the consolidated statements of operations	$	(978.4)	$	(17.6)	$	13.9
The effects of fair value hedges:
Foreign currency contracts:
Hedged items	—		—		(9.2)
Derivatives designated as hedging instruments	—		—		9.2
Amount excluded from effectiveness testing (amortized)	—		—		4.7
The effects of cash flow hedges:
Foreign currency contracts:
Amount of gain (loss) reclassified from accumulated other comprehensive loss into income	58.9		—		—
The effects of net investment hedges:
Cross currency swap contracts
Amount excluded from effectiveness testing	—		6.9		—
The effects of non-designated hedges:
Foreign currency contracts:	—		—		7.4

EMPLOYEE BENEFIT PLANS (Tables)

12 Months Ended

Dec. 31, 2024

Retirement Benefits [Abstract]

Schedule of Information Regarding Defined Benefit Pension Plans

The Company maintains defined benefit pension plans in Japan and certain European countries.


	Years Ended December 31,
	2024		2023
	(in millions)
Change in projected benefit obligation:
Beginning of year	$	111.7	$	94.1
Service cost	5.0		4.3
Interest cost	1.9		2.3
Participant contributions	2.0		1.9
Actuarial loss	3.6		9.9
Benefits paid	(1.5)		(3.8)
Plan amendment	(0.5)		(0.4)
Divestiture (Note 5)	(4.4)		—
Settlements and curtailment gain (Note 5)	(5.4)		—

Currency exchange rate changes and other	(5.7)		3.4
End of year	$	106.7	$	111.7




Change in fair value of plan assets:
Beginning of year	$	75.5	$	70.6
Actual return on plan assets	6.3		0.8
Employer contributions	6.4		3.5
Participant contributions	2.0		1.9
Divestiture (Note 5)	(4.4)		—
Settlements	(5.9)		—
Benefits paid	(1.5)		(3.8)
Currency exchange rate changes and other	(3.8)		2.5
End of year	$	74.6	$	75.5
Funded Status
Projected benefit obligation	$	(106.7)	$	(111.7)
Plan assets at fair value	74.6		75.5
Underfunded status	$	(32.1)	$	(36.2)
Net amounts recognized on the consolidated balance sheet:
Other liabilities	$	32.1	$	36.2
Accumulated other comprehensive loss, net of tax:
Net actuarial loss	$	(9.1)	$	(10.3)
Net prior service credit	4.4		5.2
Deferred income tax benefit	0.6		0.9
Total	$	(4.1)	$	(4.2)

Schedule of Pension Plans with Accumulated Benefit Obligations

Pension plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets were as follows:


	December 31,
	2024		2023
	(in millions)
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	$	89.1	$	106.8
Fair value of plan assets	61.6		75.5
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$	106.7	$	111.7
Fair value of plan assets	74.6		75.5

Schedule of Net Periodic Benefit Cost

The components of net periodic pension benefit cost are as follows (in millions):


	Years Ended December 31,
	2024		2023		2022
Service cost, net	$	5.0	$	4.3	$	5.5
Interest cost	1.9		2.3		0.5
Expected return on plan assets	(3.1)		(2.7)		(1.5)
Settlements and curtailment gain	1.2		—		0.1

Amortization of actuarial loss	0.2		—		0.5
Amortization of prior service credit	(0.8)		(0.8)		(0.7)

Net periodic pension benefit cost	$	4.4	$	3.1	$	4.4

Schedule of Weighted-Average Assumptions Used to Determine Benefit Obligations

The weighted-average assumptions used to determine the benefit obligations are as follows:


	December 31,
	2024		2023
Discount rate	1.5	%	1.8	%
Rate of compensation increase	2.8	%	2.9	%
Cash balance interest crediting rate	1.5	%	1.5	%
Social securities increase	1.8	%	1.8	%
Pension increase	2.2	%	2.2	%

The weighted-average assumptions used to determine the net periodic pension benefit cost are as follows:


	Years ended December 31,
	2024		2023		2022
Discount rate	1.8	%	2.5	%	0.5	%
Expected return on plan assets	4.3	%	3.7	%	2.1	%
Rate of compensation increase	2.9	%	2.9	%	2.6	%
Cash balance interest crediting rate	1.5	%	1.5	%	1.5	%
Social securities increase	1.8	%	1.8	%	1.6	%
Pension increase	2.2	%	2.2	%	1.8	%

Schedule of Target Weighted-Average Asset Allocations and Fair Value

Target weighted-average asset allocations at December 31, 2024, by asset category, are as follows:


Equity securities	30.9	%
Debt securities	37.2	%
Real estate	14.7	%
Other	17.2	%
Total	100.0	%

The fair values of the Company's defined benefit plan assets at December 31, 2024 and 2023, by asset category, are as follows (in millions):


December 31, 2024	Level 1		Level 2		Level 3		Total
Asset Category
Cash	$	1.1	$	—	$	—	$	1.1
Equity securities:
United States equities	2.0		—		—		2.0
International equities	21.1		—		—		21.1
Debt securities:
United States government bonds	3.2		—		—		3.2
International government bonds	24.6		—		—		24.6
Real estate	—		11.0		—		11.0
Mortgages	—		3.0		—		3.0
Insurance contracts	—		—		0.7		0.7
Total plan assets measured at fair value	$	52.0	$	14.0	$	0.7	$	66.7
Alternative investments measured at net asset value (a)							7.9
Total plan assets							$	74.6


December 31, 2023	Level 1		Level 2		Level 3		Total
Asset Category
Cash	$	2.0	$	—	$	—	$	2.0
Equity securities:
United States equities	2.6		—		—		2.6
International equities	21.0		—		—		21.0
Debt securities:
United States government bonds	3.5		—		—		3.5
International government bonds	26.0		—		—		26.0
Real estate	—		8.7		—		8.7
Mortgages	—		4.0		—		4.0
Insurance contracts	—		—		0.8		0.8
Total plan assets	$	55.1	$	12.7	$	0.8	$	68.6
Alternative investments measured at net asset value (a)							6.9
Total plan assets							$	75.5

_______________________________________

(a) Certain investments that were measured at net asset value per share have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the total plan assets.

Schedule of Changes in Fair Value of Defined Benefit Plan Assets Classified as Level 3

The following table summarizes the changes in fair value of the Company's defined benefit plan assets that have been classified as Level 3 for the years ended December 31, 2024 and 2023 (in millions):


	Insurance Contracts
Balance at December 31, 2022	$	0.8
Actual return on plan assets:
Relating to assets still held at December 31, 2023	0.2

Purchases, sales and settlements	(0.2)


Balance at December 31, 2023	0.8
Actual return on plan assets:
Relating to assets still held at December 31, 2024	0.4

Purchases, sales and settlements	(0.5)


Balance at December 31, 2024	$	0.7

Schedule of Benefit Payments Which Reflect Expected Future Service

The following benefit payments, which reflect expected future service, as appropriate, at December 31, 2024, are expected to be paid (in millions):


2025	$	6.9
2026	5.5
2027	5.8
2028	7.5
2029	7.2
2030-2034	36.5

COMMON STOCK (Tables)

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

Schedule of Accelerated Share Repurchases

The following table summarizes the terms of the ASR agreements (dollars and shares in millions, except per share data):


			Initial Delivery					Final Settlement
Agreement Date	Amount Paid		Shares Received	Price per Share		Value of Shares as % of Contract Value		Settlement Date	Total Shares Received	Average Price per Share
February 2023	$	200.0	2.0	$	80.44	80	%	March 2023	2.5	$	79.28
December 2023	$	400.0	4.6	$	70.31	80	%	December 2023	5.3	$	72.91
April 2024	$	150.0	1.4	$	85.95	80	%	May 2024	1.7	$	86.72
August 2024	$	500.0	5.8	$	68.93	80	%	December 2024	7.5	$	66.60

Schedule of Weighted-Average Assumptions for Options Granted

The Black-Scholes option pricing model was used with the following weighted-average assumptions for options granted during the following periods:

Option Awards


	Years Ended December 31,
	2024			2023			2022
Risk-free interest rate	4.5		%	3.4		%	3.0		%
Expected dividend yield	None			None			None
Expected volatility	30.9		%	32.8		%	31.4		%
Expected term (years)	5.3			5.1			5.0
Fair value, per share	$	31.14		$	30.97		$	34.59

Schedule of Weighted-Average Assumptions for ESPP Subscriptions

The Black-Scholes option pricing model was used with the following weighted-average assumptions for ESPP subscriptions granted during the following periods:

ESPP


	Years Ended December 31,
	2024			2023			2022
Risk-free interest rate	5.2		%	4.6		%	0.5		%
Expected dividend yield	None			None			None
Expected volatility	33.5		%	31.5		%	32.0		%
Expected term (years)	0.6			0.6			0.6
Fair value, per share	$	25.01		$	19.03		$	28.18

Schedule of Stock Option Activity

Stock option activity during the year ended December 31, 2024 under the Program and the Nonemployee Directors Program was as follows (in millions, except years and per-share amounts):


	Shares	Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding as of December 31, 2023	11.0	$	71.90
Options granted	1.5	85.46
Options exercised	(2.1)	43.12
Options forfeited	(0.4)	91.39
Outstanding as of December 31, 2024	10.0	79.15		3.4 years	$	57.9
Exercisable as of December 31, 2024	6.7	73.63		2.4 years	$	57.5
Vested and expected to vest as of December 31, 2024	9.6	78.61		3.3 years	$	57.9

Schedule of Restricted Stock Unit Activity

The following table summarizes nonvested restricted stock unit activity during the year ended December 31, 2024 under the Program and the Nonemployee Directors Program (in millions, except per-share amounts):


	Shares	Weighted- Average Grant-Date Fair Value
Nonvested as of December 31, 2023	2.1	$	94.35
Granted	2.1	85.48
Vested	(0.7)	92.79
Forfeited	(0.3)	90.13
Nonvested as of December 31, 2024	3.2	89.16

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

Schedule of Activity for Each Component of Accumulated Other Comprehensive Loss

Presented below is a summary of activity for each component of Accumulated Other Comprehensive Loss for the years ended December 31, 2024, 2023, and 2022.


	Foreign Currency Translation Adjustments		Unrealized Gain (Loss) on Hedges		Unrealized (Loss) Gain on Available-for-sale Investments		Unrealized Pension (Costs) Credits (a)		Total Accumulated Other Comprehensive Loss
	(in millions)
December 31, 2021	$	(172.5)	$	29.7	$	(6.9)	$	(8.0)	$	(157.7)
Other comprehensive (loss) income before reclassifications	(33.9)		75.2		(77.9)		17.3		(19.3)
Amounts reclassified from accumulated other comprehensive loss	(7.0)		(84.5)		18.8		(0.1)		(72.8)
Deferred income tax (expense) benefit	(5.4)		3.4		0.4		(3.5)		(5.1)
December 31, 2022	(218.8)		23.8		(65.6)		5.7		(254.9)
Other comprehensive income (loss) before reclassifications	6.9		43.3		32.6		(11.1)		71.7
Amounts reclassified from accumulated other comprehensive loss	(6.9)		(72.8)		8.1		(0.8)		(72.4)
Deferred income tax benefit	4.3		6.4		0.1		2.0		12.8
December 31, 2023	(214.5)		0.7		(24.8)		(4.2)		(242.8)
Other comprehensive (loss) income before reclassifications	(49.9)		91.0		34.8		(0.2)		75.7
Amounts reclassified from accumulated other comprehensive loss	(7.0)		(40.6)		(12.5)		0.6		(59.5)
Deferred income tax expense	(2.7)		(13.4)		(1.5)		(0.3)		(17.9)
December 31, 2024	$	(274.1)	$	37.7	$	(4.0)	$	(4.1)	$	(244.5)

Schedule of Change in Unrealized Pension Costs

For the years ended December 31, 2024, 2023, and 2022, the change in unrealized pension costs consisted of the following (in millions):


	Pre-Tax Amount		Tax (Expense) Benefit		Net of Tax Amount
2024
Prior service credit arising during period	$	—	$	(0.1)	$	(0.1)
Amortization of prior service credit	(0.8)		0.2		(0.6)
Net prior service cost arising during period	(0.8)		0.1		(0.7)
Net actuarial loss arising during period	1.2		(0.4)		0.8
Unrealized pension costs, net	$	0.4	$	(0.3)	$	0.1
2023
Prior service credit arising during period	$	0.7	$	0.9	$	1.6
Amortization of prior service credit	(0.8)		0.1		(0.7)
Net prior service cost arising during period	(0.1)		1.0		0.9
Net actuarial gain arising during period	(11.8)		1.0		(10.8)
Unrealized pension credits, net	$	(11.9)	$	2.0	$	(9.9)
2022
Prior service cost arising during period	$	—	$	(1.1)	$	(1.1)
Amortization of prior service credit	(0.7)		0.3		(0.4)
Net prior service cost arising during period	(0.7)		(0.8)		(1.5)
Net actuarial gain arising during period	17.9		(2.7)		15.2
Unrealized pension credits, net	$	17.2	$	(3.5)	$	13.7

Schedule of Amounts Reclassified from Accumulated Other Comprehensive Loss

The following table provides information about amounts reclassified from Accumulated Other Comprehensive Loss (in millions):


	Years Ended December 31,
Details about Accumulated Other Comprehensive Loss Components	2024		2023		Affected Line on Consolidated Statements of Operations
Foreign currency translation adjustments	$	7.0	$	6.9	Other non-operating income, net
	(1.7)		(1.7)		Provision for income taxes
	$	5.3	$	5.2	Net of tax
Gain (loss) on hedges	$	35.8	$	58.9	Cost of sales

	4.8		13.9		Other non-operating income, net
	40.6		72.8		Total before tax
	(10.1)		(15.8)		Provision for income taxes
	$	30.5	$	57.0	Net of tax
(Loss) gain on available-for-sale investments	$	12.5	$	(8.1)	Other non-operating income, net
	(3.1)		2.2		Provision for income taxes
	$	9.4	$	(5.9)	Net of tax

Amortization of pension adjustments	$	(0.6)	$	0.8	Other non-operating income, net

	0.5		(0.2)		Provision for income taxes
	$	(0.1)	$	0.6	Net of tax

OTHER NON-OPERATING INCOME, NET (Tables)

12 Months Ended

Dec. 31, 2024

Other Income and Expenses [Abstract]

Schedule of Other Non Operating Income, Net


	Years Ended December 31,
	2024		2023		2022
	(in millions)
Foreign exchange gains, net	$	(7.1)	$	(10.0)	$	(1.0)
Loss on investments	0.6		0.7		1.1
Non-service cost components of net periodic pension benefit cost	(0.6)		(1.2)		(1.1)
Gain on remeasurement of previously held equity interest upon acquisition	(55.0)		—		—
Gain on insurance settlement	—		—		(3.8)

Other	(6.8)		(3.4)		—
Total other non-operating income, net	$	(68.9)	$	(13.9)	$	(4.8)

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Schedule of Income from Continuing Operations Before Provision for Income Taxes

The Company's income from continuing operations before provision for income taxes was generated from operations in the United States and outside of the United States as follows (in millions):


	Years Ended December 31,
	2024		2023		2022
United States	$	265.7	$	290.1	$	586.0
Outside of the United States, including Puerto Rico	1,282.4		1,082.3		933.5
	$	1,548.1	$	1,372.4	$	1,519.5

Schedule of Provision for Income Taxes

The provision for income taxes consists of the following (in millions):


	Years Ended December 31,
	2024		2023		2022
Current
United States:
Federal	$	248.4	$	291.7	$	365.8
State and local	40.7		50.1		54.3
Outside of the United States, including Puerto Rico	25.8		53.0		37.1
Current income tax expense	$	314.9	$	394.8	$	457.2
Deferred
United States:
Federal	$	(117.8)	$	(165.7)	$	(197.8)
State and local	(31.0)		(54.2)		(58.9)
Outside of the United States, including Puerto Rico	(14.0)		(22.5)		(5.0)
Deferred income tax benefit	(162.8)		(242.4)		(261.7)
Total income tax provision	$	152.1	$	152.4	$	195.5

Schedule of Deferred Tax Assets and Liabilities

The components of deferred tax assets and liabilities are as follows (in millions):


	December 31,
	2024		2023
Deferred tax assets
Capitalized research and development expenses (a)	$	533.8	$	371.1
Compensation and benefits	123.7		117.9
Benefits from uncertain tax positions	89.6		63.4
Net tax credit carryforwards	289.1		144.2
Net operating loss carryforwards	132.1		73.0
Accrued liabilities	145.2		131.7
Inventories	14.9		15.1
Cash flow and net investment hedges	—		1.3
State income taxes	3.2		0.2
Investments	1.2		0.6
Lease liability obligations	6.5		5.8
Other	2.8		0.7
Total deferred tax assets	1,342.1		925.0
Deferred tax liabilities
Property, plant, and equipment	(76.4)		(78.2)
Cash flow and net investment hedges	(11.8)		—
Deferred tax on foreign earnings	(3.6)		(3.6)
Right-of-use assets	(4.3)		(4.7)

Other intangible assets	(230.3)		(46.1)
Other	(4.8)		(2.4)
Total deferred tax liabilities	(331.2)		(135.0)
Valuation allowance	(87.8)		(62.1)
Net deferred tax assets	$	923.1	$	727.9

______________________________________

(a) As required by Public Law 115-97, commonly referred to as the Tax Cuts and Jobs Act (the "2017 Act"), effective January 1, 2022, the Company's research and development expenditures were capitalized and amortized which resulted in substantially higher cash paid for taxes in 2023 and 2022 with an equal amount of deferred tax benefits.

Schedule of Net Operating Loss Carryforwards

Net operating loss and capital loss carryforwards and the related carryforward periods at December 31, 2024 are summarized as follows (in millions):


	Carryforward Amount		Tax Benefit Amount		Valuation Allowance		Net Tax Benefit		Carryforward Period Ends
United States federal net operating losses	$	9.4	$	2.0	$	—	$	2.0	2026-2037
United States federal net operating losses	132.9		27.9		—		27.9		Indefinite
United States state net operating losses	180.7		12.6		(3.7)		8.9		2029-2044
United States state net operating losses	0.4		—		—		—		Indefinite
Non-United States net operating losses	1.3		0.3		—		0.3		2028
Non-United States net operating losses	517.8		89.3		(63.2)		26.1		Indefinite

Total	$	842.5	$	132.1	$	(66.9)	$	65.2

Schedule of Tax Credit Carryforwards

The gross tax credit carryforwards and the related carryforward periods at December 31, 2024 are summarized as follows (in millions):


	Carryforward Amount		Valuation Allowance		Net Tax Benefit		Carryforward Period Ends
California research expenditure tax credits	$	232.7	$	—	$	232.7	Indefinite
Federal research expenditure tax credits	1.9		—		1.9		2025-2034
United States foreign tax credits	121.6		(17.8)		103.8		2025-2034
Non-United States tax credits	6.0		—		6.0		2025-2028
Total	$	362.2	$	(17.8)	$	344.4

Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate

A reconciliation of the United States federal statutory income tax rate to the Company's effective income tax rate is as follows (in millions):


	Years Ended December 31,
	2024		2023		2022
Income tax expense at United States federal statutory rate	$	325.1	$	288.1	$	323.7
Foreign income taxed at different rates	(190.6)		(133.8)		(135.4)
State and local taxes, net of federal tax benefit	16.0		15.9		11.3
Tax credits, federal and state	(58.9)		(55.9)		(43.4)
Build of reserve for prior years' uncertain tax positions	(31.3)		(2.9)		11.6

Tax on global intangible low-taxed income	90.2		82.3		68.4
Foreign-derived intangible income deduction	(16.5)		(20.9)		(14.3)
Contingent consideration liabilities	—		(5.5)		(7.5)
United States federal deductible employee share-based compensation	(8.3)		(11.9)		(28.5)
Nondeductible employee share-based compensation	6.2		5.7		4.9



Other	20.2		(8.7)		4.7
Income tax provision	$	152.1	$	152.4	$	195.5

Schedule of Reconciliation of Beginning and Ending Amount of Uncertain Tax Positions

A reconciliation of the beginning and ending amount of uncertain tax positions, excluding interest, penalties, and foreign exchange, is as follows (in millions):


	December 31,
	2024		2023		2022
Uncertain gross tax positions, January 1	$	583.9	$	475.3	$	358.4
Current year tax positions	125.8		127.0		120.6
Increase in prior year tax positions	3.2		0.8		3.8
Decrease in prior year tax positions	(34.1)		(16.2)		(0.6)
Settlements	—		(3.0)		(0.4)
Lapse of statutes of limitations	—		—		(6.5)
Uncertain gross tax positions, December 31	$	678.8	$	583.9	$	475.3

SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Information About Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income

The table below presents information about Edwards Lifesciences' reportable segments (in millions):


	Years Ended December 31,
	2024		2023		2022
Segment Net Sales
United States	$	3,206.0	$	2,947.9	$	2,628.2
Europe	1,321.7		1,180.2		1,040.3
Japan	339.8		350.8		359.5
Rest of World	572.0		531.1		436.0
Total segment net sales	$	5,439.5	$	5,010.0	$	4,464.0
Cost of Sales
United States	$	546.6	$	505.2	$	418.9
Europe	299.1		268.5		237.9
Japan	48.1		46.6		41.5
Rest of World	158.1		136.2		118.2
Total segment cost of sales	$	1,051.9	$	956.5	$	816.5
Selling, general, and administrative expenses
United States	$	498.0	$	432.8	$	340.7
Europe	282.6		260.6		233.0
Japan	85.1		70.1		77.4
Rest of World	181.4		166.4		142.6
Total segment selling, general, and administrative expenses	$	1,047.1	$	929.9	$	793.7
Other Segment Items
United States	$	2.4	$	2.1	$	4.8
Europe	14.9		(4.0)		(34.9)
Japan	(6.8)		21.3		(58.1)
Rest of World	(10.5)		(0.5)		(1.9)
Total other segment items (a)	$	—	$	18.9	$	(90.1)
Segment Operating Income
United States	$	2,159.0	$	2,007.8	$	1,863.8
Europe	725.1		655.1		604.3
Japan	213.4		212.8		298.7
Rest of World	243.0		229.0		177.1
Total segment operating income	$	3,340.5	$	3,104.7	$	2,943.9

_______________________________________________________________________________

(a) Other segment items include research and development expenses and foreign currency.


	Years Ended December 31,
	2024		2023		2022
Pre-tax Income Reconciliation
Segment operating income	$	3,340.5	$	3,104.7	$	2,943.9
Unallocated amounts:
Corporate items	(1,886.8)		(1,684.4)		(1,504.2)
Restructuring charges, separation costs, and other	(61.0)		—		(60.7)
Intellectual property agreement and certain litigation expenses	(40.4)		(203.5)		(15.8)
Change in fair value of contingent consideration liabilities	—		26.2		35.8
Foreign currency	26.4		65.9		99.4
Consolidated operating income	$	1,378.7	$	1,308.9	$	1,498.4
Non-operating income	169.4		63.5		21.1
Consolidated pre-tax income	$	1,548.1	$	1,372.4	$	1,519.5

Schedule of Enterprise-Wide Information

Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements. Refer to the segment information above for United States net sales for the years ended December 31, 2024, 2023, and 2022. Sales within any other individual country were less than 10 percent of the Company's consolidated net sales in each of those years.


	As of or for the Years Ended December 31,
	2024		2023		2022
Net Sales by Major Product Group
Transcatheter Aortic Valve Replacement	$	4,106.1	$	3,879.8	$	3,518.2
Transcatheter Mitral and Tricuspid Therapies	352.1		197.6		116.1
Surgical Structural Heart	981.3		932.6		829.7
	$	5,439.5	$	5,010.0	$	4,464.0
Long-lived Tangible Assets by Geographic Region
United States	$	1,249.6	$	1,186.9	$	1,113.3
Other countries	534.6		488.5		457.0
	$	1,784.2	$	1,675.4	$	1,570.3

SUMMARIZED QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2024

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Results


Years Ended December 31,	First Quarter		Second Quarter		Third Quarter		Fourth Quarter		Total Year
	(in millions, except per share data)
2024
Net sales	$	1,329.9	$	1,369.4	$	1,354.4	$	1,385.8	$	5,439.5
Gross profit	1,043.0		1,093.9		1,091.5		1,093.6		4,322.0
Income from continuing operations, net of tax	324.9		364.0		362.1		345.0		1,396.0
Income from discontinued operations, net of tax (a)	26.1		1.0		2,707.3		39.3		2,773.7
Net income (a)	351.0		365.0		3,069.4		384.3		4,169.7
Net income attributable to Edwards Lifesciences Corporation (a)	351.9		366.3		3,070.8		385.6		4,174.6
Basic earnings per share:
Continuing operations	0.54		0.61		0.61		0.58		2.34
Discontinued operations	0.04		—		4.53		0.07		4.64
Basic earnings per share	0.58		0.61		5.14		0.65		6.98
Diluted earnings per share:
Continuing operations	0.54		0.61		0.61		0.58		2.34
Discontinued operations	0.04		—		4.52		0.07		4.63
Diluted earnings per share	0.58		0.61		5.13		0.65		6.97
2023
Net sales	$	1,221.3	$	1,278.9	$	1,243.4	$	1,266.4	$	5,010.0
Gross profit	992.3		1,031.1		992.8		1,015.4		4,031.6
Income from continuing operations	300.6		251.4		334.9		333.1		1,220.0
Income from discontinued operations, net of tax	39.9		54.1		48.8		36.6		179.4
Net income	340.5		305.5		383.7		369.7		1,399.4
Net income attributable to Edwards Lifesciences Corporation	340.5		307.1		384.9		369.9		1,402.4
Basic earnings per share:
Continuing operations	0.49		0.42		0.55		0.55		2.02
Discontinued operations	0.07		0.09		0.08		0.06		0.29
Basic earnings per share	0.56		0.51		0.63		0.61		2.31
Diluted earnings per share:
Continuing operations	0.49		0.41		0.55		0.55		2.01
Discontinued operations	0.07		0.09		0.08		0.06		0.29
Diluted earnings per share	0.56		0.50		0.63		0.61		2.30

_______________________________________________________________________________

(a) The third quarter of 2024 includes a $3.3 billion gain from the sale of Critical Care. See Note 5 for additional information.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Shipping and Handling Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Product Information [Line Items]
Cost of sales	$ 1,117.5	$ 978.4	$ 723.7
Shipping and Handling
Product Information [Line Items]
Cost of sales	$ 83.9	$ 94.5	$ 83.6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investments (Details)	Dec. 31, 2024
Minimum \| Investees Voting Stock
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage (as a percent)	5.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable (Details)	12 Months Ended
	Dec. 31, 2024
Minimum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, required payment terms (in days)	30 days
Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, required payment terms (in days)	90 days

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Inventories (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Period prior to expiration date which triggers write-down of inventory (in months)	6 months
Period used to evaluate slow-moving inventory levels (in years)	2 years
General and administrative costs allocated to inventory	$ 84.2	$ 78.0	$ 71.3
General and administrative costs included in inventory	44.0	36.3
Finished goods inventories held on consignment	$ 181.7	$ 164.6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, Plant, and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Depreciation expense for property, plant and equipment	$ 137.6	$ 119.9	$ 114.5
Buildings and improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	10 years
Buildings and improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	40 years
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	3 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	15 years
Software \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	3 years
Software \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	5 years

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Long-lived Assets (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
In-process research and development
Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets		$ 0	$ 0
Developed Technology and In-Process Research and Development
Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 52,700,000			$ 52,700,000
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]				Restructuring charges, separation costs, and other (Note 4)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Net Income for Earnings Per Share Calculations:
Income from continuing operations, net of tax	$ 345.0	$ 362.1	$ 364.0	$ 324.9	$ 333.1	$ 334.9	$ 251.4	$ 300.6	$ 1,396.0	$ 1,220.0	$ 1,324.0
Net loss attributable to noncontrolling interests									(4.9)	(3.0)	0.0
Income from continuing operations attributable to Edwards Lifesciences Corporation									1,400.9	1,223.0	1,324.0
Income from discontinued operations									2,773.7	179.4	197.9
Net income attributable to Edwards Lifesciences Corporation.	$ 385.6	$ 3,070.8	$ 366.3	$ 351.9	$ 369.9	$ 384.9	$ 307.1	$ 340.5	$ 4,174.6	$ 1,402.4	$ 1,521.9
Weighted Average Shares:
Basic weighted-average shares outstanding (in shares)									597.7	606.7	619.0
Dilutive effect of stock plans (in shares)									1.6	2.7	5.2
Diluted (in shares)									599.3	609.4	624.2
Basic:
Continuing operations (in dollars per share)	$ 0.58	$ 0.61	$ 0.61	$ 0.54	$ 0.55	$ 0.55	$ 0.42	$ 0.49	$ 2.34	$ 2.02	$ 2.14
Discontinued operations (in dollars per share)	0.07	4.53	0	0.04	0.06	0.08	0.09	0.07	4.64	0.29	0.32
Basic earnings per share (in dollars per share)	0.65	5.14	0.61	0.58	0.61	0.63	0.51	0.56	6.98	2.31	2.46
Diluted:
Continuing operations (in dollars per share)	0.58	0.61	0.61	0.54	0.55	0.55	0.41	0.49	2.34	2.01	2.12
Discontinued operations (in dollars per share)									4.63	0.29	0.32
Diluted earnings per share (in dollars per share)	$ 0.65	$ 5.13	$ 0.61	$ 0.58	$ 0.61	$ 0.63	$ 0.50	$ 0.56	$ 6.97	$ 2.30	$ 2.44

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings per Share - Narrative (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Stock compensation plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of earnings per share (in shares)	8.4	6.6	3.6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Allocation of stock-based compensation expense
Total stock-based compensation expense	$ 145.6	$ 124.8	$ 113.6
Income tax benefit	(24.8)	(21.8)	(19.6)
Total stock-based compensation expense, net of tax	120.8	103.0	94.0
Cost of sales
Allocation of stock-based compensation expense
Total stock-based compensation expense	26.7	20.6	20.3
Selling, general, and administrative expenses
Allocation of stock-based compensation expense
Total stock-based compensation expense	82.5	74.0	67.3
Research and development expenses
Allocation of stock-based compensation expense
Total stock-based compensation expense	$ 36.4	$ 30.2	$ 26.0

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock-based Compensation Narrative (Details)	12 Months Ended
	Dec. 31, 2024
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage vesting upon retirement for each full year of employment subsequent to the grant date (as a percent)	25.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Derivatives (Details)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Period when cash flows associated with future transactions and certain local currency expenses are expected to occur (in months)	1 year

INTELLECTUAL PROPERTY AGREEMENT AND CERTAIN LITIGATION EXPENSES (Details) - USD ($) $ in Millions		1 Months Ended		12 Months Ended
	Apr. 12, 2023	Apr. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Intellectual property litigation expenses				$ 40.4	$ 203.5	$ 15.8
Intellectual property agreement term	15 years
Prepaid royalty asset				$ 109.9	$ 118.1
Medtronic Inc
Loss Contingencies [Line Items]
Intellectual property litigation expenses		$ 139.0	$ 37.0
Payments for legal settlements	$ 300.0
Prepaid royalty asset		$ 124.0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

RESTRUCTURING CHARGES, SEPARATION COSTS, AND OTHER - Narrative (Details) $ in Millions	1 Months Ended		3 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($) employee	Sep. 30, 2022 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2022 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 32.9
Restructuring and related cost, expected number of positions eliminated \| employee	360
Special charge		$ 62.3	$ 19.0
Restructuring contingent consideration gain		11.7
Developed Technology and In-Process Research and Development
Restructuring Cost and Reserve [Line Items]
Impairment of intangible assets		52.7		$ 52.7
Restructuring Charges, Separation Costs, and Other
Restructuring Cost and Reserve [Line Items]
Special charge		60.7
Cost of sales
Restructuring Cost and Reserve [Line Items]
Special charge		$ 1.6

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

RESTRUCTURING CHARGES, SEPARATION COSTS, AND OTHER - Restructuring Liability (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)
Restructuring Reserve [Roll Forward]
Balance at December 31, 2023	$ 0.0
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Restructuring charges, separation costs, and other (Note 4)
Restructuring charges	$ 32.9
Payments	(12.8)
Balance at December 31, 2024	$ 20.1

DISCONTINUED OPERATIONS - Narrative (Details) - USD ($) $ in Millions		3 Months Ended								12 Months Ended
	Sep. 03, 2024	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax		$ 39.3	$ 2,707.3	$ 1.0	$ 26.1	$ 36.6	$ 48.8	$ 54.1	$ 39.9	$ 2,773.7	$ 179.4	$ 197.9
Becton, Dickinson and Company
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable		28.8								28.8
Discontinued Operations, Held-for-Sale \| Critical Care
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration	$ 4,200.0
Income from discontinued operations, net of tax	$ 3,300.0		$ 3,300.0
Transition services agreement period	36 months
Unfavorable contract liability	$ 115.1	$ 88.8								88.8
Term for continued services	36 months
Amortization of unfavorable contract liability										$ 30.3

DISCONTINUED OPERATIONS - Income from Discontinued Operations (Details) - Discontinued Operations, Held-for-Sale - Critical Care - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	$ 730.7	$ 994.8	$ 918.4
Cost of sales	276.8	401.4	356.7
Gross profit	453.9	593.4	561.7
Selling, general, and administrative expenses	169.0	242.1	210.0
Research and development expenses	82.2	108.9	101.6
Separation costs and other	221.8	17.2	0.0
Operating (loss) income, net	(19.1)	225.2	250.1
Other non-operating (income) expense, net	(3,348.3)	(0.5)	2.2
Income from discontinued operations before provision for income taxes	3,329.2	225.7	247.9
Provision for income taxes from discontinued operations	555.5	46.3	50.0
Net income from discontinued operations	$ 2,773.7	$ 179.4	$ 197.9

DISCONTINUED OPERATIONS - Assets and Liabilities Held for Sale (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total current assets of discontinued operations	$ 26.8	$ 317.6
Total non-current assets of discontinued operations	10.8	311.1
Total current liabilities of discontinued operations	2.0	129.5
Total non-current liabilities of discontinued operations	0.0	25.1
Discontinued Operations, Held-for-Sale \| Critical Care
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	9.6	11.7
Accounts receivable, net of allowances	0.0	3.6
Other receivables	0.0	5.2
Inventories	15.1	264.7
Prepaid expenses	2.1	18.0
Other current assets	0.0	14.4
Total current assets of discontinued operations	26.8	317.6
Property, plant, and equipment, net	3.4	158.4
Operating lease right-of-use assets	0.0	9.6
Goodwill	7.4	108.4
Other intangible assets, net	0.0	29.0
Deferred income taxes	0.0	5.2
Other assets	0.0	0.5
Total non-current assets of discontinued operations	10.8	311.1
Accounts payable	0.0	14.8
Accrued and other liabilities	2.0	112.7
Operating lease liabilities	0.0	2.0
Total current liabilities of discontinued operations	2.0	129.5
Operating lease liabilities	0.0	7.8
Uncertain tax positions	0.0	4.3
Other liabilities	0.0	13.0
Total non-current liabilities of discontinued operations	$ 0.0	$ 25.1

DISCONTINUED OPERATIONS - Consolidated Condensed Statements of Cash Flows (Details) - Discontinued Operations, Held-for-Sale - Critical Care - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization	$ 12.0	$ 22.9	$ 22.7
Stock-based compensation	16.8	14.6	13.1
Inventory write off	8.2	23.5	6.2
Capital expenditures	$ 16.6	$ 35.4	$ 36.3

OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Components of Selected Captions in the Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Inventories
Raw materials	$ 241.1	$ 196.3
Work in process	236.2	195.8
Finished products	609.4	511.4
Total inventories	1,086.7	903.5
Property, plant, and equipment, net
Land	123.9	112.4
Buildings and leasehold improvements	1,339.8	1,189.0
Machinery and equipment	689.4	618.6
Software	83.4	77.1
Construction in progress	244.0	292.5
Total property, plant and equipment, gross	2,480.5	2,289.6
Accumulated depreciation	(794.5)	(698.6)
Total property, plant and equipment, net	1,686.0	1,591.0
Other assets
Tax receivable (Note 19)	293.9	0.0
Notes and other receivables	129.3	155.1
Acquisition options	147.1	161.3
Long-term prepaid royalties	101.6	109.9
Fair value of derivatives	34.7	23.4
Other long-term assets	15.0	13.5
Other assets, noncurrent	721.6	463.2
Accrued and other liabilities
Employee compensation and withholdings	358.6	316.4
Accrued rebates	139.3	123.5
Property, payroll, and other taxes	88.1	53.8
Research and development accruals	74.1	71.6
Legal and insurance (Notes 3 and 20)	26.8	28.9
Litigation settlement	73.8	69.1
Taxes payable	286.6	52.7
Fair value of derivatives	8.3	15.2
Accrued marketing expenses	13.8	13.7
Accrued professional services	20.1	8.5
Accrued realignment reserves	27.4	6.4
Accrued relocation costs	15.4	16.9
Unfavorable contract liability	53.7	0.0
Other accrued liabilities	96.4	79.7
Total accrued and other liabilities	$ 1,282.4	$ 856.4

OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash paid during the year for:
Interest	$ 19.6	$ 19.9	$ 19.3
Income taxes (a) (Note 19)	1,196.1	470.1	504.1
Amounts included in the measurement of operating lease liabilities	28.0	25.7	25.0
Non-cash investing and financing transactions:
Right-of-use assets obtained in exchange for new lease liabilities	42.8	27.3	23.4
Capital expenditures accruals	44.1	43.6	41.0
Income Taxes Paid	1,196.1	470.1	504.1
Discontinued Operations
Cash paid during the year for:
Income taxes (a) (Note 19)	29.7	25.2	37.4
Non-cash investing and financing transactions:
Income Taxes Paid	$ 29.7	$ 25.2	$ 37.4

OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	$ 3,045.2	$ 1,132.3
Total cash, cash equivalents, and restricted cash	3,058.8	1,148.0	$ 772.6	$ 867.4
Continuing Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	3,045.2	1,132.3	761.5
Restricted cash included in other current assets	3.2	3.3	0.5
Restricted cash included in other assets	0.8	0.7	3.1
Total cash, cash equivalents, and restricted cash	3,049.2	1,136.3	765.1
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	9.6	11.7	7.5
Total cash, cash equivalents, and restricted cash	$ 9.6	$ 11.7	$ 7.5

LEASES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
LEASES - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 28.1	$ 26.9	$ 25.6
Lease commitments for leases not yet commenced	$ 1.7
Minimum
Lessee, Lease, Description [Line Items]
Lease term (in years)	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lease term (in years)	16 years

LEASES - Assets and Liabilities of Operating Leases (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Operating lease right-of-use assets	$ 98.2	$ 84.4
Operating lease liabilities, current portion	23.4	22.9
Operating lease liabilities, long-term portion	78.9	65.2
Total operating lease liabilities	$ 102.3	$ 88.1

LEASES - Maturities Of Operating Lease Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Leases [Abstract]
2025	$ 26.4
2026	23.3
2027	19.1
2028	13.2
2029	8.4
Thereafter	23.8
Total lease payments	114.2
Less: imputed interest	(11.9)
Total lease liabilities	$ 102.3	$ 88.1
Weighted-average remaining lease term (in years)	5 years 10 months 24 days	5 years 9 months 18 days
Weighted-average discount rate	3.40%	2.30%

INVESTMENTS - Schedule of Investments in Debt Securities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Held-to-maturity
Amortized Cost	$ 57.9
Fair Value	57.9
Available-for-sale
Amortized Cost	1,026.4	$ 926.1
Gross Unrealized Gains	0.2	0.1
Gross Unrealized Losses	(5.3)	(27.5)
Fair Value	1,021.3	898.7
Bank time deposits
Held-to-maturity
Amortized Cost	57.9	64.5
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	57.9	64.5
Available-for-sale
Amortized Cost	13.9	0.0
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	13.9	0.0
Commercial paper
Available-for-sale
Amortized Cost	236.5	0.0
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	0.0
Fair Value	236.5	0.0
U.S. government and agency securities
Available-for-sale
Amortized Cost	238.1	72.7
Gross Unrealized Gains	0.1	0.1
Gross Unrealized Losses	(1.1)	(2.8)
Fair Value	237.1	70.0
Asset-backed securities
Available-for-sale
Amortized Cost	70.2	192.1
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	(1.4)	(7.8)
Fair Value	68.8	184.3
Corporate debt securities
Available-for-sale
Amortized Cost	465.0	658.5
Gross Unrealized Gains	0.1	0.0
Gross Unrealized Losses	(2.8)	(16.7)
Fair Value	462.3	641.8
Municipal securities
Available-for-sale
Amortized Cost	2.7	2.8
Gross Unrealized Gains	0.0	0.0
Gross Unrealized Losses	0.0	(0.2)
Fair Value	$ 2.7	$ 2.6

INVESTMENTS - Schedule of Cost and Fair Value of Investments in Debt Securities, by Contractual Maturity (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Amortized Cost
Due in 1 year or less	$ 57.9
Due after 1 year through 5 years	0.0
Instruments not due at a single maturity date	0.0
Amortized Cost	57.9
Fair Value
Due in 1 year or less	57.9
Due after 1 year through 5 years	0.0
Instruments not due at a single maturity date	0.0
Fair Value	57.9
Amortized Cost
Due in 1 year or less	874.0
Due after 1 year through 5 years	64.3
Instruments not due at a single maturity date	88.1
Amortized Cost	1,026.4	$ 926.1
Fair Value
Due in 1 year or less	872.8
Due after 1 year through 5 years	62.8
Instruments not due at a single maturity date	85.7
Fair Value	$ 1,021.3	$ 898.7

INVESTMENTS - Schedule of Unrealized Losses on Debt Securities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Fair value, less than 12 months	$ 8.4	$ 35.2
Gross unrealized losses, less than 12 months	(0.1)	(1.9)
Fair value, 12 months or greater	214.2	843.7
Gross unrealized losses, 12 months or greater	(5.2)	(25.6)
Total fair value	222.6	878.9
Total gross unrealized losses	(5.3)	(27.5)
U.S. government and agency securities
Debt Securities, Available-for-sale [Line Items]
Fair value, less than 12 months	0.0	0.0
Gross unrealized losses, less than 12 months	0.0	0.0
Fair value, 12 months or greater	19.9	67.1
Gross unrealized losses, 12 months or greater	(1.1)	(2.8)
Total fair value	19.9	67.1
Total gross unrealized losses	(1.1)	(2.8)
Asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Fair value, less than 12 months	8.4	10.2
Gross unrealized losses, less than 12 months	(0.1)	(1.8)
Fair value, 12 months or greater	53.3	172.7
Gross unrealized losses, 12 months or greater	(1.3)	(6.0)
Total fair value	61.7	182.9
Total gross unrealized losses	(1.4)	(7.8)
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Fair value, less than 12 months	0.0	25.0
Gross unrealized losses, less than 12 months	0.0	(0.1)
Fair value, 12 months or greater	141.0	601.3
Gross unrealized losses, 12 months or greater	(2.8)	(16.6)
Total fair value	141.0	626.3
Total gross unrealized losses	$ (2.8)	(16.7)
Municipal securities
Debt Securities, Available-for-sale [Line Items]
Fair value, less than 12 months		0.0
Gross unrealized losses, less than 12 months		0.0
Fair value, 12 months or greater		2.6
Gross unrealized losses, 12 months or greater		(0.2)
Total fair value		2.6
Total gross unrealized losses		$ (0.2)

INVESTMENTS - Schedule of Investments in Unconsolidated Affiliates (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Equity method investments
Carrying value of equity method investments	$ 34.8	$ 33.6
Equity securities
Carrying value of marketable equity securities	5.5	0.0
Carrying value of non-marketable equity securities	119.1	87.6
Total investments in unconsolidated entities	$ 159.4	$ 121.2

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References + Details

- Definition

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 80
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480078/944-80-55-14

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 80
-Name Accounting Standards Codification
-Section 55
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480078/944-80-55-9

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

INVESTMENTS - Narrative (Details) $ in Millions	12 Months Ended
INVESTMENTS - Narrative (Details) $ in Millions	Dec. 31, 2024 USD ($)
Debt and Equity Securities, FV-NI [Line Items]
Upward price adjustments	$ 0.5
Downward price adjustment, annual amount	3.1
Increase in non-marketable equity securities due to observable price changes	9.3
Decrease in non-marketable equity securities due to observable price changes	$ 6.2
Limited Liability Company
Debt and Equity Securities, FV-NI [Line Items]
Investments taken period	7 years
New Markets Tax Credit \| Limited Liability Company
Debt and Equity Securities, FV-NI [Line Items]
Investment percentage (in percent)	39.00%

INVESTMENTS IN VARIABLE INTEREST ENTITIES - Narrative (Details) - USD ($) $ in Millions	1 Months Ended			12 Months Ended
	Jul. 31, 2024	Aug. 31, 2022	Jun. 30, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2019	Feb. 28, 2025	Apr. 30, 2021
Variable Interest Entity [Line Items]
Assets				$ 13,055.3	$ 9,363.2
Total liabilities				2,992.4	2,643.8
Carrying value of non-marketable equity securities				119.1	87.6
Payment for acquisition options				46.2	30.0	$ 109.6
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Assets				252.3	272.1
Total liabilities				24.3	31.5
Variable Interest Entity, Not Primary Beneficiary \| Medical Device Company
Variable Interest Entity [Line Items]
Option to acquire investment amount		$ 47.1		35.0
Payment for acquisition options		$ 47.1					$ 35.0
Loans receivables, maximum lending amount			$ 47.5
Financing receivable				47.5
Variable Interest Entity, Not Primary Beneficiary \| Medical Device Company, 2021 Investment
Variable Interest Entity [Line Items]
Option to acquire investment amount				30.0
Additional contingent amount				10.0
Carrying value of non-marketable equity securities				20.0	5.0
Maximum secured promissory note				40.0
Variable Interest Entity, Not Primary Beneficiary \| JenaValve Technology, Inc
Variable Interest Entity [Line Items]
Maximum secured promissory note	$ 75.0
Period for merger to close	90 days
Investee drew additional amount				15.0
Variable Interest Entity, Not Primary Beneficiary \| JenaValve Technology, Inc \| Subsequent Event
Variable Interest Entity [Line Items]
Investee drew additional amount								$ 10.0
Variable Interest Entity, Not Primary Beneficiary \| Medical Device Company, April 2021 Investment
Variable Interest Entity [Line Items]
Carrying value of non-marketable equity securities				42.8	39.3
Maximum secured promissory note									$ 45.0
Investee drew additional amount				45.0	30.0
Investment option to acquire				20.9	$ 13.1
Maximum additional required investment				3.0
Maximum additional option to acquire investment				$ 6.6

BUSINESS COMBINATIONS - Narrative (Details) - USD ($) $ in Millions							3 Months Ended		12 Months Ended
	Oct. 01, 2024	Sep. 30, 2024	Aug. 19, 2024	Aug. 18, 2024	Jul. 22, 2024	Feb. 28, 2023	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2024
Innovalve Bio Medical Limited
Business Acquisition [Line Items]
Cash consideration paid at closing	$ 319.3	$ 30.0
Fair value of previously held equity interest	$ 64.6	$ 3.5
Percentage of previously held interest		4.00%						4.00%
Equity interest in acquire, excluding initial acquisition, percentage	96.00%
Step acquisition, equity interest in acquire, remeasurement gain							$ 30.5
Total purchase price, net of cash acquired	$ 380.9
Payments to acquire businesses	298.2
Cash acquired	21.1
Settlement of pre-existing relationships	5.4
Fair value of contingent consideration	12.7
Additional milestone driven contingent consideration liability	$ 25.0
Milestone achievement period	5 years
Business combination, escrow deposit	$ 34.6
Acquisition-related costs									$ 2.3
Additional research and development expenditures to be incurred prior to product introduction	$ 74.3
Innovalve Bio Medical Limited \| In-process research and development \| Discount Rate
Business Acquisition [Line Items]
Measurement input	10.50%
Endotronix, Inc
Business Acquisition [Line Items]
Cash consideration paid at closing			$ 650.3	$ 60.0
Fair value of previously held equity interest			$ 94.6	$ 10.0
Percentage of previously held interest				7.00%
Equity interest in acquire, excluding initial acquisition, percentage			93.00%
Step acquisition, equity interest in acquire, remeasurement gain								$ 24.6
Total purchase price, net of cash acquired			$ 798.8
Payments to acquire businesses			649.1
Cash acquired			1.2
Settlement of pre-existing relationships			53.1
Fair value of contingent consideration			2.0
Business combination, escrow deposit			35.0
Acquisition-related costs									6.0
Additional research and development expenditures to be incurred prior to product introduction			$ 47.1
Endotronix, Inc \| In-process research and development \| Discount Rate
Business Acquisition [Line Items]
Measurement input			18.00%
Endotronix, Inc \| Developed technology \| Discount Rate
Business Acquisition [Line Items]
Measurement input			15.50%
JC Medical, Inc.
Business Acquisition [Line Items]
Cash consideration paid at closing					$ 114.8
Total purchase price, net of cash acquired					116.3
Cash acquired					0.3
Fair value of contingent consideration					1.8
Business combination, escrow deposit					12.0
Acquisition-related costs									$ 1.6
Additional research and development expenditures to be incurred prior to product introduction			$ 55.8
Potential milestone-driven payments					$ 200.0
Contingent consideration liability, term					12 years
Escrow deposit, holding period					15 months
JC Medical, Inc. \| In-process research and development \| Discount Rate
Business Acquisition [Line Items]
Measurement input					15.00%
Medical Technology Company
Business Acquisition [Line Items]
Additional research and development expenditures to be incurred prior to product introduction						$ 68.6
Medical Technology Company \| Variable Interest Entity, Primary Beneficiary
Business Acquisition [Line Items]
Payments to acquire businesses						169.0
Cash acquired						$ 6.8
Percentage of interest acquired						61.00%

BUSINESS COMBINATIONS - Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions							12 Months Ended
	Oct. 01, 2024	Sep. 30, 2024	Aug. 19, 2024	Aug. 18, 2024	Jul. 22, 2024	Feb. 28, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill							$ 1,776.7	$ 1,145.1	$ 1,064.8
Payment for acquisition options							$ 46.2	$ 30.0	$ 109.6
Innovalve Bio Medical Limited
Business Acquisition [Line Items]
Cash consideration paid at closing	$ 319.3	$ 30.0
Settlement of pre-existing relationships	5.4
Fair value of previously held equity interest	64.6	$ 3.5
Fair value of contingent consideration	12.7
Total purchase price	402.0
Less: cash acquired	(21.1)
Total purchase price, net of cash acquired	380.9
Current assets	26.5
Property and equipment, net	1.2
Goodwill	205.4
Liabilities assumed	(8.2)
Deferred tax liabilities	(41.3)
Fair value of net assets acquired	402.0
Total purchase price, net of cash acquired	$ 298.2
Innovalve Bio Medical Limited \| In-process research and development
Business Acquisition [Line Items]
Intangibles			$ 218.4
Endotronix, Inc
Business Acquisition [Line Items]
Cash consideration paid at closing			650.3	$ 60.0
Settlement of pre-existing relationships			53.1
Fair value of previously held equity interest			94.6	$ 10.0
Fair value of contingent consideration			2.0
Total purchase price			800.0
Less: cash acquired			(1.2)
Total purchase price, net of cash acquired			798.8
Current assets			7.7
Property and equipment, net			12.6
Goodwill			382.8
Operating lease right-of-use assets			9.9
Other assets			0.7
Liabilities assumed			(26.3)
Deferred tax liabilities			(45.2)
Fair value of net assets acquired			800.0
Total purchase price, net of cash acquired			649.1
Endotronix, Inc \| In-process research and development
Business Acquisition [Line Items]
Intangibles			68.9
Endotronix, Inc \| Developed technology
Business Acquisition [Line Items]
Intangibles			$ 388.9
JC Medical, Inc.
Business Acquisition [Line Items]
Cash consideration paid at closing					$ 114.8
Fair value of contingent consideration					1.8
Total purchase price					116.6
Less: cash acquired					(0.3)
Total purchase price, net of cash acquired					116.3
Current assets					0.3
Property and equipment, net					0.3
Goodwill					46.4
Current liabilities assumed					(1.0)
Deferred tax liabilities					(16.0)
Fair value of net assets acquired					116.6
JC Medical, Inc. \| In-process research and development
Business Acquisition [Line Items]
Intangibles					$ 86.6
Medical Technology Company \| Variable Interest Entity, Primary Beneficiary
Business Acquisition [Line Items]
Less: cash acquired						$ (6.8)
Current assets						8.1
Goodwill						133.2
Intangibles						136.6
Current liabilities assumed						(1.7)
Deferred tax liabilities						(28.0)
Fair value of net assets acquired						248.2
Less: Noncontrolling interest						(72.4)
Total purchase price						175.8
Total purchase price, net of cash acquired						169.0
Noncontrolling interest, gross						94.4
Payment for option to acquire company						22.0
Payment for acquisition options						22.5
Repayments of pre-existing notes						5.3
Cash paid directly to acquired company, netted against goodwill						$ 46.0

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Changes in the Carrying Amount of Goodwill, by Segment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill
Beginning balance	$ 1,145.1	$ 1,064.8
Goodwill acquired during the year	634.6	78.4
Currency translation adjustment	(3.0)	1.9
Ending balance	1,776.7	1,145.1
United States
Goodwill
Beginning balance	710.7	710.7
Goodwill acquired during the year	429.2	0.0
Currency translation adjustment	0.0	0.0
Ending balance	1,139.9	710.7
Europe
Goodwill
Beginning balance	58.2	56.3
Goodwill acquired during the year	0.0	0.0
Currency translation adjustment	(3.0)	1.9
Ending balance	55.2	58.2
Rest of World
Goodwill
Beginning balance	376.2	297.8
Goodwill acquired during the year	205.4	78.4
Currency translation adjustment	0.0	0.0
Ending balance	$ 581.6	$ 376.2

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Other Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Finite-lived intangible assets
Weighted-Average Useful Life (in years)	12 years 1 month 6 days
Cost	$ 807.4	$ 278.3
Accumulated Amortization	(141.3)	(136.5)
Net Carrying Value	666.1	141.8
Indefinite-lived intangible assets
Cost	1,317.9	535.9
Net Carrying Value	$ 1,176.6	399.4
Patents
Finite-lived intangible assets
Weighted-Average Useful Life (in years)	10 years
Cost	$ 138.8	119.0
Accumulated Amortization	(90.5)	(87.3)
Net Carrying Value	$ 48.3	31.7
Developed technology
Finite-lived intangible assets
Weighted-Average Useful Life (in years)	12 years 2 months 12 days
Cost	$ 665.2	155.8
Accumulated Amortization	(47.4)	(45.7)
Net Carrying Value	$ 617.8	110.1
Other
Finite-lived intangible assets
Weighted-Average Useful Life (in years)	0 years
Cost	$ 3.4	3.5
Accumulated Amortization	(3.4)	(3.5)
Net Carrying Value	0.0	0.0
In-process research and development
Indefinite-lived intangible assets
In-process research and development	$ 510.5	$ 257.6

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense related to other intangible assets	$ 5.6	$ 2.2	$ 2.3

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Estimated Amortization Expense (Details) $ in Millions	Dec. 31, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 9.8
2026	19.1
2027	33.0
2028	56.8
2029	$ 81.3

DEBT AND CREDIT FACILITIES - Narrative (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Weighted-average interest rate under all debt obligations (as a percent)		3.40%	3.40%
Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Term of the credit agreement (in years)		5 years
Aggregate borrowings in multiple currencies		$ 750,000,000.0
Accordion feature, increase limit		$ 250,000,000.0
Basis spread on variable rate (as a percent)		0.10%
Debt instrument, credit spread adjustment		0.10%
Issuance costs		$ 2,100,000
Borrowings outstanding		$ 0	$ 0
Credit Agreement \| Revolving Credit Facility \| Secured Overnight Financing Rate
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		0.90%
Credit Agreement \| Revolving Credit Facility \| Low
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		0.09%
Credit Agreement \| Revolving Credit Facility \| Low \| Secured Overnight Financing Rate
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		0.785%
Credit Agreement \| Revolving Credit Facility \| High
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		0.20%
Credit Agreement \| Revolving Credit Facility \| High \| Secured Overnight Financing Rate
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		1.30%
Senior Notes \| Fixed-rate 4.3% Notes
Debt Instrument [Line Items]
Fixed-rate unsecured senior notes	$ 600,000,000.0
2018 Notes
Debt Instrument [Line Items]
Price equal to principal amount, plus accrued and unpaid interest (as a percent)	101.00%
2018 Notes \| Level 2
Debt Instrument [Line Items]
Fair value of the notes, based on Level 2 inputs		$ 587,500,000	$ 591,600,000

DEBT AND CREDIT FACILITIES - Schedule of the Notes (Details) - Senior Notes - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Unamortized discount	$ (0.5)	$ (0.7)
Unamortized debt issuance costs	(1.8)	(2.3)
Total carrying amount	$ 597.7	597.0
Fixed-rate 4.3% Notes
Debt Instrument [Line Items]
Fixed interest rate	4.30%
Amount	$ 600.0	$ 600.0
Effective Interest Rate	4.329%	4.329%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

FAIR VALUE MEASUREMENTS - Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Assets
Available-for-sale investments:	$ 1,021.3	$ 898.7
Bank time deposits
Assets
Available-for-sale investments:	13.9	0.0
Corporate debt securities
Assets
Available-for-sale investments:	462.3	641.8
Asset-backed securities
Assets
Available-for-sale investments:	68.8	184.3
United States government and agency securities
Assets
Available-for-sale investments:	237.1	70.0
Commercial paper
Assets
Available-for-sale investments:	236.5	0.0
Municipal securities
Assets
Available-for-sale investments:	2.7	2.6
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis
Assets
Cash equivalents	2,379.9	579.2
Investments held for deferred compensation plans	146.6	125.8
Derivatives	82.1	39.5
Total assets	3,635.4	1,643.2
Liabilities
Derivatives	8.2	15.2
Contingent consideration liabilities	16.5
Other	5.0	10.3
Total liabilities	29.7	25.5
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Bank time deposits
Assets
Available-for-sale investments:	13.9
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Corporate debt securities
Assets
Available-for-sale investments:	462.3	641.8
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Asset-backed securities
Assets
Available-for-sale investments:	68.8	184.3
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| United States government and agency securities
Assets
Available-for-sale investments:	237.1	70.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Commercial paper
Assets
Available-for-sale investments:	236.5
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Municipal securities
Assets
Available-for-sale investments:	2.7	2.6
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Equity investments in unconsolidated entities
Assets
Available-for-sale investments:	5.5
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 1
Assets
Cash equivalents	1,394.4	579.2
Investments held for deferred compensation plans	146.6	125.8
Derivatives	0.0	0.0
Total assets	1,546.5	705.0
Liabilities
Derivatives	0.0	0.0
Contingent consideration liabilities	0.0
Other	0.0	0.0
Total liabilities	0.0	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 1 \| Bank time deposits
Assets
Available-for-sale investments:	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 1 \| Corporate debt securities
Assets
Available-for-sale investments:	0.0	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 1 \| Asset-backed securities
Assets
Available-for-sale investments:	0.0	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 1 \| United States government and agency securities
Assets
Available-for-sale investments:	0.0	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 1 \| Commercial paper
Assets
Available-for-sale investments:	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 1 \| Municipal securities
Assets
Available-for-sale investments:	0.0	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 1 \| Equity investments in unconsolidated entities
Assets
Available-for-sale investments:	5.5
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 2
Assets
Cash equivalents	985.5	0.0
Investments held for deferred compensation plans	0.0	0.0
Derivatives	82.1	39.5
Total assets	2,088.9	938.2
Liabilities
Derivatives	8.2	15.2
Contingent consideration liabilities	0.0
Other	0.0	0.0
Total liabilities	8.2	15.2
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 2 \| Bank time deposits
Assets
Available-for-sale investments:	13.9
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 2 \| Corporate debt securities
Assets
Available-for-sale investments:	462.3	641.8
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 2 \| Asset-backed securities
Assets
Available-for-sale investments:	68.8	184.3
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 2 \| United States government and agency securities
Assets
Available-for-sale investments:	237.1	70.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 2 \| Commercial paper
Assets
Available-for-sale investments:	236.5
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 2 \| Municipal securities
Assets
Available-for-sale investments:	2.7	2.6
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 2 \| Equity investments in unconsolidated entities
Assets
Available-for-sale investments:	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 3
Assets
Cash equivalents	0.0	0.0
Investments held for deferred compensation plans	0.0	0.0
Derivatives	0.0	0.0
Total assets	0.0	0.0
Liabilities
Derivatives	0.0	0.0
Contingent consideration liabilities	16.5
Other	5.0	10.3
Total liabilities	21.5	10.3
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 3 \| Bank time deposits
Assets
Available-for-sale investments:	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 3 \| Corporate debt securities
Assets
Available-for-sale investments:	0.0	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 3 \| Asset-backed securities
Assets
Available-for-sale investments:	0.0	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 3 \| United States government and agency securities
Assets
Available-for-sale investments:	0.0	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 3 \| Commercial paper
Assets
Available-for-sale investments:	0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 3 \| Municipal securities
Assets
Available-for-sale investments:	0.0	$ 0.0
Estimate of Fair Value Measurement \| Fair Value on a Recurring Basis \| Level 3 \| Equity investments in unconsolidated entities
Assets
Available-for-sale investments:	$ 0.0

FAIR VALUE MEASUREMENTS - Narrative (Details)	Dec. 31, 2024
Revenue Volatility
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration liability measurement input	0.27
Minimum \| Discount Rate
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration liability measurement input	0.000
Minimum \| Probability of Milestone Achievement
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration liability measurement input	0.60
Maximum \| Discount Rate
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration liability measurement input	0.118
Maximum \| Probability of Milestone Achievement
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration liability measurement input	1
Weighted Average \| Discount Rate
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration liability measurement input	0.047
Weighted Average \| Probability of Milestone Achievement
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration liability measurement input	0.648

FAIR VALUE MEASUREMENTS - Schedule of Changes in Fair Value of Contingent Consideration Obligation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value beginning balance	$ 10.3	$ 40.2
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Change in fair value of contingent consideration liabilities (Note 13)	Change in fair value of contingent consideration liabilities (Note 13)
Changes in fair value	$ (5.3)	$ (29.9)
Additions	16.5
Fair value ending balance	21.5	10.3
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value beginning balance	0.0	26.2
Changes in fair value	0.0	(26.2)
Additions	16.5
Fair value ending balance	16.5	0.0
Other
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value beginning balance	10.3	14.0
Changes in fair value	(5.3)	(3.7)
Additions	0.0
Fair value ending balance	$ 5.0	$ 10.3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Derivative Financial Instruments Used to Manage Currency Exchange Rate Risk and Interest Rate Risk (Details) - Derivatives designated as hedging instruments - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Foreign currency forward exchange contracts
Derivative [Line Items]
Notional Amount	$ 1,926.9	$ 1,460.3
Cross currency swap contracts
Derivative [Line Items]
Notional Amount	$ 300.0	$ 300.0

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Location and Fair Value Amounts of Derivative Instruments Reported in Consolidated Balance Sheets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Assets
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other current assets, Other assets	Other current assets, Other assets
Liabilities
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other liabilities, Accrued and other liabilities (Note 6)	Other liabilities, Accrued and other liabilities (Note 6)
Foreign currency contracts
Assets
Fair value of derivative assets	$ 47.4	$ 16.1
Liabilities
Fair value of derivative liabilities	8.2	15.2
Cross currency swap contracts
Assets
Fair value of derivative assets	34.7	23.4
Derivatives designated as hedging instruments \| Foreign currency contracts
Assets
Fair value of derivative assets	47.4	16.1
Liabilities
Fair value of derivative liabilities	6.4	15.2
Derivatives designated as hedging instruments \| Cross currency swap contracts
Assets
Fair value of derivative assets	34.7	23.4
Derivatives not designated as hedging instruments \| Foreign currency contracts
Liabilities
Fair value of derivative liabilities	$ 1.8	$ 0.0

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Effect of Master-Netting Agreements and Rights of Offset, Derivative Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Foreign currency contracts
Derivative Assets
Gross Amounts	$ 47.4	$ 16.1
Gross Amounts Offset in the Consolidated Balance Sheet	0.0	0.0
Net Amounts Presented in the Consolidated Balance Sheet	47.4	16.1
Gross Amounts Not Offset in the Consolidated Balance Sheet
Financial Instruments	(5.4)	(9.4)
Cash Collateral Received	0.0	0.0
Net Amount	42.0	6.7
Derivative Liabilities
Gross Amounts	8.2	15.2
Gross Amounts Offset in the Consolidated Balance Sheet	0.0	0.0
Net Amounts Presented in the Consolidated Balance Sheet	8.2	15.2
Gross Amounts Not Offset in the Consolidated Balance Sheet
Financial Instruments	(5.4)	(9.4)
Cash Collateral Received	0.0	0.0
Net Amount	2.8	5.8
Cross currency swap contracts
Derivative Assets
Gross Amounts	34.7	23.4
Gross Amounts Offset in the Consolidated Balance Sheet	0.0	0.0
Net Amounts Presented in the Consolidated Balance Sheet	34.7	23.4
Gross Amounts Not Offset in the Consolidated Balance Sheet
Financial Instruments	0.0	0.0
Cash Collateral Received	0.0	0.0
Net Amount	$ 34.7	$ 23.4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Effect of Derivative Instruments on Consolidated Statements of Operations and Consolidated Statements of Comprehensive Income (Details) - Derivatives designated as hedging instruments - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Foreign currency contracts \| Cash flow hedges
Derivative Instruments, Gain (Loss)
Amount of Gain or (Loss) Recognized in Other Comprehensive Income on Derivative (Effective Portion)	$ 83.8	$ 29.2
Cross currency swap contracts \| Net investment hedges
Derivative Instruments, Gain (Loss)
Amount of Gain or (Loss) Recognized in Other Comprehensive Income on Derivative (Effective Portion)	$ 11.3	$ (17.3)

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2023 USD ($)
Derivative Instruments, Gain (Loss)
Cash flow hedge loss to be reclassified	$ 10.7
Cross currency swap contracts \| Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss)
Derivative liability, fair value	300.0		$ 300.0
Cross currency swap contracts \| Net investment hedges \| Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss)
Derivative liability, fair value	$ 300.0	€ 257.2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effects of Hedge (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative Instruments, Gain (Loss)
Cost of sales	$ (1,117.5)	$ (978.4)	$ (723.7)
Interest income, net	(19.8)	(17.6)
Other non-operating income, net	68.9	13.9	$ 4.8
Foreign currency contracts \| Cost of sales
Derivative Instruments, Gain (Loss)
Hedged items	0.0	0.0
Amount excluded from effectiveness testing (amortized)	0.0	0.0
Foreign currency contracts \| Cost of sales \| Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss)
Derivatives designated as hedging instruments	0.0	0.0
Amount of gain (loss) reclassified from accumulated other comprehensive loss into income	35.8	58.9
Foreign currency contracts \| Cost of sales \| Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss)
Foreign currency contracts:	0.0	0.0
Foreign currency contracts \| Interest income, net
Derivative Instruments, Gain (Loss)
Hedged items	0.0	0.0
Amount excluded from effectiveness testing (amortized)	0.0	0.0
Foreign currency contracts \| Interest income, net \| Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss)
Derivatives designated as hedging instruments	0.0	0.0
Amount of gain (loss) reclassified from accumulated other comprehensive loss into income	0.0	0.0
Foreign currency contracts \| Interest income, net \| Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss)
Foreign currency contracts:	0.0	0.0
Foreign currency contracts \| Other non-operating income, net
Derivative Instruments, Gain (Loss)
Hedged items	(4.0)	(9.2)
Amount excluded from effectiveness testing (amortized)	0.8	4.7
Foreign currency contracts \| Other non-operating income, net \| Derivatives designated as hedging instruments
Derivative Instruments, Gain (Loss)
Derivatives designated as hedging instruments	4.0	9.2
Amount of gain (loss) reclassified from accumulated other comprehensive loss into income	0.0	0.0
Foreign currency contracts \| Other non-operating income, net \| Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss)
Foreign currency contracts:	22.4	7.4
Cross currency swap contracts \| Cost of sales \| Derivatives designated as hedging instruments \| Net investment hedges
Derivative Instruments, Gain (Loss)
Amount excluded from effectiveness testing	0.0	0.0
Cross currency swap contracts \| Interest income, net \| Derivatives designated as hedging instruments \| Net investment hedges
Derivative Instruments, Gain (Loss)
Amount excluded from effectiveness testing	7.0	6.9
Cross currency swap contracts \| Other non-operating income, net \| Derivatives designated as hedging instruments \| Net investment hedges
Derivative Instruments, Gain (Loss)
Amount excluded from effectiveness testing	$ 0.0	$ 0.0

EMPLOYEE BENEFIT PLANS - Schedule of Information Regarding Defined Benefit Pension Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Change in projected benefit obligation:
Beginning of year	$ 111.7	$ 94.1
Service cost	5.0	4.3	$ 5.5
Interest cost	1.9	2.3	0.5
Participant contributions	2.0	1.9
Actuarial loss	3.6	9.9
Benefits paid	(1.5)	(3.8)
Plan amendment	(0.5)	(0.4)
Divestiture (Note 5)	(4.4)	0.0
Settlements and curtailment gain (Note 5)	(5.4)	0.0
Currency exchange rate changes and other	(5.7)	3.4
End of year	106.7	111.7	94.1
Change in fair value of plan assets:
Beginning of year	75.5	70.6
Actual return on plan assets	6.3	0.8
Employer contributions	6.4	3.5
Participant contributions	2.0	1.9
Divestiture (Note 5)	(4.4)	0.0
Settlements	(5.9)	0.0
Benefits paid	(1.5)	(3.8)
Currency exchange rate changes and other	(3.8)	2.5
End of year	74.6	75.5	70.6
Funded Status
Projected benefit obligation	(106.7)	(111.7)	(94.1)
Plan assets at fair value	74.6	75.5	$ 70.6
Underfunded status	(32.1)	(36.2)
Accumulated other comprehensive loss, net of tax:
Net actuarial loss	(9.1)	(10.3)
Net prior service credit	4.4	5.2
Deferred income tax benefit	0.6	0.9
Total	(4.1)	(4.2)
Other liabilities
Net amounts recognized on the consolidated balance sheet:
Other liabilities	$ 32.1	$ 36.2

EMPLOYEE BENEFIT PLANS - Schedule of Pension Plans with Accumulated Benefit Obligations (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	$ 89.1	$ 106.8
Fair value of plan assets	61.6	75.5
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	106.7	111.7
Fair value of plan assets	$ 74.6	$ 75.5

EMPLOYEE BENEFIT PLANS - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Contribution Plans
Accumulated benefit obligation	$ 102.1	$ 106.8
Expected employer contributions	2.6
Matching contributions relating to entity's employees	56.2	51.0	$ 45.1
Nonqualified deferred compensation plans
Defined Contribution Plans
Amount accrued under nonqualified plans	$ 146.5	$ 125.6
United States
Defined Contribution Plans
Maximum contributions of a participant's eligible compensation (as a percent)	25.00%
Dollar-for-dollar match of employee's annual eligible compensation (as a percent)	4.00%
Company match of eligible compensation after dollar-for-dollar basis (as a percent)	2.00%
Company match, second level (as a percent)	50.00%
Foreign Plan
Defined Contribution Plans
Maximum contributions of a participant's eligible compensation (as a percent)	25.00%
Dollar-for-dollar match of employee's annual eligible compensation (as a percent)	4.00%
Company match, first level (as a percent)	50.00%
Profit sharing contribution calculated on eligible earnings (as a percent)	2.00%

EMPLOYEE BENEFIT PLANS - Schedule of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Service cost, net	$ 5.0	$ 4.3	$ 5.5
Interest cost	1.9	2.3	0.5
Expected return on plan assets	(3.1)	(2.7)	(1.5)
Settlements and curtailment gain	1.2	0.0	0.1
Amortization of actuarial loss	0.2	0.0	0.5
Amortization of prior service credit	(0.8)	(0.8)	(0.7)
Net periodic pension benefit cost	$ 4.4	$ 3.1	$ 4.4

EMPLOYEE BENEFIT PLANS - Schedule of Weighted-Average Assumptions Used to Determine Benefit Obligations (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Weighted-average assumptions used to determine the benefit obligations
Discount rate (as a percent)	1.50%	1.80%
Rate of compensation increase (as a percent)	2.80%	2.90%
Cash balance interest crediting rate (as a percent)	1.50%	1.50%
Social securities increase (as a percent)	1.80%	1.80%
Pension increase (as a percent)	2.20%	2.20%
Weighted-average assumptions used to determine the net periodic benefit cost
Discount rate (as a percent)	1.80%	2.50%	0.50%
Expected return on plan assets (as a percent)	4.30%	3.70%	2.10%
Rate of compensation increase (as a percent)	2.90%	2.90%	2.60%
Cash balance interest crediting rate (as a percent)	1.50%	1.50%	1.50%
Social securities increase (as a percent)	1.80%	1.80%	1.60%
Pension increase (as a percent)	2.20%	2.20%	1.80%

EMPLOYEE BENEFIT PLANS - Schedule of Target Weighted-Average Asset Allocations and Fair Value (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations (as a percent)	100.00%
Plan assets at fair value	$ 74.6	$ 75.5	$ 70.6
Total plan assets measured at fair value
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	66.7	68.6
Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	52.0	55.1
Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	14.0	12.7
Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.7	0.8
Alternative investments measured at net asset value
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	7.9	6.9
Cash \| Total plan assets measured at fair value
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	1.1	2.0
Cash \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	1.1	2.0
Cash \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
Cash \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	$ 0.0	0.0
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations (as a percent)	30.90%
United States equities \| Total plan assets measured at fair value
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	$ 2.0	2.6
United States equities \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	2.0	2.6
United States equities \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
United States equities \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
International equities \| Total plan assets measured at fair value
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	21.1	21.0
International equities \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	21.1	21.0
International equities \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
International equities \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	$ 0.0	0.0
Debt securities
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations (as a percent)	37.20%
United States government and agency securities \| Total plan assets measured at fair value
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	$ 3.2	3.5
United States government and agency securities \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	3.2	3.5
United States government and agency securities \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
United States government and agency securities \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
International government bonds \| Total plan assets measured at fair value
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	24.6	26.0
International government bonds \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	24.6	26.0
International government bonds \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
International government bonds \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	$ 0.0	0.0
Real estate
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations (as a percent)	14.70%
Real estate \| Total plan assets measured at fair value
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	$ 11.0	8.7
Real estate \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
Real estate \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	11.0	8.7
Real estate \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
Mortgages \| Total plan assets measured at fair value
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	3.0	4.0
Mortgages \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
Mortgages \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	3.0	4.0
Mortgages \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
Insurance contracts \| Total plan assets measured at fair value
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.7	0.8
Insurance contracts \| Level 1
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
Insurance contracts \| Level 2
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	0.0	0.0
Insurance contracts \| Level 3
Defined Benefit Plan Disclosure [Line Items]
Plan assets at fair value	$ 0.7	$ 0.8	$ 0.8
Other
Defined Benefit Plan Disclosure [Line Items]
Target asset allocations (as a percent)	17.20%

EMPLOYEE BENEFIT PLANS - Schedule of Changes in Fair Value of Defined Benefit Plan Assets Classified as Level 3 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Insurance Contracts
Beginning of year	$ 75.5	$ 70.6
End of year	74.6	75.5
Level 3
Insurance Contracts
Beginning of year	0.8
End of year	0.7	0.8
Level 3 \| Insurance Contracts
Insurance Contracts
Beginning of year	0.8	0.8
Relating to assets still held at December 31, 2024	0.4	0.2
Purchases, sales and settlements	(0.5)	(0.2)
End of year	$ 0.7	$ 0.8

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

EMPLOYEE BENEFIT PLANS - Schedule of Benefit Payments Which Reflect Expected Future Service (Details) $ in Millions	Dec. 31, 2024 USD ($)
Retirement Benefits [Abstract]
2025	$ 6.9
2026	5.5
2027	5.8
2028	7.5
2029	7.2
2030-2034	$ 36.5

COMMON STOCK - Treasury Stock (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Aug. 31, 2024
Treasury Stock
Purchases of treasury stock	$ 1,167.8	$ 880.5	$ 1,727.1
Treasury Stock
Treasury Stock
Purchases of treasury stock (in shares)	16.8	11.4	20.1
Purchases of treasury stock	$ 1,167.8	$ 880.5	$ 1,727.1
December 2023 Stock Repurchase Program
Treasury Stock
Authorized amount for share repurchase		$ 1,000.0
Additional authorized amount				$ 1,500.0

COMMON STOCK - Schedule of Accelerated Share Repurchases (Details) - USD ($) $ / shares in Units, shares in Millions	1 Months Ended
	Dec. 31, 2024	Aug. 31, 2024	May 31, 2024	Apr. 30, 2024	Dec. 31, 2023	Mar. 31, 2023	Feb. 28, 2023
Initial Delivery Of Shares Settled February 2023
Accelerated Share Repurchase
Amount Paid							$ 200,000,000.0
Shares Received (in shares)							2.0
Initial delivery, price per Share (in dollars per share)							$ 80.44
Value of Shares as % of Contract Value							80.00%
February 2023 Stock Repurchase Program Shares Sold In March 2023
Accelerated Share Repurchase
Shares Received (in shares)						2.5
Final Settlement Average Price per Share (in dollars per share)						$ 79.28
Initial Delivery Of Shares Settled December 2023
Accelerated Share Repurchase
Amount Paid					$ 400,000,000.0
Shares Received (in shares)					4.6
Initial delivery, price per Share (in dollars per share)					$ 70.31
Value of Shares as % of Contract Value					80.00%
December 2023 Stock Repurchase Program Shares Sold In December 2023
Accelerated Share Repurchase
Shares Received (in shares)					5.3
Final Settlement Average Price per Share (in dollars per share)					$ 72.91
Initial Delivery Of Shares Settled April 2024
Accelerated Share Repurchase
Amount Paid				$ 150,000,000.0
Shares Received (in shares)				1.4
Initial delivery, price per Share (in dollars per share)				$ 85.95
Value of Shares as % of Contract Value				80.00%
April 2024 Stock Repurchase Program Shares Sold In May 2024
Accelerated Share Repurchase
Shares Received (in shares)			1.7
Final Settlement Average Price per Share (in dollars per share)			$ 86.72
Initial Delivery Of Shares Settled August 2024
Accelerated Share Repurchase
Amount Paid		$ 500,000,000.0
Shares Received (in shares)		5.8
Initial delivery, price per Share (in dollars per share)		$ 68.93
Value of Shares as % of Contract Value		80.00%
August 2024 Stock Repurchase Program Shares Sold In December 2024
Accelerated Share Repurchase
Shares Received (in shares)	7.5
Final Settlement Average Price per Share (in dollars per share)	$ 66.60

COMMON STOCK - Employee and Director Stock Plans (Details) - shares		12 Months Ended
	May 07, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Nonemployee Directors Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
New total shares authorized (in shares)		8,400,000
Option Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated annual forfeiture rate (as a percent)		5.90%
Risk-free interest rate		4.50%	3.40%	3.00%
Expected volatility		30.90%	32.80%	31.40%
Option Awards \| The Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date (in years)		7 years
Option Awards \| Nonemployee Directors Program \| Awards granted in 2012 and later
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)		1 year
Restricted stock units \| The Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized (in shares)	2,000,000
New total shares authorized (in shares)	35,600,000
MRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		4.50%	3.60%	2.90%
Expected volatility		32.40%	32.60%	33.90%
MRSUs \| The Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)		3 years
Common Stock \| The Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized (in shares)	6,900,000
New total shares authorized (in shares)	334,500,000
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		5.20%	4.60%	0.50%
Expected volatility		33.50%	31.50%	32.00%
ESPP \| ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
New total shares authorized (in shares)		50,400,000
Percentage of lower of fair market value of common stock on effective date of subscription or date of purchase (as a percent)		85.00%
Maximum percentage of compensation employees can authorize to be withheld for common stock purchases (as a percent)		15.00%
Low \| Option Awards \| The Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)		3 years
High \| Option Awards \| The Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)		4 years
High \| Option Awards \| Nonemployee Directors Program \| Annual award to nonemployee director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
New total shares authorized (in shares)		120,000
High \| Restricted stock units \| The Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)		4 years
High \| Restricted stock units \| Nonemployee Directors Program \| Annual award to nonemployee director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
New total shares authorized (in shares)		48,000

COMMON STOCK - Schedule of Weighted-Average Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Option Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	4.50%	3.40%	3.00%
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility	30.90%	32.80%	31.40%
Expected term (years)	5 years 3 months 18 days	5 years 1 month 6 days	5 years
Fair value, per share (in dollars per share)	$ 31.14	$ 30.97	$ 34.59
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	5.20%	4.60%	0.50%
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility	33.50%	31.50%	32.00%
Expected term (years)	7 months 6 days	7 months 6 days	7 months 6 days
Fair value, per share (in dollars per share)	$ 25.01	$ 19.03	$ 28.18

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

COMMON STOCK - Schedule of Stock Option (Details) - Stock option activity $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Shares
Beginning balance (in shares) \| shares	11.0
Options granted (in shares) \| shares	1.5
Options exercised (in shares) \| shares	(2.1)
Options forfeited (in shares) \| shares	(0.4)
Ending balance (in shares) \| shares	10.0
Exercisable as of period end (in shares) \| shares	6.7
Vested and expected to vest as of period end (in shares) \| shares	9.6
Weighted- Average Exercise Price
Beginning balance (in dollars per share) \| $ / shares	$ 71.90
Options granted (in dollars per share) \| $ / shares	85.46
Options exercised (in dollars per share) \| $ / shares	43.12
Options forfeited (in dollars per share) \| $ / shares	91.39
Ending balance (in dollars per share) \| $ / shares	79.15
Exercisable as of period end (in dollars per share) \| $ / shares	73.63
Vested and expected to vest as of period end (in dollars per share) \| $ / shares	$ 78.61
Weighted- Average Remaining Contractual Term
Outstanding as of period end	3 years 4 months 24 days
Exercisable as of period end	2 years 4 months 24 days
Vested and expected to vest as of period end	3 years 3 months 18 days
Aggregate Intrinsic Value
Outstanding as of period end \| $	$ 57.9
Exercisable as of period end \| $	57.5
Vested and expected to vest as of period end \| $	$ 57.9

COMMON STOCK - Schedule of Restricted Stock Unit Activity (Details) - Nonvested restricted stock unit activity shares in Millions	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Shares
Beginning balance (in shares) \| shares	2.1
Granted (in shares) \| shares	2.1
Vested (in shares) \| shares	(0.7)
Forfeited (in shares) \| shares	(0.3)
Ending balance (in shares) \| shares	3.2
Weighted- Average Grant-Date Fair Value
Beginning balance (in dollars per share) \| $ / shares	$ 94.35
Granted (in dollars per share) \| $ / shares	85.48
Vested (in dollars per share) \| $ / shares	92.79
Forfeited (in dollars per share) \| $ / shares	90.13
Ending balance (in dollars per share) \| $ / shares	$ 89.16

COMMON STOCK - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
COMMON STOCK - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Intrinsic value of stock options exercised and restricted stock units vested	$ 150.2	$ 162.7	$ 264.5
Cash from exercises of stock options	90.6	83.4	64.8
Realized tax benefits from exercises of stock options and vesting of restricted stock units	32.6	35.9	56.9
Total grant date fair value of stock options vested	44.8	$ 41.3	$ 40.4
Employee stock purchase subscriptions	$ 258.1
Weighted-average remaining requisite service period (in months)	31 months

ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Activity for Each Component of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
AOCI Attributable to Parent, Net of Tax
Beginning balance	$ 6,650.0
Ending balance	9,998.4	$ 6,650.0
Total Accumulated Other Comprehensive Loss
AOCI Attributable to Parent, Net of Tax
Beginning balance	(242.8)	(254.9)	$ (157.7)
Other comprehensive (loss) income before reclassifications	75.7	71.7	(19.3)
Amounts reclassified from accumulated other comprehensive loss	(59.5)	(72.4)	(72.8)
Deferred income tax (expense) benefit	(17.9)	12.8	(5.1)
Ending balance	(244.5)	(242.8)	(254.9)
Foreign Currency Translation Adjustments
AOCI Attributable to Parent, Net of Tax
Beginning balance	(214.5)	(218.8)	(172.5)
Other comprehensive (loss) income before reclassifications	(49.9)	6.9	(33.9)
Amounts reclassified from accumulated other comprehensive loss	(7.0)	(6.9)	(7.0)
Deferred income tax (expense) benefit	(2.7)	4.3	(5.4)
Ending balance	(274.1)	(214.5)	(218.8)
Unrealized Gain (Loss) on Hedges
AOCI Attributable to Parent, Net of Tax
Beginning balance	0.7	23.8	29.7
Other comprehensive (loss) income before reclassifications	91.0	43.3	75.2
Amounts reclassified from accumulated other comprehensive loss	(40.6)	(72.8)	(84.5)
Deferred income tax (expense) benefit	(13.4)	6.4	3.4
Ending balance	37.7	0.7	23.8
Unrealized (Loss) Gain on Available-for-sale Investments
AOCI Attributable to Parent, Net of Tax
Beginning balance	(24.8)	(65.6)	(6.9)
Other comprehensive (loss) income before reclassifications	34.8	32.6	(77.9)
Amounts reclassified from accumulated other comprehensive loss	(12.5)	8.1	18.8
Deferred income tax (expense) benefit	(1.5)	0.1	0.4
Ending balance	(4.0)	(24.8)	(65.6)
Unrealized Pension (Costs) Credits
AOCI Attributable to Parent, Net of Tax
Beginning balance	(4.2)	5.7	(8.0)
Other comprehensive (loss) income before reclassifications	(0.2)	(11.1)	17.3
Amounts reclassified from accumulated other comprehensive loss	0.6	(0.8)	(0.1)
Deferred income tax (expense) benefit	(0.3)	2.0	(3.5)
Ending balance	$ (4.1)	$ (4.2)	$ 5.7

ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Change in Unrealized Pension Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Net prior service cost arising during period
Pre-Tax Amount
Prior service credit/cost arising during period	$ 0.0	$ 0.7	$ 0.0
Amortization of prior service credit	(0.8)	(0.8)	(0.7)
Other comprehensive income (loss)	(0.8)	(0.1)	(0.7)
Tax (Expense) Benefit
Prior service credit/cost arising during period	(0.1)	0.9	(1.1)
Amortization of prior service credit	0.2	0.1	0.3
Other comprehensive income (loss)	0.1	1.0	(0.8)
Net of Tax Amount
Prior service credit/cost arising during period	(0.1)	1.6	(1.1)
Amortization of prior service credit	(0.6)	(0.7)	(0.4)
Other comprehensive income (loss)	(0.7)	0.9	(1.5)
Net actuarial gain (loss) arising during period
Pre-Tax Amount
Other comprehensive income (loss)	1.2	(11.8)	17.9
Tax (Expense) Benefit
Other comprehensive income (loss)	(0.4)	1.0	(2.7)
Net of Tax Amount
Other comprehensive income (loss)	0.8	(10.8)	15.2
Unrealized pension costs, net
Pre-Tax Amount
Prior service credit/cost arising during period	(0.2)	(11.1)	17.3
Other comprehensive income (loss)	0.4	(11.9)	17.2
Tax (Expense) Benefit
Other comprehensive income (loss)	(0.3)	2.0	(3.5)
Net of Tax Amount
Other comprehensive income (loss)	$ 0.1	$ (9.9)	$ 13.7

ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Amounts Reclassified from Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Amounts reclassified from accumulated other comprehensive loss to affected line on Consolidated Statements of Operations
Other non-operating income, net									$ 68.9	$ 13.9	$ 4.8
Provision for income taxes									(152.1)	(152.4)	(195.5)
Net income	$ 384.3	$ 3,069.4	$ 365.0	$ 351.0	$ 369.7	$ 383.7	$ 305.5	$ 340.5	4,169.7	1,399.4	1,521.9
Cost of sales									(1,117.5)	(978.4)	(723.7)
Other non-operating income, net									0.3	0.0	$ 0.0
Amount Reclassified from Accumulated Other Comprehensive Loss \| Foreign currency translation adjustments
Amounts reclassified from accumulated other comprehensive loss to affected line on Consolidated Statements of Operations
Other non-operating income, net									7.0	6.9
Provision for income taxes									(1.7)	(1.7)
Net income									5.3	5.2
Amount Reclassified from Accumulated Other Comprehensive Loss \| Gain (loss) on hedges
Amounts reclassified from accumulated other comprehensive loss to affected line on Consolidated Statements of Operations
Provision for income taxes									(10.1)	(15.8)
Net income									30.5	57.0
Cost of sales									35.8	58.9
Other non-operating income, net									4.8	13.9
Total segment operating income									40.6	72.8
Amount Reclassified from Accumulated Other Comprehensive Loss \| (Loss) gain on available-for-sale investments
Amounts reclassified from accumulated other comprehensive loss to affected line on Consolidated Statements of Operations
Other non-operating income, net									12.5	(8.1)
Provision for income taxes									(3.1)	2.2
Net income									9.4	(5.9)
Amount Reclassified from Accumulated Other Comprehensive Loss \| Amortization of pension adjustments
Amounts reclassified from accumulated other comprehensive loss to affected line on Consolidated Statements of Operations
Other non-operating income, net									(0.6)	0.8
Provision for income taxes									0.5	(0.2)
Net income									$ (0.1)	$ 0.6

OTHER NON-OPERATING INCOME, NET (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Other Income and Expenses [Abstract]
Foreign exchange gains, net	$ (7.1)	$ (10.0)	$ (1.0)
Loss on investments	0.6	0.7	1.1
Non-service cost components of net periodic pension benefit cost	(0.6)	(1.2)	(1.1)
Gain on remeasurement of previously held equity interest upon acquisition	(55.0)	0.0	0.0
Gain on insurance settlement	0.0	0.0	(3.8)
Other	(6.8)	(3.4)	0.0
Total other non-operating income, net	$ (68.9)	$ (13.9)	$ (4.8)

INCOME TAXES - Schedule of Income from Continuing Operations Before Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
United States	$ 265.7	$ 290.1	$ 586.0
Outside of the United States, including Puerto Rico	1,282.4	1,082.3	933.5
Income from continuing operations before provision for income taxes	$ 1,548.1	$ 1,372.4	$ 1,519.5

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

INCOME TAXES - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
United States:
Federal	$ 248.4	$ 291.7	$ 365.8
State and local	40.7	50.1	54.3
Outside of the United States, including Puerto Rico	25.8	53.0	37.1
Current income tax expense	314.9	394.8	457.2
United States:
Federal	(117.8)	(165.7)	(197.8)
State and local	(31.0)	(54.2)	(58.9)
Outside of the United States, including Puerto Rico	(14.0)	(22.5)	(5.0)
Deferred income tax benefit	(162.8)	(242.4)	(261.7)
Total income tax provision	$ 152.1	$ 152.4	$ 195.5

INCOME TAXES - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets
Capitalized research and development expenses	$ 533.8	$ 371.1
Compensation and benefits	123.7	117.9
Benefits from uncertain tax positions	89.6	63.4
Net tax credit carryforwards	289.1	144.2
Net operating loss carryforwards	132.1	73.0
Accrued liabilities	145.2	131.7
Inventories	14.9	15.1
Cash flow and net investment hedges	0.0	1.3
State income taxes	3.2	0.2
Investments	1.2	0.6
Lease liability obligations	6.5	5.8
Other	2.8	0.7
Total deferred tax assets	1,342.1	925.0
Deferred tax liabilities
Property, plant, and equipment	(76.4)	(78.2)
Cash flow and net investment hedges	(11.8)	0.0
Deferred tax on foreign earnings	(3.6)	(3.6)
Right-of-use assets	(4.3)	(4.7)
Other intangible assets	(230.3)	(46.1)
Other	(4.8)	(2.4)
Total deferred tax liabilities	(331.2)	(135.0)
Valuation allowance	(87.8)	(62.1)
Net deferred tax assets	$ 923.1	$ 727.9

INCOME TAXES - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2024	Nov. 30, 2022	Dec. 31, 2024	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Net deferred tax assets increase					$ 195.2
Valuation allowance			$ 87.8		87.8	$ 62.1
Carryforward amount			362.2		362.2
Foreign tax credits			121.6		121.6
Foreign tax credits expected to be utilized			103.8		103.8
Final repatriation tax installment			78.5		78.5
Foreign earnings to be indefinitely reinvested			555.2		555.2
Foreign earnings to be repatriated					1,000.0
Estimated net tax liability on permanently reinvested earnings			2.5		2.5
Liability for income taxes associated with uncertain tax positions			678.8		678.8	583.9	$ 475.3	$ 358.4
Decrease in unrecognized tax benefits is reasonably possible			319.9		319.9	250.7
Net amounts that would favorably affect effective tax rate			358.9		358.9	333.2
Accrued interest related to unrecognized tax benefits, net of tax benefit			55.4		55.4	41.4
Tax benefit of accrued interest			52.5		52.5	29.9
Interest expense (benefit), net of tax benefit					14.0	12.3	9.6
Estimate of additional tax expense					240.0
Additional tax sought in excess of filing position						269.3
Additional deposit	$ 305.1	$ 75.0
Israel Tax Authority
Operating Loss Carryforwards [Line Items]
Estimate of additional tax owed			16.0	$ 110.0
Foreign Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Valuation allowance			17.8		17.8
Non-United States net operating losses
Operating Loss Carryforwards [Line Items]
Tax reductions compared to local statutory rates					$ 271.9	$ 333.2	$ 247.4
Tax reductions compared to local statutory rates per diluted share (in dollars per share)					$ 0.45	$ 0.55	$ 0.40
California \| State and local jurisdiction \| Research expenditure tax credits \| Carryforward Period Indefinite
Operating Loss Carryforwards [Line Items]
Carryforward amount			$ 232.7		$ 232.7

INCOME TAXES - Schedule of Net Operating Loss Carryforwards (Details) $ in Millions	Dec. 31, 2024 USD ($)
Operating Loss Carryforwards [Line Items]
Carryforward Amount	$ 842.5
Tax Benefit Amount	132.1
Valuation Allowance	(66.9)
Net Tax Benefit	65.2
United States \| United States federal net operating losses \| Carryforward Period Ends 2026-2037
Operating Loss Carryforwards [Line Items]
Carryforward Amount	9.4
Tax Benefit Amount	2.0
Valuation Allowance	0.0
Net Tax Benefit	2.0
United States \| United States federal net operating losses \| Carryforward Period Indefinite
Operating Loss Carryforwards [Line Items]
Carryforward Amount	132.9
Tax Benefit Amount	27.9
Valuation Allowance	0.0
Net Tax Benefit	27.9
United States \| United States state net operating losses \| Carryforward Period Indefinite
Operating Loss Carryforwards [Line Items]
Carryforward Amount	0.4
Tax Benefit Amount	0.0
Valuation Allowance	0.0
Net Tax Benefit	0.0
United States \| United States state net operating losses \| Carryforward Period Ends 2029-2044
Operating Loss Carryforwards [Line Items]
Carryforward Amount	180.7
Tax Benefit Amount	12.6
Valuation Allowance	(3.7)
Net Tax Benefit	8.9
Non-United States \| Non-United States net operating losses \| Carryforward Period Indefinite
Operating Loss Carryforwards [Line Items]
Carryforward Amount	517.8
Tax Benefit Amount	89.3
Valuation Allowance	(63.2)
Net Tax Benefit	26.1
Non-United States \| Non-United States net operating losses \| Carryforward Period Ends 2028
Operating Loss Carryforwards [Line Items]
Carryforward Amount	1.3
Tax Benefit Amount	0.3
Valuation Allowance	0.0
Net Tax Benefit	$ 0.3

INCOME TAXES - Schedule of Tax Credit Carryforwards (Details) $ in Millions	Dec. 31, 2024 USD ($)
Tax credit carryforwards and the related carryforward periods
Carryforward Amount	$ 362.2
Valuation Allowance	(17.8)
Net Tax Benefit	344.4
California research expenditure tax credits \| California \| Research expenditure tax credits \| Carryforward Period Indefinite
Tax credit carryforwards and the related carryforward periods
Carryforward Amount	232.7
Valuation Allowance	0.0
Net Tax Benefit	232.7
Federal research expenditure tax credits \| United States \| Research expenditure tax credits \| Tax Carryforwards Expiration Period Years 2025-2034
Tax credit carryforwards and the related carryforward periods
Carryforward Amount	1.9
Valuation Allowance	0.0
Net Tax Benefit	1.9
Foreign tax credits \| United States \| Foreign tax credits \| Tax Carryforwards Expiration Period Years 2025-2034
Tax credit carryforwards and the related carryforward periods
Carryforward Amount	121.6
Valuation Allowance	(17.8)
Net Tax Benefit	103.8
Foreign tax credits \| Non-United States \| Foreign tax credits \| Tax Carryforwards Expiration Period Years 2025-2028
Tax credit carryforwards and the related carryforward periods
Carryforward Amount	6.0
Valuation Allowance	0.0
Net Tax Benefit	$ 6.0

INCOME TAXES - Schedule of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income tax expense at United States federal statutory rate	$ 325.1	$ 288.1	$ 323.7
Foreign income taxed at different rates	(190.6)	(133.8)	(135.4)
State and local taxes, net of federal tax benefit	16.0	15.9	11.3
Tax credits, federal and state	(58.9)	(55.9)	(43.4)
Build of reserve for prior years' uncertain tax positions	(31.3)	(2.9)	11.6
Tax on global intangible low-taxed income	90.2	82.3	68.4
Foreign-derived intangible income deduction	(16.5)	(20.9)	(14.3)
Contingent consideration liabilities	0.0	(5.5)	(7.5)
United States federal deductible employee share-based compensation	(8.3)	(11.9)	(28.5)
Nondeductible employee share-based compensation	6.2	5.7	4.9
Other	20.2	(8.7)	4.7
Total income tax provision	$ 152.1	$ 152.4	$ 195.5

INCOME TAXES - Schedule of Reconciliation of Uncertain Tax Positions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Unrecognized Tax Benefits
Uncertain gross tax positions, beginning balance	$ 583.9	$ 475.3	$ 358.4
Current year tax positions	125.8	127.0	120.6
Increase in prior year tax positions	3.2	0.8	3.8
Decrease in prior year tax positions	(34.1)	(16.2)	(0.6)
Settlements	0.0
Settlements		(3.0)	(0.4)
Lapse of statutes of limitations	0.0	0.0	(6.5)
Uncertain gross tax positions, ending balance	$ 678.8	$ 583.9	$ 475.3

LEGAL PROCEEDINGS (Details) $ in Millions	12 Months Ended
LEGAL PROCEEDINGS (Details) $ in Millions	Dec. 31, 2024 USD ($) lawsuit
Commitments and Contingencies Disclosure [Abstract]
Number of lawsuits that if settled could have a material adverse impact on net income or cash flows \| lawsuit	1
Threshold of disclosing material environmental legal proceedings \| $	$ 1

SEGMENT INFORMATION - Narrative (Details)	12 Months Ended
SEGMENT INFORMATION - Narrative (Details)	Dec. 31, 2024 Reportable_segment
Segment Reporting [Abstract]
Number of reportable segments	4

SEGMENT INFORMATION - Schedule of Information about Reportable Segments (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Net Sales
Total segment net sales	$ 1,385.8	$ 1,354.4	$ 1,369.4	$ 1,329.9	$ 1,266.4	$ 1,243.4	$ 1,278.9	$ 1,221.3	$ 5,439.5	$ 5,010.0	$ 4,464.0
Cost of Sales
Total segment cost of sales									1,117.5	978.4	723.7
Selling, general, and administrative expenses
Total segment selling, general, and administrative expenses									1,789.2	1,582.5	1,357.6
Operating segments
Segment Net Sales
Total segment net sales									5,439.5	5,010.0	4,464.0
Cost of Sales
Total segment cost of sales									1,051.9	956.5	816.5
Selling, general, and administrative expenses
Total segment selling, general, and administrative expenses									1,047.1	929.9	793.7
Other Segment Items
Other segment items									0.0	18.9	(90.1)
Segment Operating Income
Total segment operating income									3,340.5	3,104.7	2,943.9
Operating segments \| United States
Segment Net Sales
Total segment net sales									3,206.0	2,947.9	2,628.2
Cost of Sales
Total segment cost of sales									546.6	505.2	418.9
Selling, general, and administrative expenses
Total segment selling, general, and administrative expenses									498.0	432.8	340.7
Other Segment Items
Other segment items									2.4	2.1	4.8
Segment Operating Income
Total segment operating income									2,159.0	2,007.8	1,863.8
Operating segments \| Europe
Segment Net Sales
Total segment net sales									1,321.7	1,180.2	1,040.3
Cost of Sales
Total segment cost of sales									299.1	268.5	237.9
Selling, general, and administrative expenses
Total segment selling, general, and administrative expenses									282.6	260.6	233.0
Other Segment Items
Other segment items									14.9	(4.0)	(34.9)
Segment Operating Income
Total segment operating income									725.1	655.1	604.3
Operating segments \| Japan
Segment Net Sales
Total segment net sales									339.8	350.8	359.5
Cost of Sales
Total segment cost of sales									48.1	46.6	41.5
Selling, general, and administrative expenses
Total segment selling, general, and administrative expenses									85.1	70.1	77.4
Other Segment Items
Other segment items									(6.8)	21.3	(58.1)
Segment Operating Income
Total segment operating income									213.4	212.8	298.7
Operating segments \| Rest of World
Segment Net Sales
Total segment net sales									572.0	531.1	436.0
Cost of Sales
Total segment cost of sales									158.1	136.2	118.2
Selling, general, and administrative expenses
Total segment selling, general, and administrative expenses									181.4	166.4	142.6
Other Segment Items
Other segment items									(10.5)	(0.5)	(1.9)
Segment Operating Income
Total segment operating income									$ 243.0	$ 229.0	$ 177.1

SEGMENT INFORMATION - Schedule of Reconciliation of Segment Operating Income and Pre-Tax Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Operating Income
Operating income	$ 1,378.7	$ 1,308.9	$ 1,498.4
Unallocated amounts:
Restructuring charges, separation costs, and other	(61.0)	0.0	(60.7)
Intellectual property agreement and certain litigation expenses	(40.4)	(203.5)	(15.8)
Change in fair value of contingent consideration liabilities	0.0	26.2	35.8
Foreign currency	7.1	10.0	1.0
Non-operating income	169.4	63.5	21.1
Income from continuing operations before provision for income taxes	1,548.1	1,372.4	1,519.5
Operating segments
Segment Operating Income
Operating income	3,340.5	3,104.7	2,943.9
Corporate items
Unallocated amounts:
Corporate items	(1,886.8)	(1,684.4)	(1,504.2)
Reconciling items
Unallocated amounts:
Restructuring charges, separation costs, and other	(61.0)	0.0	(60.7)
Intellectual property agreement and certain litigation expenses	(40.4)	(203.5)	(15.8)
Change in fair value of contingent consideration liabilities	0.0	26.2	35.8
Foreign currency	$ 26.4	$ 65.9	$ 99.4

SEGMENT INFORMATION - Schedule of Enterprise-Wide Information (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Net Sales by Major Product Group
Net sales	$ 1,385.8	$ 1,354.4	$ 1,369.4	$ 1,329.9	$ 1,266.4	$ 1,243.4	$ 1,278.9	$ 1,221.3	$ 5,439.5	$ 5,010.0	$ 4,464.0
Long-lived Tangible Assets by Geographic Region
Long-lived Tangible Assets by Geographic Region	1,784.2				1,675.4				1,784.2	1,675.4	1,570.3
Transcatheter Aortic Valve Replacement
Net Sales by Major Product Group
Net sales									4,106.1	3,879.8	3,518.2
Transcatheter Mitral and Tricuspid Therapies
Net Sales by Major Product Group
Net sales									352.1	197.6	116.1
Surgical Structural Heart
Net Sales by Major Product Group
Net sales									981.3	932.6	829.7
United States
Long-lived Tangible Assets by Geographic Region
Long-lived Tangible Assets by Geographic Region	1,249.6				1,186.9				1,249.6	1,186.9	1,113.3
Other countries
Long-lived Tangible Assets by Geographic Region
Long-lived Tangible Assets by Geographic Region	$ 534.6				$ 488.5				$ 534.6	$ 488.5	$ 457.0

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Allowance for credit losses
Movement in Valuation Allowances and Reserves
Balance at Beginning of Period	$ 11.7	$ 11.6	$ 15.6
Charged to Costs and Expenses	7.6	2.0	0.9
Charged to Other Accounts	2.7	0.0	0.1
Deductions	(9.7)	(1.9)	(5.0)
Balance at End of Period	12.3	11.7	11.6
Tax valuation allowance
Movement in Valuation Allowances and Reserves
Balance at Beginning of Period	62.1	72.0	58.4
Charged to Costs and Expenses	25.2	0.0	0.0
Charged to Other Accounts	4.5	0.1	14.2
Deductions	(4.0)	(10.0)	(0.6)
Balance at End of Period	$ 87.8	$ 62.1	$ 72.0

SUMMARIZED QUARTERLY FINANCIAL INFORMATION (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended								12 Months Ended
	Sep. 03, 2024	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Effect of Fourth Quarter Events [Line Items]
Net sales		$ 1,385.8	$ 1,354.4	$ 1,369.4	$ 1,329.9	$ 1,266.4	$ 1,243.4	$ 1,278.9	$ 1,221.3	$ 5,439.5	$ 5,010.0	$ 4,464.0
Gross profit		1,093.6	1,091.5	1,093.9	1,043.0	1,015.4	992.8	1,031.1	992.3	4,322.0	4,031.6	3,740.3
Income from continuing operations, net of tax		345.0	362.1	364.0	324.9	333.1	334.9	251.4	300.6	1,396.0	1,220.0	1,324.0
Income from discontinued operations, net of tax		39.3	2,707.3	1.0	26.1	36.6	48.8	54.1	39.9	2,773.7	179.4	197.9
Net income		384.3	3,069.4	365.0	351.0	369.7	383.7	305.5	340.5	4,169.7	1,399.4	1,521.9
Net income attributable to Edwards Lifesciences Corporation.		$ 385.6	$ 3,070.8	$ 366.3	$ 351.9	$ 369.9	$ 384.9	$ 307.1	$ 340.5	$ 4,174.6	$ 1,402.4	$ 1,521.9
Basic
Continuing operations (in dollars per share)		$ 0.58	$ 0.61	$ 0.61	$ 0.54	$ 0.55	$ 0.55	$ 0.42	$ 0.49	$ 2.34	$ 2.02	$ 2.14
Discontinued operations (in dollars per share)		0.07	4.53	0	0.04	0.06	0.08	0.09	0.07	4.64	0.29	0.32
Basic earnings per share (in dollars per share)		0.65	5.14	0.61	0.58	0.61	0.63	0.51	0.56	6.98	2.31	2.46
Diluted:
Continuing operations (in dollars per share)		0.58	0.61	0.61	0.54	0.55	0.55	0.41	0.49	2.34	2.01	2.12
Discontinued operations (in dollars per share)		0.07	4.52	0	0.04	0.06	0.08	0.09	0.07	4.63	0.29	0.32
Diluted earnings per share (in dollars per share)		$ 0.65	$ 5.13	$ 0.61	$ 0.58	$ 0.61	$ 0.63	$ 0.50	$ 0.56	$ 6.97	$ 2.30	$ 2.44
Discontinued Operations, Held-for-Sale \| Critical Care
Effect of Fourth Quarter Events [Line Items]
Income from discontinued operations, net of tax	$ 3,300.0		$ 3,300.0

SUBSEQUENT EVENT (Details) - February 2025 Stock Repurchase Program - Subsequent Event shares in Millions, $ in Millions	1 Months Ended
	Feb. 28, 2025 USD ($) shares
Subsequent Event [Line Items]
Amount Paid \| $	$ 250.0
Shares repurchased (in shares) \| shares	2.6
Value of Shares as % of Contract Value	80.00%